Assessment of TWIST1 as an immunotherapeutic target of cancer by Poon, E.C.C.
1 
 
 
 
 
 
 
 
Assessment of TWIST1 as an immunotherapeutic 
target of cancer 
 
 
 
Edmund Chee Chung Poon 
 
 
A thesis submitted for the Degree of Doctor of Philosophy 
 
 
Institute of Child Health 
University College London 
 
2011 2 
 
I, Edmund Chee Chung Poon confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis 3 
 
Abstract 
CD8
+ T lymphocytes are key mediators of anti-tumour immunity, eliminating tumour 
cells through the recognition of tumour antigens. Increasing the number of characterised 
tumour antigens, especially those with highly specific tumour expression, may enable 
the development of more effective immunotherapy of cancers. TWIST1 is a basic-helix-
loop-helix  transcription  factor  (bHLB)  with  an  important  role  in  cell  lineage 
determination and differentiation. It is expressed by a number of carcinomas where it 
functions  as  a  pro-metastatic  oncogene,  but  is  absent  or  expressed  at low  levels  in 
normal tissues. The main aim of this study was to investigate whether anti-TWIST1 
immune responses could be generated and used to target cancer cells. 
 
  Two potential HLA-A0201 restricted TWIST1-derived epitopes, SLNEAFAAL 
and  KLAARYIDFL  (referred  to  as  SLN  and  KLA)  were  identified  by  in  silico 
prediction methods and their binding to HLA-A*0201 confirmed in vitro. The peptides 
were assessed for their capacity to induce specific immune responses by generating 
cytotoxic T lymphocyte (CTL) lines from the peripheral blood of HLA-A2-positive
 
healthy donors.  SLN peptide-specific CTLs were detected in 1 out of 5 healthy donors 
by  peptide/MHC  class  I  pentamers  and  the  CTL  line  generated  showed  specific 
cytotoxicity and the release of interferon-γ on recognition of T2 target cells pulsed with 
SLN.  KLA  peptide-specific  CTLs  were  not  detected  in  the  four  healthy  HLA-A2-
positive
  donors  tested.  The  immunogenicity  of  KLA  was  also  assessed  by  peptide 
immunisation  of  HLA-A*0201  transgenic  mice  and  the  in  vitro  stimulation  of 
alloreactive  peptide-specific  CD8
+  T  cells  from  HLA-A2-negative  healthy  blood 
donors. CTLs capable of specifically killing T2 cells pulsed with KLA peptide were 
isolated  from  an  alloreactive  CTL  bulk  line  using  peptide/HLA-A*0201  pentamer 
reagents and magnetic cell sorting.  The data presented here shows the existence of 
functional anti-TWIST1 CTL precursors within the autologous and allogeneic HLA-
A*0201-restricted T cell repertoires of healthy donors, and therefore merits the further 
evaluation of SLN and KLA as target epitopes for the treatment of TWIST1
+ tumours.  4 
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PLC  Pre-assembled MHC class I loading complexes  
PMA  Phorbol 12-myristate 13-acetate 
PRAME  Preferentially expressed antigen in melanoma 
qPCR  Real-time quantitative polymerase chain reaction 
RAG  Recombination-activating gene 
RBC  Red blood cell 
RIPA  Radio-immunoprecipitation assay 
RNA  Ribonucleic acid 
rpm  Revolutions per minute 
RPMI  Roswell park memorial institute 
RT  Room temperature 
RT  Reverse transcriptase 
s.c.  Subcutaneous 
SDS  Sodium dodecyle sulphate 
SDS-PAGE  Sodium dodecyle sulphate polyacrylamide analysis 
sfc  Spot forming cells 
Sffv  Spleen focus forming virus  
SIN  Self-inactivating lentivirus vector 
SLN  Refers to the following peptide sequence: SLNEAFAAL 
TAA  Tumour-associated antigen 
TAP  Transporter-associated with antigen processing 
TBS  Tris-buffered saline 
TBS-T  Tris-buffered saline-Tween 
TCR  T cell receptor 18 
 
TEMED  Tetramethylethylenediamine  
TIL  Tumour infiltrating lymphocytes 
TIR  Toll-interleukin 1 receptor 
TLR  Toll-like receptor 
TNF-α  Tumour necrosis factor-alpha 
Treg  T regulatory cell 
TU  Transducing units 
UTR  Untranslated regions 
VIL  Refers to the following peptide sequence: VILKKATEYV 
VSV-G  Vesicular stomatitis virus G glycoprotein  
WB  Western blotting 
WPRE  Woodchuck hepatitis virus post-transcriptional response element  
WT1  Wilms tumour protein 1 
β2m  Beta-2-microglobulin 
 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. CHAPTER 1 
INTRODUCTION 20 
 
1.1.  Tumour Immunology 
1.1.1.  Overview of cancer immunity 
The immune system plays a major role in the immunosurveillance and prevention of 
cancer development. Malignant cells are capable of inducing both innate and adaptive 
immune  responses  that  lead  to  the  killing  of  tumour  cells.  But  there  is  also  clear 
evidence showing that the complex interactions between the tumour and the immune 
environment  can  facilitate  tumour  progression.  Cancer  immunity  has  long  been  a 
controversial field; W.H. Wolgom in 1929 stated that ‘It would be as difficult to reject 
the right ear and leave the left ear intact as it is to immunize against cancer’ (Woglom, 
1929)  summing  up  the  scepticism  towards  cancer  immunotherapy  approaches. 
Significant  progress  has  been  made  since  and  the  role  of  immunity  in  cancer 
progression is indisputable.  
 
Evidence for tumour immunosurveillance was supported by advances made in 
gene targeting and the development of complex transgenic mouse models. Key studies 
came from examining the roles of interferon-  and perforin in the tumour development 
process.  Interferon-  receptor  α-chain  knockout  mice,  which  are  unresponsive  to 
interferon-  signalling, when compared with wild type mice were shown to have a 
higher incidence of tumours when induced with a chemical carcinogen (Kaplan et al., 
1998).  Similarly  the  roles  of  perforin-dependent  cytotoxicity,  effector  function  of 
cytotoxic  T  lympocytes  (CTLs)  and  natural  killer  (NK)  cells,  in  cancer 
immunosurveillance were assessed in a murine model lacking perforin expression (van 
den Broek et al., 1996). The availability of gene-targeting and knockout mice allow for 
a better understanding of the components contributing towards tumour development by 
the immune system. One such study on double mutant immuno-deficient mice, (RAG2
-/- 
IFNGR1
-/-), demonstrated the overlapping tumour suppressor functions of lymphocytes 
and interferon-  signalling but also their role in shaping the tumour’s immunogenicity, 
promoting immune evasion (Shankaran et al., 2001). 
 
Tumour  immunoediting  is  an  important  conceptual  framework  upon  which 
scientists attempt to build understanding of the dynamic relationship that exists between 
the host immune system and cancer. The concept divides the tumour cells and host 21 
 
immunity interactions into three phases: elimination, equilibrium and escape (Dunn et 
al., 2004) as illustrated in Figure 1.1.  
 
Figure 1 Figure 1.1 The three phases of cancer immunoediting 
The elimination phase of immunoediting describes the generation of innate and 
adaptive immune responses against antigenic tumour cells. In this phase the immune 
system takes on a tumour suppressive role and the total eradication of tumour cells 
results in the end of immunoediting without progression to the next two phases. The 
presence of anti-tumour immunity is supported by evidence from clinical observations 
in cancer patients reporting the presence of tumour-infiltrating lymphocytes (TIL) in 
different types of cancer; which is now understood to be evidence of anti-tumour T cell 
immunity. Large-scale analysis of cutaneous melanoma patient samples by histological 
examination revealed a large percentage of samples containing CD3
+  TILs and this 
correlated with an overall survival rate advantage, compared to patients with no TILs  
(Clark, Jr. et al., 1989; Mihm, Jr. et al., 1996; Clemente et al., 1996). Moreover, a study 
looking  at  patients  with  ovarian  carcinomas  with  complete  clinical  response  after 
surgical  de-bulking  and  chemotherapy  treatment  reported  that  73.9  percent  of  the 
patients  whose    tumour  masses  contained  TILs,  had  a  5  year  overall  survival  rate, 
compared to only 11.9 percent for those patients which did not (Zhang et al., 2003). 
This  observation  resonates  with  the  current  views  on  the  synergistic  effects  of 
chemotherapy  and  immunotherapy  on  cancer  treatment  by  promoting  anti-tumour 
immunity  through  the  induction  of  immunogenic  tumour  cell  death  (Lake  and 
Robinson, 2005).  
Figure  1.1  The  three  phases  of  cancer  immunoediting.  Innate  and  adaptive 
immune responses are mounted against tumour cells (purple). Selective pressure 
exerted by the immune system is sufficient to contain tumour growth. New tumour 
cell  variants  arise  (red  and  black)  and  evade  immunosurveillance  mechanisms. 
Adapted from Dunn, et al. 2004. 
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The equilibrium and escape phases of immunoediting describe how tumour cells 
evade and survive the host immune system. Less is known about the equilibrium phase, 
which is characterised by a period of undetectable tumour progression and development. 
Evidence supporting the equilibrium phase came indirectly from clinical observations of 
apparent transfer of metastatic melanoma from donor to recipients receiving kidney 
transplantations (MacKie et al., 2003). The donor was later discovered to have been 
treated for melanoma 16 years before the organ donations. Remnants of tumour cells 
may have been suppressed by the donor’s immune system, but were able to proliferate 
within the immunosuppressed environment of the recipients. The escape phase occurs 
when the immune system becomes incapable of suppressing tumour progression. It was 
reasoned that tumours are only diagnosed clinically when they reach the escape phase of 
cancer immunoediting.  The  first  two phases exert selective pressures,  favouring the 
survival of tumour cell variants that are capable of circumventing the immune system. 
Scientists  have  uncovered  a  plethora  of  immune  evasion  mechanisms  employed  by 
tumours, such as the down-regulation of MHC class  I complexes to escape tumour 
recognition by effector T cells (discussed in section section 1.2.3.)  
 
1.1.2.  Human tumour antigens 
The mechanisms by which tumours are recognised by T lymphocytes have been studied 
extensively in the past few decades. Melanoma antigen family A1 (MAGE-1) is the first 
tumour-associated antigen (TAA) identified using a gene cloning approach. MAGE-1 
antigen was found to be expressed on the cell surfaces of melanoma tumours (van der et 
al., 1991). Similar to viral antigens, TAA of class I MHC-restriction are short peptide 
fragments  bound  to  major  histocompatibility  (MHC)  class  I  molecules  on  the  cell 
surfaces  of  tumour  cells.  These  peptides  are  initially  generated  intracellularly  from 
larger precursor proteins by proteosomal cleavage, and are then transported into the 
endoplasmic reticulum where  they are  assembled onto MHC molecules;  and  finally 
transported to the cell membrane as peptide-MHC complexes (discussed in more detail 
in section 1.2). An adaptive immune response against a specific epitope, mediated by 
CD8
+ T cells or cytotoxic T lymphocytes (CTL), is only triggered when an antigen-
specific  T  cell  receptor  (TCR)  recognises  the  conformational  shape  formed  by  the 
peptide-MHC class I complex. 
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  A vast number of tumour antigens and their immunogenic peptide sequences 
have  been  identified  to  date.  The  expression  patterns  of  the  identified  TAAs  were 
examined  in  both  healthy  tissues  and  in  the  different  types  of  tumours  and  can  be 
categorised  into  four  major  groups:  Unique  tumour-specific,  differentiation, 
cancer/testis and overexpressed antigens (Kessler and Melief, 2007; Dunn et al., 2004; 
Rosenberg, 1999; Van den Eynde and van der, 1997). Unique tumour antigens are found 
only in one tumour type and are not expressed in normal cells. They are immunogenic 
peptides arising as a result of mutations such as point mutations and translocations. The 
differentiation antigens are found expressed in both tumours and the cells of origin of 
the tumours. For example, the melanocyte antigens, such as MART-1/Melan-A, gp100 
and  tyrosinase  were  found  expressed  in  both  melanoma  and  its  normal  tissue, 
melanocytes. Cancer/testis antigens are found expressed in a wide range of tumours but 
not in normal tissues except for the germ cells of the testes; these include antigens from 
the MAGE family and NY-ESO-1. The last group called the overexpressed antigens 
have an elevated expression in a wide range of tumours as well as in normal tissues but 
at a much lower level. Examples of overexpressed antigens include HER2/neu, p53 and 
WT1  (An  extensive  list  of  T-cell  defined  tumour  antigens  can  be  found  at 
www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm). Unlike pathogen-derived 
antigens which are considered ‘foreign’, most TAAs are derived from proteins encoded 
in the human genome. Mobilisation of the immune system against ‘self’-proteins can be 
difficult due to the body’s natural mechanisms to prevent autoimmunity. Examples of 
self-tolerance mechanisms will be discussed in section 1.3. The increasing knowledge 
of  molecular  targets  of  tumour-specific  CTL,  by  the  identifying  and  characterising 
TAAs,  have  obvious  clinical  implications  for  the  development  of  targeted  tumour 
immunotherapies.  
 
1.2.  MHC Class I-restricted Antigen Presentation  
1.2.1.  MHC class I molecules and peptide interaction 
The major histocompatibility complex (MHC) is a large cluster of genes located on 
chromosome 6. It is subdivided into three main groups: MHC Class I, MHC Class II 
and MHC Class III genes. In humans, the MHC molecules are referred to as the human 
leukocyte antigens (HLA). In the following paragraphs, we will only focus on MHC 24 
 
Class I molecules and their role in antigen presentation. The HLA Class I molecules are 
encoded by the A, B, C, E, F and G loci. The genes encoding the HLA molecules are 
highly polymorphic, there are 3,937 alleles reported for HLA Class I alone (Robinson et 
al., 2003). However, certain alleles are more common than others and variations can be 
observed  across  populations  and  ethnicity  groups.  For  example,  of  the  60,000 
individuals sampled from the American Caucasian population, 47.4% carried the HLA-
A*0201 allele (Middleton et al., 2003).  
 
  HLA Class I molecule is a membrane-bound heterodimeric protein consisting of 
an α-chain, encoded by the polymorphic HLA Class I alleles, and a β2-microglobulin 
protein.  The  α-chain  consists  of  three  extracellular  domains  α1,  α2  and  α3,  a 
transmembrane domain and a short cytoplasmic tail. Structural analysis of the α1and α2 
domains showed that it consisted of a platform of β-strands, on top of which two α-
helices ran in parallel and in opposite directions. Together they form the peptide binding 
cleft with enclosed ends – a space in which a short peptide can bind. Antigenic peptides 
are presented for T cell recognition by antigen presenting cells, in complex with an 
MHC molecule. T cell receptor (TCR) and peptide-MHC ligand interaction involves the 
recognition of not only the peptide determinant, but also the TCR contact surface on the 
MHC molecule. 
 
 
  Each allelic variant of the MHC Class I molecule is able to bind to a distinct but 
overlapping spectrum of antigenic peptides. Characterisation of peptides eluted from 
MHC Class I molecules have identified the following 1) peptides are usually nine amino 
acids in length but can vary between 8-10 amino acids 2) similar amino acids are found 
at the C-terminus end and at the second and third position from the N-terminus end. 
These amino acids, called anchor residues, are buried within the cleft of the MHC class 
I molecule and are responsible for holding the complex together. Peptides containing 
similar or same anchor residues will usually bind to the same MHC Class I molecule. 
Similarly, different allelic MHC Class I variants are able to bind to different anchor 
residue motifs, therefore each HLA class I allele is able to present a different sets of 
peptides.  
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1.2.2.  MHC class I antigen presentation pathway and CTL epitope generation 
Peptides presented on MHC Class I molecules are normally derived from the processing 
of endogenous ‘self’-proteins or pathogen-derived proteins in the cytosol. Figure 1.2 
shows  an  overview  of  the  MHC  Class  I  antigen  presentation  pathway.  Intracellular 
proteins are subjected to constant turnover by the cytosolic proteolytic system, in which 
proteins are targeted  for  degradation  in  the  proteasome  by  ubiquitination.  Resulting 
peptides generated are then selectively translocated into the endoplasmic reticulum (ER) 
by transporter-associated with antigen processing (TAP) proteins, in an ATP-dependent 
manner. Peptides with high affinity for the MHC class I molcule are then loaded onto 
pre-assembled MHC class I loading complexes (PLC) which consist of the following 
components:  calreticulin,  tapasin  (TAP-associated  glycoprotein)-ERp57  (protein 
disulfide  isomerase)  conjugate  (Dick  et  al.,  2002),  MHC  class  I  α-chain,  β2-
microglobulin and TAP heterodimer (Wright et al., 2004). Peptide-loaded MHC class I 
complexes are then released from the PLC and transported to the cell surface via the 
golgi apparatus.  
 
  The proteasome plays an important role in determining the repertoire of CTL 
epitopes available on the plasma membrane, presented on MHC class I complexes. It 
was first demonstrated by Rock et al that the inhibition of proteosome function with 
peptide aldehydes prevented the processing of ovalbumin (OVA), thus abrogating the 
presentation  of  an  OVA-derived  peptide  (SIINFEKL)  to  OVA-specific  T  cell 
hybridomas (Rock et al., 1994). Moreover, protease inhibition resulted in the retention 
of  MHC  class  I  molecules  within  the  ER  due to  the  lack  of  peptides  available  for 
loading (Hughes et al., 1996).  
 
  Low molecular mass polypeptide (LMP) 2 and LMP7 are located within the 
MHC gene cluster (Martinez and Monaco, 1991; Ortiz-Navarrete et al., 1991). They 
encode for β-subunits which form the active sites of the 20S proteasome core structure 26 
 
  
a
b
c d Endoplasmic reticulum 
Golgi apparatus
Cytoplasm
Cell surface
Peptides
Proteasome
Intracellular 
protein
pre-assembled MHC class I 
loading complex
Mature MHC class I 
complex
Poly-ubiquitin 
chain
 
Figure 2 Figure 1.2. MHC class I antigen processing and presentation 
MHC class I 
α-chain
β2-
microglobulin Calreticulin
Tapasin-ERp57 
conjugate
TAP1/TAP2 
complex
 
 
Figure 1.2. MHC class I antigen processing and presentation. (a) In general, most 
CTL  epitopes  are  generated  from  intracellular  proteins.  Ubiquitinated-protein 
substrates are degraded into short peptide fragments by proteasomes, which are then 
(b) selectively transported into the endoplasmic reticulum (ER) by the TAP1/TAP2 
complex.  (c)  Peptides  with the appropriate  MHC  class  I-restriction  associate  and 
stabilise  the  pre-assembled  MHC  class  I  loading  complex.  (d)  Fully  assembled 
mature MHC class I complexes, loaded with optimal peptides are delivered to the cell 
surface through the Golgi apparatus. 27 
 
where  the  catalytic  activity  occurs.  The  incorporation  of  these  subunits  alters  the 
cleavage  site  preference  of  the  proteasomes.  LMP7  has  been  shown  to  alter  the 
specificity  of  proteosomes  towards  cleaving  peptides  after  a  hydrophobic  or  basic 
residue; whereas LMP2 has a reduced rate of proteolytic activity after an acidic residue 
in a polypeptide chain (Gaczynska et al., 1994). LMP2/LMP7 containing proteosomes, 
also known as immunoproteasomes, preferentially produce peptides with a hydrophobic 
carboxyl-terminus which is an important anchor residue for binding to MHC class I 
molecules. LMP expression can be up-regulated by cell exposure to interferon-γ thus 
changing  the  proteasome’s  specificity  and  increasing  the  efficiency  of  CTL  epitope 
generation (Gaczynska et al., 1993). 
 
  TAP is a heterodimer of TAP1 and TAP2 transmembrane proteins, members of 
the ATP-binding cassette (ABC) transporter family.  As mentioned before, its role is to 
translocate peptides into the lumen of the ER for loading onto MHC class I molecules. 
However, the transport of peptides is not entirely a random process. The propensity of 
nonomer  peptides  to  bind  to  TAP,  and  thence  be  translocated  into  the  lumen,  is 
dependent on the first three N-terminal positions and the C-terminal residue (Uebel et 
al.,  1997).    Adopting  a  combinatorial  peptide  library  approach,  it  was  shown  that 
hydrophobic or charged residues at these terminal positions increased peptide binding 
affinity to TAP; and conversely acidic or proline residues  were detrimental to TAP 
binding (van Endert et al., 1995). The selectivity of TAP-mediated uptake of peptides 
therefore plays an important role in generation of CTL epitopes, whereby peptides with 
particular binding motifs are preferentially processed and presented on MHC class I 
molecules.   
 
   Traditionally, it was thought that the MHC class I antigen presentation pathway 
only  presented  endogenously  synthesised  proteins.  A  phenomenon  called  cross-
presentation by the professional antigen presenting cells, such as dendritic cells and 
macrophages,  has  recently  been  uncovered.  This  process  involves  the  uptake  of 
extracellular cell-associated antigens, via various endocytic mechanisms,  which then 
undergo processing into antigenic peptides and are presented on surface MHC class I 
molecules to induce antigen-specific CD8
+ T cell responses (Bevan, 2010; Rock and 
Shen, 2005; Villadangos et al., 2007). However, there is still an ongoing debate as to 28 
 
whether  this  alternate  MHC  class  I  antigen-presentation  pathway  shares  the  same 
processing machineries as the classical pathway. Burgdof et al argued that the cross-
presentation  of  exogenous  antigens  involved  the  assembly  of  peptide-MHC  class  I 
molecules within the early endosomal compartments instead of the ER (Burgdorf et al., 
2008).  Therefore,  the  relationship  between  cross-presentation  and  CTL  eptitope 
generation is still being resolved. 
 
1.2.3.  Antigen presentation by tumour cells 
The immune system is capable of generating anti-tumour T cell responses through the 
recognition of tumour-associated antigens. However, the cancer immune surveillance 
hypothesis  suggests  that  tumour  progression  is  often  accompanied  by  evasion  of 
immune detection. Down-regulation of total HLA class I surface expression or a single 
allelic variant are reported frequently in different malignancies; in one study 50% (n = 
118) of all prostate lesions analysed had low levels of HLA Class I expression (Chang 
et al., 2003).  
   
  Further investigation into the underlying molecular mechanisms of HLA class I 
down-regulation revealed heterogeneity across the tumours analysed. Down-regulation 
of TAP and LMP expression caused aberrant peptide generation and transportation into 
the  ER,  and  was  associated  with  low MHC  class  I  expression  in  human  renal  cell 
carcinomas  (Seliger  et  al.,  1996;  Johnsen  et  al.,  1998).  Analysis  carried  out  on  a 
metastatic melanoma sample uncovered deleterious mutations in the gene encoding the 
β2-microglobulin protein, which consequently prevented the proper folding of the MHC 
class I α-chain (Paschen et al., 2003). Abnormalities in the antigen presentation pathway 
in tumours could be a result of selective pressure exerted by the immune system leading 
to immune escape variants. 
 
1.2.4.  Tumour antigen discovery using reverse immunology 
‘Reverse immunology’ is a term for a systematic method towards the identification of 
CTL epitopes (Viatte et al., 2006). Different to conventional methods, it is not based on 
the natural immunity against undefined tumour-derived epitopes. Therefore, it does not 
have  the  prior  requirement  of  having  to  isolate  tumour-specific  CTL  clones  before 29 
 
screening  for  the  immunogenic  peptide  that  it  recognises.  Reverse  immunology  is 
separated into two phases: the prediction and validation phase. In the prediction phase 
potential TAAs are selected for, based on three main criteria: high expression in a wide 
range  of  cancer  types;  low  to  absent  expression  in  normal  tissues;  and  playing  an 
important role in tumour survival and in oncogenic processes. Potential CTL epitopes 
restricted to a specific MHC allele are then predicted using in silico tools, and validated 
experimentally.  
 
The validation phase looks at the immunogenicity of the predicted CTL epitopes 
in vitro by inducing antigen-specific CTL lines with peptide-pulsed professional antigen 
presenting cells. The resulting CTL lines undergo rigorous testing in target recognition 
assays, in order to demonstrate cytotoxicity against tumour cells in a peptide-specific 
and  MHC-restricted  fashion.  Examples  of  TAAs  identified  using  the  ‘reverse 
immunology’  approach  are  WT1  (Gao  et  al.,  2000),  hTERT  (Gao  et  al.,  2000; 
Vonderheide et al., 1999), Tie-2  (Ramage et al., 2006)  and survivin(Schmitz et al., 
2000). 
 
1.3.  T cells 
1.3.1.  T cell activation and differentiation 
T cells undergo maturation within the thymus and enter the circulatory system as naïve 
T cells. They recirculate between the blood and the secondary lymphoid tissues; such as 
the lymph nodes, spleen and Peyer’s patch where they may recognise specific antigens 
presented on professional antigen presenting cells (APC). A primary adaptive immune 
response  occurs  when  a  naïve  T  cell  becomes  activated  by  recognising  a  specific 
antigen presented on a self-MHC molecule via its T cell receptor (TCR) complex; and 
also receiving the appropriate co-stimulatory signals from the APC. TCR signalling and 
the essential co-stimulatory molecules will be discussed in the following section. 
 
  Activation  of  a  naïve  T  cell  (also  known  as  priming)  triggers  rapid  clonal 
expansion causing the stimulated cell to undergo multiple rounds of division for up to 
five days. The pattern of gene expression also changes simultaneously, for example, 
expression  levels  of  interleukin-2  (IL-2)  and  the  α-chain  of  IL-2  receptor  complex 30 
 
(CD25) increase dramatically. Originally called T cell growth factor, IL-2 signalling is 
essential for providing growth and survival signals to the proliferating cells. Activated 
naïve T cells then differentiate into effector T cells  which have specialised roles in 
eliminating antigens; naïve CD4
+ T cells  differentiate into T helper cells and naïve 
CD8
+  T cells into cytotoxic T lymphocytes.  After clearance of antigen the immune 
system enters a homeostasis phase, large clonal populations of antigen-specific effector 
T  cells  contract  in  size  through  apoptotic  cell  death.  A  population  of  long-living 
memory T cells remains; ready to initiate a rapid secondary adaptive immune response 
against the same antigen. 
 
  It was observed in earlier studies, that the priming of naïve CTL precursors in 
vivo required the help of CD4
+ T cell activity. Evidence came from in vivo CD8
+ T cell 
priming  models  using  the  male-specific  minor  histocompatibility  antigen  H-Y;  and 
cytotoxicity assay against antigen loaded stimulators were used to gauge the level of 
initial CD8
+ priming response. The depletion of T helper cells with anti-CD4 antibody 
had a negative impact on the level of CD8
+ priming response generated (Husmann and 
Bevan, 1988; Cassell and Forman, 1988). The association between the priming of naïve 
CTLs and necessary ‘help’ provided by  CD4
+ T cells have opened up new research 
efforts to resolve the underlying mechanisms. 
 
  Almost  a  decade  later,  the  role  of  antigen  presenting  cells,  and  especially 
dendritic cells, came to the forefront in understanding T cell activation. The role of APC 
in  delivering  CD4
+  T  cell  ‘help’  to  CD8
+  T  cell  priming  was  demonstrated  when 
ovalbumin-specific CTL response was only induced when CD4
+ helper T cells engaged 
with the same antigen presenting cells (Bennett et al., 1997). Figure 1.3 illustrates how 
CD4
+  T  cells  deliver  ‘help’  towards  the  generation  of  CTL  immunity,  through  the 
stimulation of CD40 on DCs which in turn increases their capacity to prime naïve CD8
+ 
T cells. CD40 signalling by antibody cross-linkage, on dendritic cells, was later shown 
to  provide  the  necessary  T  cell  help  for  CTL  priming  in  the  absence  of  CD40L 
expressing CD4
+ cells; and the blockade of CD40/CD40L interaction between T helper 
cells and DC abrogated CTL priming (Schoenberger et al., 1998; Ridge et al., 1998; 
Bennett et al., 1998a). ‘Licensed’ DCs activated by CD40 signalling have increased 
CD8
+ T cell stimulatory capacity; this could be attributed to the CD40-mediated up- 31 
 
 
 
 
 
 
 
 
 
 
Figure 3 Figure 1.3. CD4+ T cell-dependent dendritic cell licensing enables the priming of CTL responses 
 
 
 
 
 
 
Figure 1.3. CD4
+ T cell-dependent dendritic cell licensing enables the priming 
of CTL responses. (A) In the absence of CD4
+ T cell ‘help’, naïve CD8
+ T cells 
cannot be primed. (B) CD4
+ T cell recognition of antigen allows the stimulation of 
CD40 on the dendritic cell by CD40L on CD4
+  T  cell.  ‘Licensed’  DC  has 
increased  expression  of  costimulatory  molecules  (CD80,  CD86),  MHC  class  I 
molecules and secretion of interleukin-12. The increased stimulatory capacity of 
‘licensed’ DC enables the priming of naïve CD8
+ T cells. 
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regulation of T cell co-stimulatory molecules (CD80, CD86)  and MHC class I molecule 
expression on DCs, and the increased production of interleukin-12 (Koch et al., 1996; 
Cella et al., 1996). 
 
  Cytokines play a major role in regulating the expansion and differentiation of 
naïve T cells into effector and memory CD8 T cells. As mentioned before, IL-2 signals 
through the IL-2 receptor (IL-2R) complex comprising of α (CD25), β (CD122) and γ 
(CD132) chain subunits (Wang et al., 2005). Signal transduction is mediated by the β 
and γ chains (Smith, 1988). 
 
  IL-2/IL-2R  signalling  in  lymphocytes  results  in  the  activation  of  multiple 
downstream pathways: mitogen-activated protein kinase (MAPK), phosphatidylinositol 
3-kinase (PI3K)  and JAK/STAT (Janus Kinase, Signal Transducer and Activator of 
Transcription) pathways, providing both mitogenic signalling but also the induction of 
anti-apoptotic  signalling  via,  for  example,  B-cell  Leukemia-2  (Bcl-2)  expression 
(Lindemann et al., 2003). A range of other cytokine receptors also utilise the common γ 
chain subunit for ligand binding and signalling, these include: IL-7, IL-15 and IL-21 
receptors. They have overlapping and distinct functions to IL-2 signalling; without the 
mitogenic property of IL-2,  IL-7 and IL-15 were found to be important in promoting 
survival of naïve CD8
+ T cells and the generation, and maintenance of CD62L
+ memory 
T cells (Schluns et al., 2000; Berard et al., 2003; Tan et al., 2002). 
 
  IL-2 signalling also appears to have a negative-feedback regulatory role in T cell 
activation; the pre-treatment of activated CD8
+ TCR-transgenic T lymphocytes with IL-
2 sensitised the cells to apoptosis upon TCR cross-linking, a process coined activation-
induced  cell  death  (AICD)  (Lenardo,  1991;  Dai  et  al.,  1999).  Persistent  antigen 
challenge in chronic LCMV infection, in melanoma patients, or by repeated in vitro re-
stimulation of antigen-specific CTLs, often results in the induction of ‘exhausted’ T 
cells – prone  to AICD or to exist in a non-responsiveness state (Lee et al., 1999; Zajac 
et al., 1998). AICD is mediated by Fas (CD95) and Fas Ligand (CD95L) interaction 
resulting  in  the  activation  of  the  caspase  cascade  leading  to  the  apoptosis  of  T 
lymphocytes.  Programmed  death-1  (PD-1)  and  cytotoxic  T-lymphocyte  antigen-4 33 
 
(CTLA-4) mediated inhibition of T cell responses are currently being investigated in the 
context of exhausted T cell regulation. 
 
1.3.2.  T cell activation and B7 co-stimulatory molecules on APC 
  An immune synapse is illustrated in Figure 1.4, showing the molecules which 
play important roles in orchestrating the T cell/APC interaction and the regulation of T 
cell activation.  The two signal model is commonly used for  explaining  the optimal 
activation of naïve T cells. Signal one is provided by TCR complex interaction with a 
specific antigen presented on MHC class I or class II complexes. Signal two is provided 
by  co-stimulation  via  CD28  interaction  with  B7  co-stimulatory  molecules  (CD80, 
CD86)  on  APCs.  T  cell  responses  are  also  negatively  regulated  by  immune  co-
stimulatory  proteins  such  as  PD-1  and  CTLA-4,  which  play  important  roles  in  the 
establishment of peripheral tolerance (Zou and Chen, 2008). For some non-pathogenic 
adaptive immune responses, CD8
+ naïve T cell priming requires the prior modulation of 
DC  effector  function  via  CD40  signalling.  Without  the  appropriate  co-stimulatory 
signalling T cells may become anergic – a term to describe T cells becoming refractory 
to further stimulation.  
 
  CD80  and  CD86,  also  known  as  B7.1  and  B7.2  respectively,  are  type  I 
transmembrane  proteins  and  are  members  of  the  B7  family.  As  part  of  the 
immunoglobulin (Ig)-superfamily, they both contain two Ig-like domains (Acuto and 
Michel,  2003).  Cellular  distribution  is  restricted  to  haematopoietic  cells,  mainly 
professional  APCs  (pAPC),  which  are  up-regulated  upon  maturation  with microbial 
stimuli (Inaba et al., 1995; Inaba et al., 1994).  The kinetics of surface CD80 and CD86 
up-regulation was examined on lipopolysaccharide stimulated pAPC; CD86 expression 
was  detected after  6  hours  and  CD80  became  detectable  after  24  hours.  Moreover, 
quantitatively CD86 was constantly expressed at a higher level than CD80 (Hathcock et 
al., 1994). 
 
  The counter receptors for CD80 and CD86 are CD28, and CTLA-4. Engagement 
of CD80 and CD86 with CD28 has significant importance in T cell activation. Both 
ligands  can  augment  CD4
+  and  CD8
+  T  cell  responses  through  CD28  resulting  in 
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Figure  1.4.  Molecular  interactions  within  the  immune  synapse.  T  cell 
recognition occurs when the TCR of a T cell binds to a specific antigen presented on 
a surface MHC complex of an APC. T cell activation is modulated by a combination 
of immune co-stimulatory molecules. Interaction of CD80 and CD86 with CD28 on 
T cells provides a positive signal, however they are also ligands for CTLA-4 which 
negatively regulates T cell activation. B7-H1 and B7-DC expression on APC can 
inhibit T cell responses through PD-1 signalling. Immune responses can also be 
limited through the Fas/FasL-mediated induction of T cell or APC apoptosis. LFA3, 
ICAM1, CD2 and LFA1 are cell adhesion molecules which play an important role 
in the binding efficiency of APCs to T cells and the formation of immune synapses. 
CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed cell death 1; LFA1, 
lymphocyte function-associated antigen 1; LFA3, lymphocyte function-associated 
antigen 3; ICAM1, intercellular adhesion molecule 1. 35 
 
increased proliferation and cytokine production, such as IL-2, IFN-γ and IL-4 (McAdam 
et al., 1998). As mentioned in the previous section, AICD is often observed upon TCR 
cross-linking of pre-activated T cells; CD28 signalling can overcome AICD by up-
regulating the expression of pro-survival genes such as Bcl-X (Boise et al., 1995). CD28 
signalling is an area that has been studied intensively. Gene microarray studies have 
shown that it acts synergistically with TCR signalling, activating transcription factors 
such as nuclear factor-κB, NFAT (nuclear factor of activated T cells) and  activator 
protein 1 (AP1); and consequently increasing the expression levels of their target genes 
(Diehn et al., 2002; Kane et al., 2002; Rincon and Flavell, 1994). Naïve T cells are 
constantly ‘scanning’ antigen-MHC complexes on APCs that are often present at low 
amounts. The role of CD80/CD86 co-stimulation in naïve T cell priming is important 
when TCR signalling is low, and the CD28 interaction amplifies TCR signalling above 
the required threshold to enable activation and subsequent expansion.  
 
1.3.3.  Central tolerance and the T cell repertoire 
Each individual human expresses on their cells HLA molecules encoded by the two 
alleles  at  each  MHC  locus;  for  example  a  maximum  of  6  different  HLA  class  I 
molecules can be found in a heterozygous individual expressing different A, B and C 
alleles from each parent. When describing the MHC molecules that are expressed on the 
cells of an individual; these particular allelic variants will be referred to as self-MHCs, 
but only in the context of the same person’s immune system. When discussing MHC 
alleles  that  are  not  encoded  in the  genome  of  the  host,  they  will  be  referred to  as 
allogeneic (allo)-MHC molecules. The distinction between self-MHC and allo-MHC is 
essential to the understanding of central tolerance, MHC restriction and T cell-mediated 
alloreactivity. 
 
  T  cell  development  occurs  within  the  thymus  (reviewed  in  (Anderson  and 
Jenkinson, 2001)). The following paragraphs will discuss the functional importance of 
the thymus in shaping the mature naïve T cell repertoire. The T cell arm of adaptive 
immunity responds to antigen only when it’s presented by a  self-MHC molecule, a 
property called MHC-restriction. But cells are constantly degrading self-proteins and 
presenting  self-protein-derived  peptides  on  surface  MHC  complexes,  therefore  it  is 36 
 
important for  the immune system  to select for T cells that are  not reactive  to self-
antigens. 
 
  Self-MHC restriction arises from a process called positive selection and is an 
integral part of T cell development. T cell precursors (thymocytes) committed to the αβ 
lineage  must  initially  form  a  pre-TCR  complex  by  successfully  rearranging  and 
expressing  the  TCR  β-chain;  this  enables  it  to  progress  with  development  and 
proliferate. The rearrangement of TCR α-chain gene only occurs when the cells become 
CD4 and CD8, quiescent double positive  (DP) cells. Thymocytes expressing the αβ 
TCR-CD3 complex undergo positive selection; the process by which cells must engage 
and receive signalling from a self-MHC molecule in order to progress with development 
into single positive CD4
+ or CD8
+ thymocytes. The majority of DP cells die at this stage 
because they either fail to generate a functional TCR-chain or fail to bind self-MHC 
ligands. Positive selection results in a self-MHC restricted T cell repertoire.  
 
  Negative  selection  establishes  the  ‘central  tolerance’  to  self-antigens.  After 
positive thymic selection, double positive cells continue to interact with the thymic 
stromal  cells.  According  to  the  avidity  model  of  negative  selection,  thymocytes 
expressing  TCRs  with  high-affinity  for  self-peptide-MHC  ligands  undergo  death  by 
apoptosis.  Consequently,  mature  thymocytes,  expressing  a  spectrum  of  low-affinity 
TCR for self-peptides presented by self MHC molecules, migrate into the peripheral 
circulatory system as naïve T cells.   
 
1.4.  Antigen Presenting Cells 
1.4.1.  Antigen presenting cells (APC) and the immune system 
The  main  aims  of  the  work  described  in  this  thesis  involve  the  induction  of  CTL 
responses  against  specific  antigens  and  the  evaluation  of  the  immunogenicity  of 
TWIST1  protein  and  TWIST1  expressing  tumours.  TCR  recognition  of  antigens, 
presented in the context of MHC Class I molecules on antigen presenting cells triggers 
the effector functions of CTL, resulting in the death of target cells. Most cells, including 
tumour cells, are capable of presenting antigens. However, in order to mount a robust 
adaptive immune response in vivo, naïve T cells require activation and differentiation 37 
 
into effector and memory T cells by professional antigen presenting cells. The following 
sections describe the characteristics of professional APCs. 
 
1.4.2.  Dendritic cells 
The  term  ‘dendritic  cell’  (DC)  was  first  used  by  Steinman  and  Cohn  when  they 
discovered DCs present in small numbers in the adherent fraction of mouse splenocytes 
(Steinman and Cohn, 1973). Dendritic cells have since come to be recognised as a key 
professional  APC  capable  of  initiating  different  types  of  cell-mediated  responses 
depending  on  the  lineage,  maturation  status  and  activatory  signals  present  in  the 
microenvironment. Studies have also shown that under certain conditions DCs are able 
to induce T cell tolerance against ‘self-antigen’ thus providing a regulatory mechanism 
against autoimmunity (Steinman et al., 2003). Therefore, dendritic cells play a critical 
role in not only the triggering of an adaptive immune response, but also determining the 
type of response mounted by sensing the environmental cues. 
 
  Mouse dendritic cells are better characterised than human due to the readily 
available access to tissue  samples. Three main subsets  of mature conventional DCs 
(cDC)  are found  to be present  in the spleen distinguished by  their  CD4 and CD8α 
marker expression (Vremec et al., 2000). CD4
-CD8α
+ cells are localised in the T cell 
zones,  whereas  CD4
-CD8α
-  and  CD4
+CD8α
-  DC  subsets  are  found  in  the  marginal 
zones of the spleen. CD11b and DEC-205 markers can also be used to discern between 
CD8α
+ and CD8α
- groups; the former being CD11b
+ DEC-205
- and the latter CD11b
- 
DEC-205
+ (Vremec and Shortman, 1997).  A unique subset of immature DCs called 
interferon-α producing cells  (mIPC) was also described, characterised by  its plasma 
cell-like morphology but lacking B cell lineage markers, such as CD19 (Nakano et al., 
2001). They closely resemble human plasmacytoid DCs (pDC) in which they have a 
limited capacity to induce proliferation in an alloreactive T cell response compared to 
cDC. Moreover, mIPC produce high levels of type I interferon and IL-12 in response to 
viral stimuli (sselin-Paturel et al., 2001). 
 
  There is still ongoing debate on the developmental origin of the different DC 
subsets  described.  Historically,  DCs  have  been  broadly  divided  into  myeloid  or 
lymphoid  origin  but  studies  have  demonstrated  that  isolated  common  lymphoid 38 
 
precursors and common myeloid precursors can both give rise to all of the DC subsets 
(Wu  et  al.,  2001).  Cytokines  also  play  an  important  role  in  the  regulation  of  DC 
development. Granulocyte macrophage-colony stimulating factor (GM-CSF) promotes 
the development of cDC from early progenitors and monocytes; and FMS-like tyrosine 
kinase receptor -3 ligand (Flt3L) is responsible for the development of both cDC and 
pDC (O'Keeffe et al., 2002). Understanding the roles of cytokines in DC development 
has led to the development of an important in vitro culture technique, allowing the 
generation of large numbers of cDC-like cells with high T cell stimulation capacity 
(Inaba et al., 1992b). 
 
  Limited information about mature human DCs in vivo exists due to the restricted 
access to tissues other than blood, and most studies have relied on cytokine driven in 
vitro  culture  systems  of  DC  development.  Four  types  of  human  DCs  have  been 
described:  the  Langerhans  cells,  interstitial  DCs,  plasmacytoid  DCs  (pDC)  and 
monocyte-derived DCs (moDC).  Monocytes isolated from blood are the most readily 
available  source  of  precursor  cells  for  generating  DCs  in  vitro.  GM-CSF  and 
interleukin-4 (IL-4) drive the differentiation of immature DCs from blood monocytes 
which matures upon exposure to tumour necrosis factor-α (TNF-α) or microbial stimuli 
such  as  lipopolysaccharide  (LPS)  (Sallusto  and  Lanzavecchia,  1994;  Rissoan  et  al., 
1999; Hartmann et al., 1999). Direct comparison of human DCs to mouse DC subsets is 
difficult as human DCs do not express the CD8 marker and in vitro DC cultures may 
not be comparable to freshly isolated DCs from murine lymphoid tissues. Nevertheless, 
mature monocyte-derived DCs characterised by CD1
+ CD11c
+ CD11b
+ CD14
- MHC
High 
ICAM-1
+ and B7 have the exquisite capacity to stimulate T cells (Rissoan et al., 1999); 
and the use of moDCs has formed the basis of many DC-mediated  immunotherapy 
studies. 
 
1.4.3.  Maturation of dendritic cells 
Immature  dendritic  cells  are  able  to  capture  antigens  via  different  processes: 
endocytosis, pinocytosis and receptor-mediated internalisation, involving receptors such 
as  DC-SIGN  a  C-type  lectin  molecule  (Engering  et  al.,  2002).  Captured  antigens 
undergo processing and eventually presentation to T cells in the context of MHC Class I 
or  Class  II  complexes.  Trafficking  of  DCs  between  the  periphery  and  secondary 39 
 
lymphoid  tissues  allow  the  priming  of  T  cells  against  antigens  that  it  may  not 
necessarily encounter outside of lymphatic tissues. In vivo administration of LPS in 
mice induced migration of DCs towards the T cell area of the spleen which suggests 
maturation also regulates DC trafficking.  
 
  Immature DCs have limited capacity for T cell stimulation and in some cases 
were  found  to  be  tolerogenic  (Steinman  et  al.,  2003).  In  order  to  become  fully 
immunogenic, immature DCs have to undergo maturation (outlined in Figure 1.5); this 
process  switches  the  function  of  the  DC  from  one  which  captures  and  processes 
antigens (Immature DC) to one which is highly effective at inducing adaptive immune 
responses (Mature, licensed DC). Segregation of DC functions were demonstrated in 
early studies testing the ability of freshly isolated and cultured epidermal Langerhans 
cells (LC) to process and present intact antigens to myoglobin-specific T cell clones 
(Romani et al., 1989). The investigators formally proved that antigen processing and 
presentation  occurs  separately  and  prior  to  the  acquisition  of  T  cell  stimulation 
properties. 
 
   Regulation of DC maturation by exogenous stimuli was later examined in  in 
vitro culturing models of DC precursors. Studies have shown that maturation of DCs 
could  be  triggered  by  a  variety  of  stimuli  such  as  inflammatory  cytokine  TNF-α 
(Romani et al., 1989; Sallusto and Lanzavecchia, 1994); pathogen-associated molecular 
patterns (PAMPS) (for example microbial  product LPS and CpG oligonucleotides); and 
CD40L signalling from T helper cells. Depending on the activation signals from the 
environment,  DCs  adopt  different  effector  functions  thus  providing  a  crucial  link 
between innate and adaptive immune responses. 
   
  Phenotypically  matured  dendritic  cells,  as  briefly  mentioned  before,  are 
associated  with  the  up-regulation  of  surface  MHC  Class  II  molecules,  CD40,  B7 
molecules (CD80, CD83, and CD86) (Larsen et al., 1992), CCR7, DC-LAMP and IL-12 
secretion.  
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Figure 5 Figure 1.5. Maturation of dendritic cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Maturation of dendritic cells. It is unclear whether the process of 
antigen sampling and antigen processing is constitutive to immature DC. Studies 
performed  in  vitro  suggest  that  they  do  not  acquire the  abilities to  capture and 
process  antigens  before  receiving  a  maturation  signal.  However,  immature  DCs 
have shown to be able to induce T cell tolerance and it was argued that this process 
required the presentation of antigens to naïve T cells. Induction of maturation leads 
to an increase in capacity to prime CD4
+ T helper cells and a decrease in antigen 
acquisition  abilities.  Mature  DCs  have  increase  expression  of  co -stimulatory 
molecules and production of interleukin-12. Mature DC receives ‘licensing’ signals 
from activated CD4
+ T helper cells which allows for the priming of n aïve CD8
+ T 
cells.  
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1.4.4.  Toll-like receptors and dendritic cell subsets 
Toll-like  receptors  (TLR),  also  known  as  the  pattern-recognition  receptors,  are 
important sensors for the detection of invading pathogens. They are expressed on APCs 
such as macrophages and dendritic cells, and play an important role in the initiation of 
innate immunity, and the development of the appropriate adaptive immune  response. 
Members  of  the  TLR  family  recognise  different  ligands  called  pathogen-associated 
molecular  patterns  (PAMPS),  which  are  highly  conserved  molecules  derived  from 
microbes.  Originally  discovered  in  Drosophila  melanogaster,  the  TLR  family  has 
expanded to consist of 11 members found in human and mouse  (Rock et al., 1998; 
Takeuchi et al., 1999; Chuang and Ulevitch, 2001; Chuang and Ulevitch, 2000). TLR 
receptors function as heterodimers or homodimers; and each dimer pair have different 
ligand specificities (see Table 1.1 for a list of TLRs and their ligands). TLRs are mainly 
expressed on cell surfaces except TLR3, TL7 and TLR9 which are found localised 
intracellularly (Nishiya and Defranco, 2004). TLR1 to TLR9 are conserved between 
mouse  and  human,  TLR10  expression  has  only  been  detected  in  human,  while 
functional TLR11 protein is only found in mice (Yarovinsky et al., 2005). 
 
  Toll-like  receptor  4  (TLR4),  like  other  TLR  family  members,  is  a  type  I 
transmembrane  protein  that  contains  a  cytosolic  Toll-interleukin  1  receptor  (TIR) 
domain. TLR signalling in general requires the recruitment of TIR-containing adaptor 
proteins  to  propagate  downstream  signalling  cascades.  LPS,  found  in  the  outer 
membrane  of  gram-negative  bacteria is one  of the ligands  that  bind  to TLR4.  LPS 
activation of TLR4 is a multistep process which begins with the formation of complexes 
with  LPS-binding  protein  (LBS)  in  the  serum  and  then  binds  to  CD14,  a 
glycosylphosphatidylinositol-linked protein, found on most immune cells of myeloid 
origin (Jiang et al., 2000; Wright et al., 1990). MD-2 was also found to be an important 
co-receptor  of  LPS-recognition  by  regulating  the  intracellular  distribution  of  TLR4 
protein (Nagai et al., 2002). LPS/LBS/CD14 associates with MD-2/TLR4 homodimer 
and  triggers  downstream  signalling.  LPS-mediated  TLR4  activation  induces  both 
MyD88-dependent  and  MyD88-independent  pathway  triggering  the  expression  of 
inflammatory  cytokines  or  type  I  interferon  respectively,  and  both  have  important 
functions in the initiation of adaptive immune responses (Kagan et al., 2008). 
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Table  1.1 Toll-like receptors and their ligand specificities
 
 
Receptor pair  Cellular location  Ligand(s)  Reference 
TLR1/TLR2  Cell surface  Triacyl LP (Pam3CSK4)  (Akira, 2003) 
TLR2/TLR6  Cell surface  Zymosan, diacyl LP (MALP-2)  (Akira, 2003) 
TLR3/TLR3  Intracellular  double-stranded RNA, poly(I:C)  (Akira, 2003) 
TLR4/TLR4  Cell surface  LPS,  HSPs,  fibrinogen,  heparan 
sulfate fragments  (Akira, 2003) 
TLR5/TLR?  Cell surface  Flagellin  (Akira, 2003) 
TLR7/TLR7  Intracellular  Single-stranded RNA  (Akira, 2003) 
TLR8/TLR8  Intracellular  Single-stranded RNA  (Akira, 2003) 
TLR9/TLR9  Intracellular  Unmethylated CpG DNA  (Akira, 2003) 
TLR10/TLRx 
(human only)  Cell surface  unknown  (Hasan  et  al., 
2005) 
TLR11/TLR11 
(mouse only)  Cell surface  Profilin-like protein  (Yarovinsky  et 
al., 2005) 
 
   
 
Table 1 Table 1.1 Toll-like receptors and their ligand specificities  
  Toll-like  receptor  9  (TLR9)  binds  to  unmethylated  CpG  oligodinucleotides 
(CpG  ODN)  which  are  found  in  both  bacterial  genomic  DNA  and  viral  DNA. 
Recognition of murine cytomegalovirus (MCMV) via TLR9 induced the production of 
type  I  IFN  and  IL-12  promoting  NK  cell-mediated  anti-viral  response  (Krug  et  al., 
2004). In contrast to TLR4 which is expressed on the cell surface, TLR9 expression is 
distributed to the endoplasmic reticulum (ER), the endosomes and lysosomes. Studies 
have  shown  that  trafficking  of  CpG  DNA  to  the  endosomal  compartments  via 
endocytosis  coincides  with  co-localisation  of  TLR9  resulting  in  MyD88-dependent 
signalling (Latz et al., 2004).  
 
Abbreviation:  LP,  lipoprotein;  MALP,  macrophage-activating  lipoprotein;  LPS, 
lipopolysaccharide;  HSP,  heat  shock  protein;  poly(I:C),  polyinosinic:  polycytidylic 
acid; CpG, cytosine-phosphatidyl-guanine. 43 
 
  Different subsets of dendritic cells have distinct TLR expression profiles and 
there  are  differences  between  human  and  mouse.  In  human  DCs,  freshly  isolated 
myeloid  DCs  from  PBMC  express  TLR1,  TLR2,  TLR3,  TLR5,  TLR6,  TLR7  and 
TLR8; and pDC expresses TLR7 and TLR9 (Jarrossay et al., 2001; Kadowaki et al., 
2001). In mouse, splenic DC subsets express TLR1 to TLR9, except for TLR 3 which is 
absent on CD4
+ subset; TLR5 and TLR7 are absent from the CD8
+ splenic DC subset 
(Iwasaki  and  Medzhitov,  2004).  DCs  generated  from  in  vitro  culturing  of  early 
progenitors,  such  as  human  monocytes  and  murine  bone-marrow  cells  yield  DCs 
expressing high levels of TLR4 that are highly responsive to LPS stimulation; this is in 
contrast  to  freshly  isolated  DCs.  The  distinct  TLR  expression  patterns  found  on 
different  DC  subsets  reflect  their  role  in  regulating  innate  and  adaptive  immune 
responses to pathogens. 
 
1.5.  Cancer Immunotherapy 
 
An overview of basic tumour immunology, antigen presentation and T cell biology was 
given  in  the  previous  sections.  The  expansion  of  knowledge  in  these  fields  has 
generated a great deal of effort to translate research into the clinics. By understanding 
the mechanisms underpinning immunosurveillance and tumour escape; one would hope 
to  exploit  the  former,  for  example,  inducing  an  effective  tumour-killing  immune 
response  whilst  devising  immunotherapy  strategies  to  counteract  the  latter.  In  the 
subsequent  sections  the  following  will  be  reviewed:  different  forms  of  cancer 
immunotherapy  treatments,  the  potential  of  targeting  TWIST1  in  a  cancer 
immunotherapy setting, and the clinical implications.  
 
1.5.1.  Adoptive T cell transfer therapy 
Adoptive T cell transfer therapy (ACT) is one of the promising approaches in cancer 
immunotherapy that is currently under clinical investigation. This strategy involves the 
ex  vivo  expansion  of  autologous  or  allogeneic  T  lymphocytes  with  anti-tumour 
specificity; followed by the infusion of expanded cells into cancer patients for treatment 
(the ACT process is outlined in Figure 1.6). The mode of action is achieved through 
cytotoxic effector function by the infused tumour-reactive lymphocytes. ACT treatment 44 
 
with donor lymphocyte infusion after allogeneic stem cell transplantation in leukaemia 
patients with refractory disease, is one of the few proven immunotherapeutic strategies 
against malignancies of non-viral origin (Peggs and Mackinnon, 2001). Encouraging 
data were reported from trials using the ACT approach in solid tumours. A group of 
patients  with  metastatic  melanoma  were  treated  with  autologous  tumour-infiltrating 
lymphocytes  (TIL),  expanded  ex  vivo  and  infused  back  into  the  original  patient. 
Objective clinical responses were achieved by 51% of the patient group (Dudley et al., 
2005; Dudley et al., 2002).  As discussed in earlier sections, longitudinal studies of 
cancer patients with TILs were often associated with better prognosis. However, TILs 
isolated  from  patients  often  lacked  proliferative  and  cytotoxicity  capacity  which 
hampers clinical efficacy when used as an ACT (Mulder et al., 1995). Tumours can also 
be  infiltrated  by  T  regulatory  (Treg)  cells,  which  are  characterised  by  CD25
+  and 
forkhead  box  P3  (FOXP3)  expression.  Due  to  the  immunosuppressive  functions  of 
Tregs, it has been postulated that tumour-infiltrating Tregs are associated with poorer 
prognosis; and indeed this was found to be the case in non-small-cell lung (Petersen et 
al., 2006) and ovarian carcinoma patients (Curiel et al., 2004). Nevertheless, the general 
prognostic  value  of  TILs  in  different  cancer  settings  are  still  being  debated  since 
tumours cells may interact differently with the host immune system.  
 
  The clinical implications of using gene-modified lymphocytes in ACT treatment 
of  tumours  are  also  being  evaluated.  Studies  have  shown  that  the  specificity  of 
lymphocytes  can  be  manipulated  by  the  introduction  of  genes  encoding  for  tumour 
antigen specific-TCRs using retroviral or lentiviral vectors (Zhao et al., 2005). Tumour-
specific TCRs can be transferred into naïve T cells, which are readily available from the 
patient’s blood compared to TILs. It also avoids the need to isolate and expand tumour-
reactive T cells from cancer patients, using in vitro culturing systems, which is both 
technically challenging and resource intensive.   
 
  Genetic modification of T cells enables the targeting of multiple tumour antigens 
expressed  on  the  tumour  cells  of  patients  –  a  form  of  personalised  cancer 
immunotherapy whereby targeting the right combination of TAAs could minimise the 
chance of tumour escape and relapse. Therefore, increasing the arsenal of TAA-specific 
T cell receptors available could benefit adoptive T cell therapy treatments. 45 
 
Figure 6 Figure 1.6. Adoptive cell therapy for cancer patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Adoptive cell therapy for cancer patients. (A) Tumour-reactive T 
lymphocytes can be generated ex vivo from the peripheral blood of cancer patients 
and/or healthy donors, and from excised tumours using various in vitro stimulation 
methods  (high  dose  IL-2,  co-culturing  with  APC)  (B)  Specificity  and  effector 
function of T cell cultures are characterised (C) High avidity, tumour-reactive T 
cell cultures,  with  or  without  T  cell cloning,  are  expanded  rapidly  (D)  Patient 
receives  non-myeloablative  but  lymphodepleting  chemotherapy  followed  by 
infusion  of  expanded  autologous  or  allogeneic  tumour-reactive  T  lymphocytes. 
Figure adapted from Dudley, et al. 2003. 
(A) In vitro stimulation of T cells
Peripheral blood 
/ excised tumour 
Expansion of TILs 
with high dose IL-2
Stimulate T cells with 
antigen-presenting cells
(B) Selection of tumour-reactive T cell cultures
• cytotoxicity
• peptide/MHC multimer staining
• cytokine release profiling
(C) T cell cloning and rapid expansion
(D) Systemic immunosuppression
and adoptive transfer of anti-tumour 
lymphocytes
Cancer patient/ 
Healthy donor 
Cancer patient 46 
 
1.5.2.  Dendritic cell cancer vaccines 
The aim of DC cancer vaccines is to stimulate the adaptive immune system to mount a 
tumour-specific  response  in  order  to  cause  tumour  regression  or  to  prevent  cancer 
patients  from  relapsing.  DC  cancer  vaccines  use  matured  dendritic  cells  to  present 
tumour-associated antigens, such as melanocyte antigen gp100, on its surface. When 
administered,  dendritic  cells  will  activate  antigen-specific  T  cells,  triggering  their 
differentiation into cytotoxic T effector cells, which in turn recognise and destroy TAA-
expressing tumour cells. 
 
  As mentioned previously (section 1.4.2), in vitro cultured matured dendritic cells 
are potent stimulators of adaptive T cell responses. A lot of translational work has gone 
into optimising the DC vaccination protocol towards generating an effective anti-tumour 
T  cell  response.  A  multitude  of  parameters  have  been  examined,  for  example:  DC 
maturation conditions (Dhodapkar et al., 2001); loading of DCs with different TAAs 
specific for the cancer of interest; using various sources of antigen, such as autologous 
tumour lysates, synthetic peptides and endogenous antigen protein expression by APCs 
using  gene  transfer  technology  (Lopes  et  al.,  2008).  A  early  phase  I  trial  using 
autologous  monocyte-dervied  DCs  pulsed  with  a  mixture  of  melanoma-associated 
peptides as a cancer vaccine, demonstrated an increase in TAA-specific CD8
+ T cells in 
13  out  of  20  patients  treated  (Bedrosian  et  al.,  2003).  Comparison  of  different  DC 
maturation factors and their impact on generating anti-tumour immunity in vivo were 
also  conducted  (Brunner  et  al.,  2000).  Cytidine-Phosphate-Guanosine,  or  CpG, 
containing oligonucleotide (ODN-1826) treatment of immature DCs resulted in greater 
interleukin-12  secretion,  consistent  with  previous  findings  of  TLR9  function,  and 
provided effective protection against tumour challenge in vivo.  
 
1.5.3.  Evaluating TWIST1 as an immunotherapeutic target 
Evaluating  new  tumour-associated  antigens  is  still  cruical  to  developing  novel 
immunotherapy treatments, especially for tumour types other than melanoma. Here we 
consider the transcription factor TWIST1 as a potential immunotherapeutic target.  
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  TWIST1 is a 202 amino acid protein belonging to the basic helix-loop-helix 
(bHLH) transcription factor family (Wang et al., 1997). The evolutionarily conserved 
bHLH motif comprises of a short region of basic residues followed by an amphiphatic 
helix, then a connecting loop and then another α-helix. The motif enables TWIST1 to 
interact  with  other  bHLH  transcription  factors  allowing  the  formation  of  homo-  or 
hetero-dimers. The result of dimerisation of two bHLH factors is the juxtaposition of the 
two basic regions forming a combined DNA-binding domain that recognises regulatory 
elements containing a consensus sequence, called E-Box (5’-NCANNTGN-3’). Other 
features of TWIST1 include a glycine-rich region located in the N-terminus; and the C-
terminus containing a 20 amino acids long domain called the Twist box (Bialek et al., 
2004). The latter motif was found to inhibit the function of runt-related transcription 
factor 2 (Runx2), a master regulator of osteogenesis, by binding and blocking its DNA-
binding domain (Bialek et al., 2004). 
 
  bHLH  transcription  factors  can  be  catergorised  into  3  main  classes:  the 
ubiquitously  expressed  (Class  A),  which  includes  the  products  of  E2A  genes  also 
known as the E-proteins; the tissue-restricted (Class B), which includes Twist1; finally 
the inhibitory bHLH factors, which comprises of the Id proteins (Franco et al., 2011; 
Connerney et al., 2006). TWIST1 function is essential to a range of developmental 
processes; such as the regulation of mesodermal formation and neural crest migration 
during embryogenesis (Chen and Behringer, 1995); also the regulation of osteoblast 
differentiation  during  bone  formation  and  myogenesis  (Firulli  and  Conway,  2008; 
Bialek et al., 2004). Its apparent diverse functionality is due to its ability to act as either 
an activator or inhibitor of gene transcription. Its regulatory activity was found to be 
dependent on its choice of bHLH binding partner and also the cellular concentration of 
the  dimeric  complexes  (Connerney  et  al.,  2006;  Firulli  and  Conway,  2008).  In  the 
context  of  osteoblast  differentiation,  Twist1/E-protein  heterodimers  inhibit  the 
expression of fibroblast growth factor receptor 2 (Fgfr2) and Runx2, which keeps the 
cells in a preosteoblast state. In contrast, Twist1 homodimers promotes the maturation 
of osteoblasts by up-regulating Fgfr2 and Runx2 expression at a transcriptional level.  
 
  Mutations in TWIST1 have been found to be associated with Saethre-Chotzen 
syndrome  (SCS),  an  autosomal  dominant  form  of  craniosynostosis  (Howard  et  al., 48 
 
1997). A large number of TWIST1 mutations have been identified in SCS patients to 
date (Gripp et al., 2000; El, V et al., 2000; El, V et al., 1999; Howard et al., 1997); these 
include  nonsense  mutations  found  located  5’  of  the  DNA-binding  domain  and 
throughout  the  bHLH  motif  resulting  in  premature  protein  termination.  Missense, 
insertion and deletion mutations were also found throughout the bHLH motif (Gripp et 
al., 2000). The lack of a mutation hotspot, and a clear correlation between genotype and 
phenotype, suggests that the main underlying molecular mechanism of SCS is caused by 
haploinsufficiency for the functional TWIST1 protein (Howard et al., 1997; El, V et al., 
2000).  
 
  The role of TWIST1 overexpression has also been implicated in the oncogenic 
processes of a variety of cancers. A study suggested TWIST1 interferes with the pro-
apoptotic  pathway  by  inhibition  of  the  ADP  ribosylation  factor/  p53  pathway, 
promoting  the  survival  of  cells  whilst  MYCN  oncogene  drives  the  uncontrolled 
proliferation of malignant cells in neuroblastoma (Puisieux et al., 2006). Recent focus 
on TWIST1 has identified it as a regulator of miR-10b a microRNA that is involved in a 
novel pathway mediating metastasis in breast cancer (Ma et al., 2007). Studies have also 
implicated  the  inverse  relationship  of  TWIST  and  E-cadherin  expression;  the 
overexpression  of  TWIST1  was  associated  with  increased  metastatic  potential  and 
invasiveness in breast and liver cancer (Cheng et al., 2008; Yang et al., 2004; Lo et al., 
2007; Lee et al., 2006). Elevated TWIST1 expression has also been reported in wide 
range  of  cancer  types  including  neuroblastoma  (Puisieux  et  al.,  2006),  paediatric 
osteosarcoma(Man et al., 2005), prostate cancer (Yuen et al., 2007), metastatic breast 
carcinoma(Ma et al., 2007) and rhabdomyosarcoma(Maestro et al., 1999).  High levels 
of relative TWIST1 mRNA expression were found in placenta tissue and low expression 
levels in the skeletal muscle and heart  (Wang et al., 1997).  Taking it all together, 
TWIST1 seems to fit the expression profiles of an overexpressed tumour antigen which 
also plays an important role in tumour survival and metastasis. The shared expression of 
TWIST1 in a range of cancer types also adds to its attractiveness as a target for cancer 
immunotherapy. 
 
  Using a 4T1 syngeneic metastatic breast cancer model; Demaria et al. has shown 
that  localised  radiation  treatment  of  primary  tumour,  together  with  anti-CTLA-4 49 
 
antibody mediated- blockade (a T cell inhibitory molecule), generated an anti-tumour 
response that recognises the peptide pTw9, a CTL epitope derived from Twist (Demaria 
et al., 2007). This study provides the rationale for exploring the potential of targeting 
TWIST1 expressing metastatic tumours by immunotherapy as an adjuvant treatment. 
No known studies to date have examined the immunogenicity of TWIST1 in humans; 
nor examined cancer patients with  TWIST1-expressing tumours for  the presence of 
TWIST1-derived antigen specific T cells. This represents an opportunity to determine 
whether TWIST1 is a novel tumour-associated antigen in human cancers.   
 
1.6.  Project Aims 
 
The aim of the project is to investigate the immunotherapeutic potential of TWIST1 as a 
tumour-associated antigen target. This involves:  
 
1) Characterisation of TWIST1 expression profiles in representative cancer cell lines 
and in healthy tissues of different anatomical sites will enable the initial assessment of 
the  types  of  cancers  that  can  be  potentially  targeted,  and  the  likelihood  of  causing 
autoimmunity against normal tissues.  
 
2)  Investigation  of  the  immunogenicity  of  TWIST1  by  identifying  putative  CTL 
epitopes via a systematic ‘Reverse Immunology’ approach. This involves screening for 
immunogenic  peptide  sequences  in  silico;  experimental  validation  of  the  predicted 
peptides binding to their corresponding MHC class I molecules; and the induction of 
peptide-specific CTLs to demonstrate immunogenicity of the peptides. 
 
3) Examination of the natural presentation of predicted peptides complexed with MHC 
class I molecules on the cell surface of TWIST1
+ target cells utilising TWIST1-peptide 
specific T cells generated above. 
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2.1.  Reagents and Buffer 
2.1.1.  Reagents 
Chemicals and GIBCO® cell culture products were purchased from VWR, UK and 
Invitrogen, Paisley, UK respectively unless stated otherwise. Restriction enzymes were 
purchased  from  Promega,  USA  unless  stated  otherwise.  Oligonucleotides  were 
synthesised  and  purchased  from  Sigma-Genosys  Ltd,  Suffolk,  UK.  Recombinant 
cytokines were purchased from Peprotech EC, London, UK 
 
2.1.2.  Cell Lines 
CLB-Bou-LT, CLB-Pec and CLB-Bab (neuroblastoma) cells were kindly provided by 
Dr. S. Wittmann (Lyon, France); the cells require co-culturing with irradiated (40Gy) 
MRC5 cells. T2 cells (TAP deficient and HLA-A0201
+); SKNAS, SK-N-Mc, SH-SY5Y 
and  LAN1  (neuroblastoma);  HEK  293FT  clonal  isolate  derived  from  transformed 
embryonal  kidney  cells  (Invitrogen);  293T  (transformed  human  embryonic  kidney); 
SW620,  SW480  (gastric  carcinoma);  RDES,  TC32  (Ewing’s  sarcoma);  Saos2 
(osteosarcoma);  RH1,  RH30  (rhabdomyosarcoma);  ZR-75-1,  MCF7,  MBA-MD-231 
(breast carcinoma) were all from American Type Culture Collection (ATCC). RH18 
(rhabdomyosarcoma)  were  originally  from  Peter  Houghton  (St.  Jude  Children's 
Research Hospital, Memphis, TN). NALM27, NALM6M, NALM6Ja (leukaemia) were 
originally  from  Dr.  Akira  Harashima  (Fujisaki  Cell  Center,  Okayama,  Japan).  SH-
SY5Y-A2 and LAN1A2 cells derived from the stable transfection of parental cells with 
HLA-A*0201  were  kindly  provided  by  Dr.  Liquan  Gao  (UCL,  London,  UK).  BC7 
EBV-transformed  lymphoblastoid  cell  line  (BC7-LCL;  HLA-A0201
+)  were  kindly 
provided by Dr. Mengyong Yan (Institute of Child Health, London, UK). A549, A459 
(lung carcinoma); MEL15 (melanoma); MKN45 (stomach adenocarcinoma); BXPC3 
(pancreatic  carcinoma);  EL4  (mouse  lymphoma),  EL4-A2  (stably  expressing  HLA-
A0201
+), and tCD40L (murine  L fibroblasts stably transfected with human CD40L) 
were originally from Dr. John Anderson (Institute of Child Health, London, UK). Cell 
lines were maintained in Roswell Park Memorial Institute 1640 (RPMI 1640) medium 
or  Dulbecco’s  Modified  Eagle’s  medium  (DMEM)  supplemented  with  10%  heat-
inactivated foetal calf serum (FCS, Sigma-Aldrich), 50 units/ml penicillin/streptomycin 
(Gibco) and 2mM L-glutamine (Gibco). 52 
 
2.1.3.  Buffers and solutions 
Table 2.1 Buffers and solutions 
Buffer or solution  Components 
Luria-Bertani (LB) 
broth  1% tryptone, 0.5% yeast extract, 1% NaCl (pH 7.0) 
LB agar  LB broth plus 15 g/litre of agarose 
FACS buffer  Phosphate  buffered  saline  (PBS)  (Invitrogen)  containing  0.1% 
bovine serum albumin (BSA) and 0.1% sodium azide 
RBC lysis buffer  10mM KHCO3, 150mM NH4Cl and 0.1mM EDTA pH 8 
4 x PFA  4% paraformaldehyde in PBS 
Permeabilisation 
buffer 
0.1% saponin (Sigma), 1% fetal calf serum, 0.1% sodium azide 
in PBS 
5x Laemmli sample 
buffer (LSB) 
60mM Tris-HCl pH 6.8, 2% sodium dodecyle sulphate (SDS), 
10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue 
TBS  20mM Tris-HCl pH 7.5, 150 mM NaCl 
TBS-T  20mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20 
Running Buffer  25 mM Tris-HCL pH 7.5, 192 mM Glycine, 0.1% SDS 
Transfer Buffer  25 mM Tris-HCL pH 8.3, 192 Glycine, 20% methanol 
 
Table 2 Table 2.1 Buffers and solutions 
2.1.4.  Antibodies and pentamer staining 
Cells were stained with monoclonal antibodies conjugated to fluorescein isothiocyanate 
(FITC),  phycoerythrin  (PE)  or  allophycocyanin  (APC),  unless  stated  otherwise  (see 
Table  2.2).  Cells  were  incubated  with  100µl  of  diluted  fluorochrome-conjugated 
primary antibody in FACS buffer (see Table 2.1). Mouse cells were pre-incubated with 
0.5µg of purified anti-mouse CD16/CD32 (eBioscience), clone 93, for 10 minutes at 
4
oC.  Flow cytometry was performed using a CyAn  ADP flow cytometer (Beckman 
Coulter) and data was analysed using Summit version 4.3 software (Dako). 
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Table 2.2 Antibodies used for flow cytometry 
Name  Reactivity  Manufacturer  clone  Isotype  Working 
Dilution 
Anti-HLA-A2-FITC  Human  BD Pharmingen  BB7.2  Ms IgG2b, κ  1:100 
Anti-HLA-DR-FITC  Human  BD Pharmingen  L243  Ms IgG2a, κ  20µl/test 
Anti-CD3-APC  Human  Immunotools  UCHT-1  Ms IgG1, κ  1:10 
Anti-CD8-FITC  Human  Dako  DK25  Ms IgG1, κ  10µl/test 
Anti-CD11c-PE  Human  BD Pharmingen  B-ly6  Ms IgG1, κ  20µl/test 
Anti-CD14-FITC  Human  BD Pharmingen  M5E2  Ms IgG2a, κ  20µl/test 
Anti-CD19-APC  Human  BD Pharmingen  HIB19  Ms IgG1, κ  20µl/test 
Anti-CD80-PE  Human  BD Pharmingen  L307.4  Ms IgG1, κ  20µl/test 
Anti-CD86-FITC  Human  BD Pharmingen  2331  Ms IgG1, κ  20µl/test 
Anti-CD3-PE  Mouse  eBioscience  145-2C11  ArmH IgG  1:100 
Anti-CD4-FITC  Mouse  Caltag Laboratories  CT-CD4  Rat IgG2a  1:100 
Anti-CD8a-FITC  Mouse  Caltag Laboratories  5H10  Rat IgG2b  1:100 
Anti-CD8a-APC  Mouse  eBioscience  53-6.7  Rat IgG2a  1:100 
Anti-CD11c-PE  Mouse  eBioscience  N418  ArmH IgG  1:100 
Anti-CD80-PE  Mouse  eBioscience  16-10A1  ArmH IgG  1:100 
Anti-CD86-APC  Mouse  eBioscience  GL1  Rat IgG2a  1:100 
Anti-MHC class II (I-A/I-E)-PE  Mouse  eBioscience  M5/114.15.2  Rat IgG2b  1:100 
Biotinylated Anti-IFNγ  Mouse  BD Pharmingen  R4-6A2  Rat IgG1  1:100 
Streptavidin-PE  -  eBioscience  -  Streptavidin  1:100 
Biotinylated Rat IgG1  -  BD Pharmingen  R3-34  Rat IgG1  1:100 
PE Mouse IgG1, κ Isotype  -  BD Pharmingen  MOPC-21  Ms IgG1, κ  20µl/test 
FITC Mouse IgG2a, κ Isotype  -  BD Pharmingen  G155-178  Ms IgG2a, κ  20µl/test 
FITC Mouse IgG2b, κ Isotype  -  BD Pharmingen  27-35  Ms IgG2b, κ  1:100 
FITC Mouse IgG1, κ Isotype  -  BD Pharmingen  MOPC-21  Ms IgG1, κ  20µl/test 
PE Armenian Hamster IgG Isotype  -  eBioscience  eBio299Arm  Arm IgG  1:100 
APC Rat IgG2a Isotype  -  eBioscience  -  Rat IgG2a  1:100 
PE Rat IgG2b Isotype  -  eBioscience  -  Rat IgG2b  1:100 
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  Antigen-specific  T  cells  were  stained  with  PE-conjugated-  or  biotinylated- 
Pro5® MHC class I pentamers (Proimmune, Oxford, UK) and the latter was visualised 
with streptavidin-PE diluted in FACS buffer. The following pentamers with different 
peptide/MHC  class  I  combinations  were  purchased:  KLAARYIDFL/HLA-A*0201, 
SLNEAFAAL/HLA-A*0201,  SLLMWITQV/HLA-A*0201,  GILGFVFTL/HLA-
A*0201 and VILKKATEYV/HLA-A*0201. The peptide sequences will be referred to 
by their names listed in Table 2.3.  
 
2.2.  General Molecular Biology Techniques 
2.2.1.  Isolation of total RNA 
Cell lines were grown to approximately 80% confluency before harvesting. Total RNA 
was isolated using TRIzol Reagent (Invitrogen) following the manufacturer’s protocol. 
Briefly, 5-10 x10
6 cells were pelleted and lysed in 1 ml of TRIzol reagent by incubating 
for 5 minutes at room temperature (RT). 200 µl of chloroform was added to every 1ml 
of TRIzol used, mixed vigorously and centrifuged at 12,000 x g for 15 minutes at 4
oC. 
Upper layer was transferred to a new tube and the RNA was precipitated with 0.5ml of 
isopropanol by incubating for 10 minutes at RT. Precipitated RNA was pelleted and 
washed in 1ml of 75% ethanol by vortexing, and centrifuged again at 7,500 xg for 5 
minutes  at  4
oC.  RNA  pellet  was  vacuum-dried  before  dissolving  in  diethyl 
pyrocarbonate (DEPC)-treated water. RNA concentration and purity was determined 
using the NanoDrop 1000 Spectrophotometer (Thermo Scientific). 
 
2.2.2.  First strand cDNA synthesis 
First  strand  cDNA  synthesis  was  carried  out  using  SuperScript
TM  II  Reverse 
Transcriptase  (Invitrogen).  Briefly,  2  µg  of  RNA  was  mixed  together  with  1  µl  of 
10mM  deoxynucleotide  triphosphate  (dNTPs)  mix  (Promega)  and  50  ng  of 
hexanucleotide primers (Sigma), and was heated to 65
oC for 5 minutes. Reaction was 
then carried out in a final volume of 20 µl containing 1X First-Strand Buffer, 10mM of 
dithiothreitol (DTT), 40 units of RNaseOUT and 200 units of reverse transcriptase (all 
from Invitrogen). Reaction tube was incubated at 25
oC for 10 minutes, followed by 
42
oC for 50 minutes and finally 70
oC for 15 minutes. cDNA was stored at -20
oC until 
used. 55 
 
2.2.3.  Polymerase Chain Reaction (PCR) 
PCR was used to generate various TWIST1 cDNA fragments incorporating nucleotide 
sequences encoding for the FLAG-tag epitope and flanking restriction enzyme sites to 
the cDNA inserts, prior to subcloning into vectors. PCR was carried out using reagents 
from GoTaq® DNA Polymerase (Promega) unless stated otherwise. 50 µl PCR reaction 
volume were used containing 1X Colourless GoTaq® Reaction buffer, 0.2mM of each 
dNTP (Promega), 0.5 µM of each primer, 0.5 µg of template DNA and 1.25 units of 
GoTaq® DNA polymerase. Standard thermal cycling conditions used were 1X (95
oC 2 
minutes); 30X (95
oC 1 minute, 48-60
oC 30 seconds, 72 
oC 1 minute); 1X (72
oC 5 
minutes). Annealing temperatures of 5
oC below the lowest melting temperature of the 
primer pairs were used. 
 
2.2.4.  Liposome-mediated transient transfection of 293T cells 
pCI-neo mammalian expression vector encoding the TWIST1 cDNA (pCI-neo-TWIST1) 
and the vector backbone plasmid (pCI-neo) were kindly provided by Dr. S. Wittmann 
from  Centre  Léon  Bérard  (Lyon,  France).  Transfections  were  carried  out  using 
Lipofectamine
TM 2000 (Invitrogen) according to manufacturer’s protocol. Briefly, 293T 
cells were seeded at a cell density of 5 x 10
5 cells/well in a 6-well plate in its growth 
medium without antibiotics added and incubated for 18 hours. Optimised transfection 
condition used was 6 µg of plasmid DNA and 10 µl of Lipofectamine
TM 2000 reagent. 
0.6 µg of pmaxGFP® vector was was used with pCI-neo-TWIST1 and pCI-neo vectors 
to monitor the transfection efficiencies between experiments. DNA/ Lipofectamine
TM 
2000 mix was incubated at room temperature for 20 minutes before adding 500 µl of the 
mix to each well containing the adhered 293T cells. Medium was replaced with 3 mls of 
fresh growth medium after 18 hours. Cells were harvested by trypsinisation after 48 
hours and washed twice with PBS for further downstream analysis or use in chromium-
51 cytotoxicity assay. 
 
2.2.5.  Transformation of E.coli 
100 µl of XL1-Blue competent cells (Stratagene) was used per transformation and was 
incubated with 1.7 µl of β-mercaptoethanol on ice, for 10 minutes before use. 10 ng of 
plasmid  DNA  or  2  µl  of  ligation  reaction  was  added  to  the  competent  cells  and 56 
 
incubated on ice for 30 minutes. Cells were heat-pulsed at 42
oC for 45 seconds in a 
water bath and transferred immediately onto ice for 2 minutes. 500 µl of LB broth 
(Table 2.1) was added to the cells and incubated at 37
oC for  1 hour with shaking. 
Volumes of 50 µl to 200 µl of the transformed cells were plated onto LB-agar plates 
(Table 2.1) containing 100ug/ml of ampicillin (Sigma) and incubated at 37
oC overnight. 
 
2.2.6.  DNA plasmid preparation 
5  ml  of  LB  broth  containing  ampicillin  was  inoculated  with  a  single  colony  of 
transformed bacteria and cultured at 37
oC for 6 hours with shaking at 300 rpm. If a 
larger scale of DNA preparation was required 200 ml of LB broth plus ampicillin was 
inoculated with the starter culture and cultured overnight at 37
oC with shaking. Plasmid 
DNA was purified from 5 ml of bacterial cultures using the Qiaprep Spin Miniprep Kit 
(Qiagen) or the Plasmid Maxi Kit (Qiagen) for 200 ml of bacterial cultures. DNA was 
eluted in the appropriate volume of double distilled water and stored at -20
oC. 
 
2.2.7.  DNA sequencing 
Sequencing was carried out by GATC Biotech AG, Kostanz, Germany. 
 
2.3.  Animals 
Mice were maintained in the animal facilities of the Windeyer Institute and the Institute 
of Child Health (UCL, London). Experiments were performed according to institutional 
guidelines  and  Home  Office  regulations.  HLA-A*0201  transgenic  mice  (genetic 
background of C57BL/6J, kindly provided by Professor M. Collins, UCL, London) are 
homozygous for H-2D
b -/- and mouse β2-microglobulin
 -/- (β2m), and transgenic for a 
recombinant HLA-A2.1/H-2D
b monochain, which is covalently linked to a human β2-
microglobulin at the N-terminal (Pascolo et al., 1997). The engineered α-chain region 
comprises of the human α1 and α2 domains, mouse α3, transmembrane and cytoplasmic 
domains. 
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2.4.  Analysis of TWIST1 by Real-Time Quantitative PCR (qPCR) 
Total RNA from human adult tissues was purchased from Clontech, France. 2µg of total 
RNA was used to synthesis first-strand cDNA templates as described in section 2.2.2. 
The  relative  expression  of  TWIST1  was  measured  using  TWIST1  TaqMan®  gene 
expression assay (Hs00361186_m1, Applied Biosystems) together with glyceraldehyde-
3-phosphate  dehydrogenase  (GAPDH)  TaqMan®  gene  expression  assay  
(Hs99999905_m1, Applied Biosystems).  
 
  Each assay contains an unlabelled primer pair for the amplification of genetic 
sequences of interest. The assays also contain TaqMan MGB (minor groove binder) 
probes  which  anneals  between  the  forward  and  reverse  primer  sites  of  the  target 
sequence. A 6-FAM reporter dye is linked to the 5’ end of the TaqMan MGB probe and 
a nonfluorescent quencher is attached to the 3’end. The reporter dye does not fluoresce 
in the proximity of the quencher due to a process called fluorescence resonance energy 
transfer (FRET). The principle of the assay is based on the 5’- 3’exonuclease activity of 
the  DNA  polymerase.  During  the  polymerisation  reaction,  the  DNA  polymerase 
displaces the 5’end of the probe, creating a fork-like structure, which results in the 
cleavage  probe  and  the  release  of  the  reporter  dye  into  the  solution  where  it  can 
fluoresce.  Therefore  the  amount  of  specific  PCR  product  can  be  monitored  by  the 
increase in fluorescence signal. 
 
  Each qPCR reaction contained approximately 100ng of first-strand cDNA, 1x 
TaqMan  fast  universal  PCR  master-mix  (Applied  Biosystems)  and  1  x  TWIST1  or 
GAPDH primer probe set diluted in 50ul of RNase-free water. Reactions were prepared 
in MicroAmp Fast Optical 96-well reaction plate and the PCR was performed using the 
7900HT  Fast  Real-Time  PCR  System  (both  from  Applied  Biosystems).  Data  were 
analysed by the comparative CT method (∆∆CT). Number of TWIST1 template in each 
sample is normalised against an endogenous reference, which is the housekeeping gene 
GAPDH. Expression levels of TWIST1 in each sample were compared to a calibrator 
sample (RH30 cell line). Briefly, threshold CT values for each sample were determined 
from the amplification plots. Relative quantitations (2
-∆∆CT) were calculated using the 
following formula: 
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Relative quantitation = 2
-∆∆CT 
2
-∆∆CT = 2^-[(CT, TWIST1 – CT, GAPDH) test sample – (CT, TWIST1 – CT, GAPDH) calibrator sample] 
CT, TWIST1 = threshold cycle of TWIST1, CT, GAPDH = threshold cycle of GAPDH 
 
To calculate the standard deviation (SD) of the test sample reaction: 
SD = √(SD TWIST1
2 + SD GAPDH
2) 
2
-∆∆CT MAX (upper level of relative TWIST1 expression) = 2
-∆∆CT - SD 
2
-∆∆CT MIN (lower level of relative TWIST1 expression) = 2
-∆∆CT + SD 
 
2.5.  Synthetic peptides 
Peptides were synthesised by Zinsser Analytic (Germany) or ProImmune (Oxford, UK) 
and were made to >95% purity, as determined by reverse phase HPLC. Peptides were 
dissolved in dimethyl sulfoxide (DMSO; Sigma) drop-wise and diluted further with 
sterile-filtered water to a give a stock concentration of 2mM and aliquots were stored at 
-80
oC. Peptides used in this study are listed in Table 2.3 and they will be referred to by 
their names in the thesis. 
 
Table 2.3 Synthetic Peptides 
Name  Peptide Sequence  MHC allele  Epitope of Origin 
KLA  KLAARYIDFL  HLA-A*0201  TWIST1150-159 
SLN  SLNEAFAAL  HLA-A*0201  TWIST1123-131 
NY-ESO-1  SLLMWITQV  HLA-A*0201  NY-ESO-1157-165 
FLU  GILGFVFTL  HLA-A*0201  Influenza A MP 58-66 
VIL  VILKKATEYV  HLA-A*0201  MYCN421-430 
HBVc128-140  TPPATRPPNAPIL  H-2 Class II I-Ab  HBV nucleocapsid128-140 
Table 4 Table 2.3 Synthetic Peptides 
2.6.  T2 Binding Assay 
10
6 cells/ml of T2 cells were incubated for 4 hours at 37
oC or 27
oC overnight in serum-
free  RPMI  1640  medium  supplemented  with  5  µg/ml  of  human  β2-microglobulin 
(Sigma). 100 µl of cell suspension was plated out to each well of a 96-well U-bottomed 
plate. 100 µl of test peptides and FLU peptide were added to the wells containing T2 
cells with a final concentration range of 1mM to 1nM. Cells were washed and labelled 59 
 
for  30  minutes  on  ice  with  saturating  concentration  of  fluorescein  isothiocyanate-
conjugated  anti-HLA-A2  monoclonal  antibody  (BD  Pharmigen)  in  100µl  of  FACS 
buffer (Table 2.1). Cells were washed twice and fixed with 1% paraformaldehyde for 
analysis. HLA-A2 molecule expression level was represented by the mean fluorescent 
index (MFI) and was calculated as follows – mean fluorescent intensity observed for 
each test peptide divided by mean fluorescent intensity of isotype control. 
 
2.7.  Primary T Cell Culturing 
2.7.1.  Cryopreservation of cells 
Cells  were  cryopreserved  in  freezing  solution  containing  10%  dimethyl  sulfoxide 
(DMSO), 50% human AB serum (Lonza) and 40% RPMI 1640 medium. Cells were 
frozen in 1.8 ml cryovials (Nunc) by storing in a freezing box containing isopropanol at 
-80
oC overnight and then transferred to liquid nitrogen storage. Frozen stocks of 5x10
6, 
10
7 and 5x10
7 PBMC per cryovial were prepared from the same donor for use at various 
stages of CTL line generation. 
 
2.7.2.  Peptide-pulsing of antigen presenting cells 
APCs  were  harvested  and  washed  twice  with  warm  RPMI  1640  medium  with  no 
addictives.  Pelleted  cells  were  resuspended  in  RPMI  1640  medium  containing  5% 
boiled FCS (pre-incubated at 95
oC for 10 minutes) at a cell density of approximately 
5x10
5 to 10
6 cells per 0.5ml. Peptide of interest was added to the cells giving final 
concentrations  of  10-100  µM  and  supplemented  with  2.5  µg/ml  of  human  β2-
microglobulin. Peptide/cell suspension was incubated at 37
oC for 2 to 4 hours, washed 
once with RPMI 1640 medium and irradiated before use as stimulator cells. 
 
2.7.3.  Phytohaemagglutinin-L (PHA) T cell stimulation 
1-10 responder T cells from established CTL lines were stimulated in a total culture 
volume  of  200  µl/well  in  RPMI  1640  medium  containing  10%  human  AB  serum 
(Lonza),  25mM  HEPES  (Gibco),  50  units/ml  penicillin/streptomycin  and  50M  2-
mercaptoethanol (complete medium) in a 96-well U-bottomed plate. Each well also 
contained 1 µg/ml of PHA (Sigma), 100 IU/ml of recombinant human IL-2 and 2 x 10
5 60 
 
irradiated autologous PBMC (30Gy). PHA stimulated cultures were incubated at 37
oC 
for 7 to 14 days depending on the initial number of responder cells. For T cell cloning a 
second round of PHA stimulation was performed by replacing 100 µl of medium from 
each well with 100 µl of complete medium containing the same amounts of PHA, IL-2 
and irradiated autologous PBMC used previously. 
 
2.7.4.  Anti-CD3 and anti-CD28 antibody coated microbead T cell expansion 
T cell expansion was performed using Dynabeads® Human T-Activator CD3/CD28 
(Invitrogen) according to manufacturer’s protocol. Briefly, expansion of T cells was 
performed  in a  flat-bottomed  96-well  culture  plate containing  8  x  10
4  cells/well  of 
responding T cells from CTL lines and 8 x10
4 beads/well of Dynabeads® Human T-
Activator CD3/CD28, in 200 µl of complete medium supplemented with 30 IU/ml of 
recombinant human IL-2. Cultures were split when the growth medium turned yellow 
and were cultured for a period of 7 days before requiring re-stimulation. 
 
2.8.  Induction of Peptide-Specific Cytotoxic T lymphocyte Response 
2.8.1.  Isolation of peripheral blood mononuclear cells (PBMC) 
Buffy  coat  blood  packs  from  National  Blood  Services  (London,  UK)  were  used  to 
prepare peripheral blood mononuclear cells (PBMCs) by density gradient centrifugation 
using Lymphoprep (Axis-Shield). Briefly, blood was diluted with an equal volume of 
RPMI  1640  medium  and  25  ml  of  the  blood  layered  gently  on  top  of  20  ml  of 
Lymphoprep in a 50 ml Falcon tube and centrifuged at 2000 rpm for 30 minutes with 
the brake turned off. The interface fraction containing the PBMC was collected and 
washed twice with serum free RPMI 1640 medium. RBC lysis buffer (Table 2.1) was 
used  to  remove  erythrocytes.  Each  donor  was  stained  for  the  surface expression  of 
HLA-A2 with FITC-conjugated anti-HLA-A2 antibody (BD Pharmigen) and analysed 
by flow cytometry. 
 
2.8.2.  Generation of human dendritic cells from PBMC 
Plastic adherence technique was used to enrich for monocytes from PBMCs. Briefly, 
1.5x10
7 PBMCs was seeded into each well of a 6-well culture plate in 3 ml of X-Vivo 61 
 
15 medium (Lonza) containing 5%  Human AB serum and incubated at 37
oC  for  2 
hours. Non-adherent cell fraction was removed by washing with medium. Adherent 
fraction was cultured in X-Vivo 15 medium containing 5% human AB serum, 25mM 
HEPES (Gibco), 50 units/ml penicillin/streptomycin and supplemented with 125IU/ml 
of recombinant human Il-4 and 1000IU/ml of  recombinant human GM-CSF. On day 2 
and 4 of culturing fresh Il-4 and GM-CSF were added. On day 6 half the volume of 
medium was replaced with fresh medium containing final concentrations of 125U/ml of 
Il-4,  1000U/ml  of  GM-CSF,  200ng/ml  of  LPS  (Sigma-aldrich),  500ng/ml  of 
recombinant  huamn  CD40L  protein  (Peprotech)  and  1000IU/ml  of  interferon- 
(Peprotech), and incubated for a further 24 hours. Surface expression markers HLA-DR, 
CD86, CD11c and CD14 were assessed by flow cytometric analysis using antibodies 
listed in Table 2.2. 
 
2.8.3.  CD40L-activated B cell generation from PBMC 
CD40L-activated B cells were generated as described previously (Schultze et al., 1997). 
Briefly,  t-CD40L  cells  stably  transfected  with  human  CD40  ligand  were  irradiated 
(96Gy) and co-cultured with PBMC (from HLA-A2
+ donors) at 2-3 x 10
6 cells/ml with 
2ng/ml of recombinant IL-4 (Peprotech) and 1g/ml of cyclosporine A (Sigma). Surface 
marker CD19
+ expression was analysed weekly by flow cytometric analysis and these 
cells were used as autologous peptide-pulsed APCs when the percentage of CD19
+ cells 
was higher than 80%. 
 
2.8.4.  Generation of T cell lines from HLA-A2
+ donors 
CTL lines were cultured in RPMI 1640 medium containing 10% human AB serum, 
25mM  HEPES  (Gibco),  50  units/ml  penicillin/streptomycin  and  50M  2-
mercaptoethanol (complete T cell medium, CM) unless stated otherwise. Matured DCs 
were pulsed with 50g/ml of KLA or SLN peptides for 4 hours and irradiated (30 Gy). 
They were co-cultured with autologous CD8
+ and CD4
+ cells purified from HLA-A2-
positive  PBMC  by  magnetic  cell  sorting  using  CD8
+  cell  isolation  kit  II,  CD4 
MicroBeads  and  MACS  Columns  (all  from  Miltenyi  Biotec)  according  to  the 
manufacturer’s instructions. 1 x 10
6 CD8
+ cells were cultured with peptide-pulsed DCs 
at 5 to 1 ratio, with 1 x 10
5 CD4
+ cells added, in a single-well of a 24 well plate in CM 62 
 
supplemented  with  human  IL-7  (10U/ml)  and  IL-12  (0.1ng/ml).  On  day  7,  T  cell 
cultures were restimulated with peptide-pulsed (10M) matured DCs, fresh cytokines in 
fresh  CM.  Two  further  stimulations  on  day  14  and  day  21  were  with  autologous 
CD40L-activated B cells (irradiated 80 Gy) pulsed with 10M of peptide (ratio of 1 to 4 
T  cells),  in  the  presence  of  human  IL-2  (20U/ml)  and  Il-12  (1ng/ml).  Human  IL-2 
(20U/ml) was added every 2-3 days to the cultures between stimulations. 5-7 days after 
the fourth stimulation, T cell cultures were tested for antigen specificity in a chromium-
51  cytotoxicity  assay  (see  Section  2.9)  or  cloned  by  limiting  dilution  and  PHA 
stimulation as described in section 2.7.3. 
 
2.8.5.  Generation of CTL lines from HLA-A2
- donors 
HLA-A2-positive DCs generated as described in section 2.8.2 were pulsed with 100M 
of peptide for 4 hours and irradiated at 30 Gy. They were co-cultured with allogeneic 
HLA-A2-negative CD8
+ T cells purified from HLA-A2-negative PBMC by magnetic 
cell sorting as described previously. 1 x 10
6 CD8
+ T cells were cultured with 2 x 10
5 
peptide-pulsed DCs, at a 5 to 1 ratio in 2ml of CM supplemented with IL-7 (10U/ml) 
per well of a 24-well culture plate. On day 7 and 14, T cell cultures were harvested and 
the number of viable cells determined by trypan blue exclusion. For every 10
6 cells, T 
cell cultures were restimulated with 2 x 10
5 peptide-loaded irradiated T2 cells (80Gy),
 2 
x 10
6 autologous irradiated PBMC (30 Gy), IL-2 (10U/ml) and IL-7 (5U/ml). T cell 
cultures were maintained by weekly stimulations. Chromium-51 cytotoxicity assays (see 
Section 2.9) and T cell isolation or cloning was performed after the third stimulation 
(see Section 2.8.6). 
 
2.8.6.  T-cell cloning from alloreactive CTL lines 
CTL lines generated from HLA-A2
- donors, described in section 2.8.5, were harvested 
after three rounds of peptide stimulations. Cells were re-suspended in large volumes of 
complete medium such that every 100 µl of the cell suspensions contained 10, 1 or 0.3 
cells. Limiting dilution plates were setup by adding 100l of the cell suspensions to 
each well of a 96-well U-bottomed culture plate. 100l of CM containing the following 
were also added to each well: 2x10
4 irradiated peptide-loaded T2 cells (80Gy), 2x10
5 
autolgous PBMC irradiated (30Gy), Il-2 (20U/ml) and Il-7 (10U/ml). Micro-cultures 63 
 
were restimulated once on day 14 by replacing 100 µl of the culture medium from each 
well with 100 µl of complete medium containing the same number of peptide-pulsed 
irradiated T2 cells, irradiated autologous PBMC and the same concentrations of IL-2 
and IL-7.  Split-well analysis was performed at day 21 of culturing to identify peptide 
specific cultures. 50l of CTL from each well were tested against chromium-labelled T2 
cells pulsed with peptide as described before (Gao et al., 2005). 
 
2.8.7.  Isolation of pentamer-specific T cells by magnetic cell sorting 
CTL lines generated from HLA-A2
- donors, described in section 2.8.5, were harvested 
after three to five rounds of peptide stimulations. 15 x 10
6 cells from the cultures were 
stained with pentamers (see Section 2.1.4) according to the manufacturer’s instruction. 
After a single wash in PBS containing 0.5% BSA, pentamer stained antigen-specific T 
cells were enriched by using the anti-phycoerythrin (PE) Multisort Kit or anti-biotin 
microbeads and MACS® cell separation columns (Miltenyi Biotec). Pentamer-specific 
cells were eluted and resuspended in 100µl of CM in a single well of a 96-well plate. 
The number of antigen-specific T cells in the pentamer ‘enriched’ fractions is usually 
too small for direct flow cytometric analysis. Pentamer enriched and depleted fractions 
were restimulated as described in section 2.8.6. 
 
2.9.  Chromium-51 Cytotoxicity Assay 
Specific CTLs were identified in a standard 4 hour chromium release assay. Briefly, 10
6 
target cells were labelled with 50µCi of Na2
51
 CrO4 (Amersham GE Healthcare) for 1 
hour at 37
oC, with or without peptide-pulsing for 1 hour beforehand at 37
oC, 5% CO2 in 
serum-free RPMI 1640 medium. Target cells were washed and plated in a 96-well U-
bottom plate at a cell density of 5 x 10
3 cells/200µl/well along with effector T cells at 
different effector to target ratios (E:T). After 4 hours incubation at 37
oC, cells and debris 
were spun down by centrifuging at 1000rpm for 4 minutes and 50 µl/well of medium 
was transferred to an isoplate-96 microplate (Wallac). 100µl of OptiPhase Supermix 
Cocktail (PerkinElmer) was added to the medium and incubated at room temperature 
overnight. Release of radioisotopes into the supernatant of the test wells were measured 
using a gamma-counter (PerkinElmer). Percentage specific lysis was calculated from 
the following formula: [(experimental c.p.m – spontaneous c.p.m)/(maximum c.p.m – 64 
 
spontaneous c.p.m)]  x 100. Maximum release was determined by lysis of the same 
number of target cells in 1% Triton X-100 (Sigma).  
 
2.10.  Split-well Analysis 
Limiting dilution plates for T cell cloning, described in section 2.8.6, were screened by 
this method which is similar in principle to the chromium-51 cytotoxicity assay. Briefly, 
T2 cells were pulsed with 100 µM of relevant test peptide or irrelevant control peptide 
for 1 hour at 37
oC followed by labelling with 50µCi of Na2
51
 CrO4 per 10
6 cells for 
another  hour.  Meanwhile  two  round-bottom  96-well  plates  were  setup  per  limiting 
dilution plate. Cells in the limiting dilution plate were resuspended by gentle pipetting 
and 50 µl of cells from each well was transferred into the corresponding wells of the 
two 96-well plates. The cells were pelleted by centrifuging at 1300rpm for 3 minutes 
and medium was replaced with 100 µl of complete medium. Target cells were washed 
and re-suspended to 5 x 10
4 cells/ml. 100 µl of T2 cells pulsed with irrelevant peptide 
was added to each of the wells in one of the 96-well plates and similarly 100 µl of T2 
cells pulsed with relevant test peptide was added to the other plate. Wells containing 
target  cells  to  measure the  spontaneous  and  maximum chromium  release  were  also 
setup.  The  plates  were  incubated  for  4  hours  at  37
oC  and  the  measurement  of 
radioactivity was carried out as described in section 2.9.  
 
2.11.  Cold Target Inhibition Assay 
Cold  target  inhibition  assay  was  performed  using  T2  cells  pulsed  with  100  µM  of 
relevant peptide (NY-ESO-1) or irrelevant peptide (FLU) and labelled with Na2
51
 CrO4 
as described in section 2.9 (hot targets). 20 to 1 effector to hot target ratio per well was 
setup in a 96-well U-bottom plate as previously described, in the presence or absence of 
2 x 10
4 unpulsed T2 cells not labelled with Na2
51
 CrO4 (cold targets). Radioisotope 
release into the supernatant was measured after 4 hour incubation at 37
oC as described 
above. 
2.12.  Enzyme-Linked Immunosorbent Spot (ELISPOT) Assay 
Wells of a MultiScreenHTS-IP Filter Plate (Millipore) were prepared by adding 15µl of 
70% methanol for 1 minute and rinsed three times with PBS. 100 µl of 10µg/ml anti-
interferon-γ (IFNγ) monoclonal antibody (Mabtech), clone D1K, diluted in PBS were 65 
 
added to each well and incubated overnight at 4
oC. Antibody was removed and the 
wells washed twice with sterile filtered Milli-Q® water. Wells were blocked with 150 
µl of culture medium (RPMI 1640, 10% FBS, glutamine,  50 units/ml penicillin and 
streptomycin) for  2 hours at 37
oC. Effector T cells were washed once with culture 
medium and re-suspended at the appropriate cell density. Target cells such as peptide-
pulsed T2 cells were also prepared and resuspended at 2x10
5 cells/ml. Blocking medium 
was removed and 100µl of effector cells were added to each well and incubated for 1 
hour at 37
oC. 50µl of target cells were then added gently to the wells and incubated for 
20 hours. On day three, the co-cultured cells were discarded and the wells were washed 
6  times  with  PBS  containing  0.01%  Tween®  20  (PBS-Tween).  100  µl  of  1µg/ml 
biotinylated anti-IFNγ antibody (Mabtech), clone 7-B6-1, diluted in PBS with 0.5% 
BSA was added to each well and incubated for 2 hours at 37
oC. The plate was washed 6 
times  with  PBS-Tween.  ExtrAvidin®-  alkaline  phosphatase  solution  (Sigma)  was 
diluted 1 in 1000 in PBS, 100µl/well was added and incubated for 1 hour at room 
temperature. Wells were washed 3 times with PBS-tween and 3 times with PBS. Spots 
were  developed  using  BCIP/NBT  substrates  (5-bromo-4-chloro-3-indolyl-
phosphate/nitro  blue  tetrazolium)  from  the  AP  Conjugate  Substrate  Kit  (Bio-Rad) 
according to manufacturer’s manual. Spot development was stopped after <30 minutes 
with excess amount of water. Wells were allowed to dry in the dark before counting of 
spots with the ELISPOT plate reader (Autoimmun Diagnostika, Germany). 
 
2.13.  Quantitation of CTL Response by MHC Class I Pentamer 
Staining 
It was important to analyse as many cells as possible when looking at rare populations 
such as antigen-specific CTLs. Seven to ten days after the last restimulation; 5x10
5 cells 
from CTL lines generated from HLA-A2
+ donors or 5-15x10
6 cells from CTL lines 
generated from HLA-A2
- donors were washed with FACS buffer (Table 2.1) and re-
suspended  at  a  density  of  5x10
5  -  2x10
6  cells  per  50µl  of  FACS  buffer.  10  µl  of 
pentamer (see Section 2.1.4) was added to every 50µl of cell suspension and incubated 
at  room  temperature  for  10  minutes.  Cells  were  washed  with  FACS  buffer  and 
incubated with FITC-conjugated anti-CD8 and APC-conjugated anti-CD19 (Table 2.2) 
for 20 minutes at 4
oC. If a biotinylated-pentamer was used, a secondary staining was 66 
 
also performed using streptavidin-PE. Finally, cells were washed with FACS buffer and 
fixed with 1% PFA followed by flow cytometric analysis. 
 
2.14.  Peptide Immunisation of HLA-A2
+ Transgenic Mice 
HLA-A*0201
+ transgenic mice were immunised as previously described (Firat et al., 
1999). Briefly, 60g of HBVc128-140 plus or minus 60g of KLA peptide, emulsified in 
Incomplete Freund’s adjuvant (IFA, Sigma) were injected subcutaneously (s.c.) at the 
base of the tail. After 10 days, a second immunisation was performed similarly. A week 
later, the mice were sacrificed and the spleens removed for  further  ex vivo peptide 
stimulations, see section 2.15.  
 
2.15.  Ex vivo Peptide Stimulation of Mouse Splenocytes 
3 x 10
6 splenocytes were seeded into each well of a 24-well plate in 2 ml of Iscove's 
Modified Dulbecco's medium  (IMDM)  containing 10%  FCS, 2mM  L-glutamine,  50 
units/ml penicillin/streptomycin and 50µM 2-mercepatoethanol and supplemented with 
20U/ml  of  recombinant  murine  IL-2.  Splenocytes  were  stimulated  with  10µM  of 
peptide and incubated for 7 days at 37
oC with 5% CO2. 
 
2.16.  Generation of Mouse Bone-Marrow-Derived Dendritic Cells 
Bone-marrow  cells  were  obtained  from HLA-A*0201
+  transgenic  mice  or  C57BL/6 
mice by flushing the cells out from the femur and tibia with PBS using a 28 gauge 
needle and a syringe.  Bone-marrow derived DCs (BM-DC) were  generated using a 
standard 8 days culture protocol (Inaba et al., 1992a). Briefly, red blood cells were lysed 
using RBC lysis buffer (Table 2.1). Bone-marrow cells were re-suspended to a density 
of 10
6 cells/ml in IMDM growth medium (10% FCS, 2mM L-glutamine, 50 units/ml 
penicillin/streptomycin and 50µM 2-mercepatoethanol) supplemented with 25 ng/ml of 
murine GM-CSF and 20 ng/ml of murine IL-4. 10 ml of cell suspension was added to a 
10 cm culture dish and placed in a humidified culture incubator at 37
oC for 6 days. On 
day 2-3, 7.5 ml of the culture medium containing non-adherent cells was removed and 
replaced with fresh IMDM growth medium containing GM-CSF and IL-4 (25ng/ml and 
20ng/ml). On day 6, cells were harvested; counted and 10
6 cells were added to a new 10 
cm dish in IMDM medium containing GM-CSF, IL-4 and 100ng/ml of tumour-necrosis 67 
 
factor-α (TNF-α) for maturation for 2 days. Matured BM-DC was ready for peptide-
pulsing on day 8. 
 
2.17.  Peptide-Pulsed BM-DC Immunisation of C57BL/6 Mice 
Matured BM-DCs (HLA-A0201
+) were pulsed with or without KLA peptide (100 M) 
and  HBVc128-140  peptide  (10  M)  for  2  hours.  Peptide-pulsed  BM-DCs  were  re-
suspended at 0.5–1x10
6 cells per 100l DPBS and injected s.c. at the base of the tail of 
C57BL/6 mice. As negative control, mice were injected with 100l of DPBS only. Two 
more immunisations with peptide-pulsed DCs were done, seven days apart. 7 days after 
the  third  immunisation,  mice  were  sacrificed  and  the  spleens  removed.  3x10
6 
splenocytes were plated into a well of a 24-well plate in 2 ml of IMDM containing 10% 
FCS, 2mM L-glutamine, penicillin/streptomycin and 50µM 2-mercepatoethanol and co-
cultured with: 3x10
6 irradiated C57BL/6 splenocytes (30Gy), 3x10
5 irradiated T2 cells 
(80Gy) pulsed with 100µM of KLA peptide or unpulsed. Cultures were re-stimulated 
one week later. T cell cultures were analysed by flow cytometry or Cr
51 cytotoxicity 
assay, 5 days after the last re-stimulation. Alternatively, 10
4 splenocytes were cultured 
in 200µl of the same IMDM medium and plated into wells of a 96-well plate. Each well 
also contained: 2x10
5 irradiated C57BL/6 splenocytes (30Gy), 2x10
4 irradiated T2 cells 
(80Gy) pulsed with 100µM of KLA peptide or left unpulsed. 
 
2.18.  Transduction of Bone-Marrow Derived Dendritic Cells 
2.18.1. Generation of FLAG-tagged TWIST1 lentiviral vectors 
The  plasmid  pCI-neo  mammalian  expression  vector  containing  the  TWIST1  cDNA 
(pCI-neo-TWIST1) was used as a template for molecular sub-cloning.  Three cDNA 
fragments encoding TWIST1 amino acid residues 1-202 (TFULL), 1-108 (Tx1) and 
101-202 (Tx2) were amplified by PCR reactions using primer pairs listed in Table 2.4, 
to incorporate restriction enzyme sites (underlined) and nucleotide sequences encoding 
for the FLAG-tag epitope - DYKDDDDK (lower case). One of the following Kozak 
sequences  (Italic):  CGAGAGATG,  TCCACCATG  or  GCCACCATG  were  also 
included upstream of the start codons in all the constructs made. TFULL cDNA was 
amplified using primer 1 and primer 4; Tx1 cDNA was amplified using primer 1 and 
primer 2; and Tx2 was amplified using primer 3 and primer 4.  68 
 
 
  TFULL and Tx1 were amplified using the PCR conditions described in section 
2.2.3.  Tx2  fragment  was  amplified  using  Taq  DNA  Polymerase  and  Q-Solution 
(Qiagen). Briefly, the PCR reaction was carried out in a volume of 50 µl containing 1X 
PCR Buffer, 1X Q-Solution, 0.2mM of each dNTP (Promega), 0.5 µM of each primer, 
0.5 µg of template DNA and 2.5 units of Taq DNA Polymerase. The following PCR 
thermal cycling condition was  used, beginning with a hot start 1X (95
oC 2 minutes); 
30X (95
oC 1 minute, 48-60
oC 30 seconds, 72 
oC 1 minute); 1X (72
oC 5 minutes).  
 
  Resulting  PCR  products  were  mixed  with  1X  Blue/Orange  Loading  Dye 
(Promega) and resolved by gel electrophoresis using a 2% agarose gel containing 0.5 
µg/ml of ethidium bromide. This allowed the estimation of sizes by using the molecular 
weight maker – 1 Kb Plus DNA Ladder (Invitrogen). PCR products were purified using 
the QIAquick PCR Purification Kit (Qiagen) following the manufacturer’s guide before 
carrying  out  a  restriction  digestion  with  BamHI  (Promega)  and  SbfI  (New  England 
Biolabs) in NEBuffer 4 at 37
oC overnight. Digests were analysed by gel electrophoresis 
and purified as above.  
 
  pHR'SIN-cPPT-SEW  (LNT-GFP)  lentiviral  vector  (kindly  provided  by 
Professor A. Thrasher, UCL, London, UK) was digested with BamHI and SbfI as above, 
resolved by  gel electrophoresis, and the 8895bp DNA fragment extracted using the 
QIAquick Gel Extraction Kit  (Qiagen) following the manufacturer’s guide.  Ligation 
reactions  were  performed  using  T4  ligase  (Promega),  1X  Ligase  buffer,  and 
approximately 15 ng of digested inserts and 100 ng of digested pHR'SIN-cPPT-SEW, 
incubated at 4
oC overnight. The resulting constructs were referred to as LNT-TFULL, 
LNT-Tx1 and LNT-Tx2. 
 
  TFULL and Tx1 cDNA inserts were then transferred from the pHR'SIN-cPPT-
SEW vector into the pHR’-SIN-IRES-WPRE bicistronic vector by PCR amplification 
using primers 1 and 5 (Table 2.4) replacing the  SbfI restriction site with XhoI. The 
purified PCR products were then ligated into the similarly digested pHR’-SIN-IRES-
WPRE construct to generate LNT-TF-EGFP and LNT-Tx1A-EGFP. 
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Table 2.4 Nucleotide sequences of primers 
Primer  Forward/ 
Reverse  Nucleotide sequences (5’ to 3’) 
1  Forward  GAGGATCCCGAGAGATGATGCAGGACGTGT 
2 
Reverse  CTCCTGCAGGCTActtatcgtcgtcatccttgtaatcCGTCTGCAGC
TCCTCGTAAGACT 
3 
Forward  GAGGATCCTCCACCATGCAGTCTTACGAGGAGCTGCAG
ACGCA 
4 
Reverse  CTCCTGCAGGCTActtatcgtcgtcatccttgtaatcGTGGGACGCG
GACATGGACC 
5  Reverse  CTCTCGAGCTActtatcgtcgtcatccttg  
6 
Reverse  CTCTCGAGCTActtatcgtcgtcatccttgtaatcCGCCAGCTTGAG
GGTCTGAATC 
7 
Forward  GAGGATCCGCCACCATGgattacaaggatgacgacgataagCTGAG
CAACAGCGAGGAAGAG 
8 
Forward  GAGGATCCGCCACCATGgattacaaggatgacgacgataagGGGAG
TCCGCAGTCTTACGA 
9 
Forward  GAGGATCCGCCACCATGgattacaaggatgacgacgataagTCGGA
CAAGCTGAGCAAGAT 
10  Reverse  CTCTCGAGATTTATTTATTGCAGAAAAATATACAAAGA 
 
  Four  additional  TWIST1  cDNA  fragments  were  amplified  from  pCI-neo-
TWIST1 encoding amino acid residues: 1-144 (Tx1B), 17-202 (Tx2A), 98-202 (Tx2B) 
and 130-202 (Tx2C). Restriction sites BamHI and XhoI were incorporated at the 5’-end 
and 3’-end respectively. Tx1B was amplified using primers 1 and 6; primers 7 and 10 
(Tx2A); primers 8 and 10 (Tx2B); and primers 9 and 10 (Tx2C); with the FLAG-tag 
epitope (lowercase) incorporated at the N-terminus end except for Tx1B, which was 
included at the C-terminus end (primer sequences are listed in Table 2.4). pHR’-SIN-
IRES-WPRE construct and purified PCR products were digested with BamHI and XhoI 
and  ligated  together  to  generate  LNT-Tx1B-EGFP,  LNT-Tx2A-EGFP,  LNT-Tx2B-
EGFP and LNT-Tx2C-EGFP constructs. 70 
 
 
2.18.2. Lentiviral production in 293FT packaging cell line 
Packaging 293FT cell line - clonal isolate derived from transformed embryonal kidney 
cells (Invitrogen), was seeded at 4 x 10
6 cells per 10cm culture dish in growth medium 
(DMEM, 10% FBS, 6 mM L-glutamine, 0.1  mM MEM Non-Essential Amino Acids, 
50 units/ml penicillin/streptomycin, and 500μg/ml mM Geneticin) and placed in the cell 
culture incubator overnight. On day 1, growth medium was replaced with 5 ml of fresh 
growth medium without antibiotics at least 2 hours before performing transfection. 30 
µl of Lipofectamine
TM 2000 reagent was added to 1.5 ml of Opti-MEM® medium and 
incubated at room temperature for 5 minutes. This was then combined with another 1.5 
ml of the same medium containing 5 µg of lentiviral vector, 3.75 µg of psPAX2 and 1.5 
µg of pMD2G, and incubated for 20 minutes at room temperature. The resulting DNA 
plasmids/Lipofectamine
TM 2000 complexes was added to the culture dish containing the 
293FT cells and incubated overnight at 37
oC in a cell culture incubator. Day 2, medium 
was removed and replaced with 8 ml of virus production medium (DMEM containing 
10% FBS, 2 mM L-glutamine, 0.1  mM MEM Non-Essential Amino Acids, 50 units/ml 
penicillin/streptomycin, and 1 mM MEM Sodium Pyruvate). Supernatant was collected 
on day 3 and centrifuged at 3000 rpm for 5 minutes to remove cell debris. Lentivirus 
particles were concentrated by ultracentrifugation by  spinning supernatant at 13,200 
rpm at 4
oC for 1 hour, pelleted lentivirus was then re-suspended in 50 µl of IMDM 10% 
FBS medium for every 1 ml of supernatant before concentration.  
 
2.18.3. Transduction of bone-marrow-derived dendritic cells 
BM-DCs  were  generated  as  described  in  section  2.16  until  day  4  when  lentiviral 
transduction was carried out. Non-adherent cells and adherent cells were collected by 
incubating the latter with 3mM EDTA in PBS for 5 minutes. 5 x 10
5 cells were seeded 
into each well of a 24-well culture plate in 1 ml of IMDM growth medium containing 5 
µg/ml  of  polybrene  (Sigma),  25  ng/ml  of  GM-CSF,  20  ng/ml  of  IL-4  and  the 
concentrated  lentivirus  at  a  multiplicity  of  infection  (MOI)  of  23.  Cells  were  spin 
infected by centrifuging at 1800 rpm at room temperature for 45 minutes and incubated 
at 37
oC in a CO2 incubator overnight. Medium was replaced on day 5 with fresh IMDM 
growth  medium  supplemented  with  cytokines  and  again  on  day  7  with  or  without 71 
 
100ng/ml TNF-α. BM-DCs were harvested for use on day 8 or 9 by washing twice in 
PBS.  Cells  pre-incubated  with  purified anti-CD16/CD32  (eBioscience)  were  stained 
with PE-conjugated anti-murine CD11c (eBioscience) antibody (working dilution listed 
in Table 2.2) and analysed by flow cytomertry. 
 
2.18.4. Measuring lentivirus titres 
The first method used measures the functional titres of lentiviral stocks. Briefly, 5 x 10
5 
cells from BM-DC cultures, in 1ml of medium, were transduced with 10-fold serial-
diluted concentrated lentivirus on day 4 of BM-DC culturing as described in section 
2.18.3. Percentage of enhanced green fluorescent protein (eGFP) transduced BM-DCs 
for each dilution used was determined by flow cytometry on day 8. Functional titre – 
defined as transducing units per ml (TU/ml) was calculated using the following formula 
– (frequency of eGFP positive cells x 5 x 10
5) ÷ volume (1ml) x
 dilution factor. The 
final titre was the average of the two calculated titres from the dilutions which gave 
approximately 10% eGFP positivity. 
 
  Physical titres of lentiviral stocks were determined by measuring the reverse 
transcriptase activity using the Reverse Transcriptase Colourimetric Assay (Roche) kit 
following the manufacturer’s instruction. Briefly, 2 ml of lentiviral stock was pelleted as 
described in section 2.18.2 and 40 µl of lysis buffer provided by the kit was added and 
incubated for 30 minutes at room temperature. Serial dilution of lysates was performed 
with the lysis buffer. Reverse transcriptase reaction was carried out by adding 20 µl of 
solution 3a containing template/primer hybrid mixture to the lysates and the HIV-1-
reverse  transcriptase  standard  (Roche),  and  incubated  for  1  hour  at  37
oC.  Enzyme-
linked  immunosorbent  assay  (ELISA)  procedure  as  outlined  in  the  manufacturer’s 
manual  was  performed  using  the  reagents  provided.  After  colour  development,  the 
absorbances of the samples were measured at 405 nm wavelength with a microplate 
reader (Bio-Rad). 
 
2.19.  Prime-Boost Vaccination of HLA-A2 Transgenic Mice 
HLA-A*0201 transgenic mice were immunised with approximately 5 x 10
5 matured 
LNT-NY-ESO-1  vector  (kindly  provided  by  Professor  M.K.  Collins)  or  pHR’-SIN-72 
 
IRES-WPRE transduced BM-DC in 100µl of sterile PBS by subcutaneous injections at 
the base of the tail. BM-DC vaccine contained more than 90% CD11c positive cells as 
determined  by  flow  cytometry.  On  day  11,  a  boosting  immunisation  was  intra-
muscularly administered in the right flank containing 50 µg of either LNT-NY-ESO-1 
or pHR’-SIN-IRES-WPRE plasmid DNA (low levels of endotoxin in preparation), and 
50 µg  of CpG oligodinucleotide  1826 (InvivoGen Europe,  France)  in 50µl of PBS. 
DNA vaccination was repeated on day 21 and the mice were euthanized on day 31. The 
splenocytes were harvested for characterisation or further ex vivo peptide stimulation 
(section 2.15) 
 
2.20.  Flow Cytometric Analysis of Intracellular Interferon-γ  
Freshly harvested or restimulated splenocytes were cultured in a 24-well culture dish 
(3x10
6  cells/1ml/well) in IMDM  growth medium (10%  FCS, 2mM  L-glutamine,  50 
units/ml  penicillin/streptomycin  and  50µM  2-mercepatoethanol)  with  10  µg/ml  of 
Brefeldin A (Sigma); stimulated with either 10µM of NY-ESO-1 or FLU peptide (Table 
2.3); and as a positive control, cells were also stimulated with 50ng/ml of phorbol 12-
myristate 13-acetate (PMA) and 500ng/ml of ionomycin (both from Sigma). Cells were 
incubated at 37
oC in a CO2 incubator for 24 hours.  
 
  Flow cytometric analysis was performed using APC conjugated anti-mouse CD8 
(eBioscience) antibody and intracellular staining was carried out using a biotinylated 
anti-mouse interferon-γ antibody (BD Pharmingen); working dilutions can be found in 
Table 2.2. Briefly, stimulated splenocytes were harvested and washed once in cold PBS. 
Anti-CD8 staining was performed in a 100ul of FACS buffer (Table 2.1). After 20 
minutes of incubation on ice, cells were washed and fixed in 4% PFA for another 20 
minutes on ice. Cells were re-suspended in 200 µl of permeabilisation buffer (Table 2.1) 
and incubated at room temperature for 10 minutes. Intracellular staining was performed 
with biotinylated anti-IFN-γ antibody diluted in 100 µl of permeabilisation buffer. Cells 
were  incubated  at  room  temperature  for  20  minutes  and  washed  twice  with 
permeabilisation  buffer.  Secondary  staining  with  streptavidin-PE  (eBioscience)  was 
carried out in the same buffer. Stained samples were washed, re-suspended in 1% PFA 
and stored at 4
oC for analysis later.  
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2.21.  Cell lysis and sodium dodecyl sulphate polyacrylamide analysis 
Cells were washed twice in cold PBS and pelleted by centrifugation at 2,500 x g for 5 
minutes. Approximately 5x10
6 cells were lysed for 15 minutes, on ice, in 1 ml of RIPA 
buffer  (Thermo  Scientific)  containing  10  µl  of  Halt
TM  Protease  Inhibitor  Cocktail 
(Thermo Scientific). Cell debris was removed from lysates by centrifugation at 14,000 x 
g for 15 minutes. Protein concentrations were determined by Bio-Rad Protein Assay 
(Bio-rad)  according  to  manufacturer’s  instructions.    Cell  lysates  were  prepared  by 
diluting one part 5x LSB (Table 2.1) to 4 parts lysates and heated at 100
oC for 5 minutes 
and then kept on ice.  
 
  50 µg of proteins were resolved in a resolving gel containing 12% acrylamide, 
375  mM  Tris-HCl  pH  8.8,  0.1%  SDS  (Protogel,  National  Diagnostics),  0.1% 
ammonium  persulphate  (Sigma)  and  0.1%  tetramethylethylenediamine  (TEMED, 
Sigma). Stacking gel contained 4% acrylamide stacking gels (Protogel), 125 mM Tris-
HCl pH 6.8, 0.1% SDS, 0.1% ammonium persulphate and 0.1% TEMED. Proteins were 
resolved at 100 V at room temperature in running buffer (Table 2.1)  
 
2.22.  Anti-FLAG Immunoprecipitation  
Cell lysates were pre-cleared by incubation with 20µl of Protein G-Sepharose® (Sigma) 
at  4
oC,  rotating  for  30  minutes.  Protein  G-Sepharose  was  removed  by  brief 
centrifugation and the supernatant transferred into a new 1.5 ml Eppendorf tube. 1µg of 
anti-FLAG M2 monoclonal antibody (Sigma) was added and incubated at 4
oC, rotating 
for 1 hour. 20µl of fresh Protein G-Sepharose® was then added and incubated at 4
oC, 
rotating for a further 2 hours. Sepharose beads were pelleted by centrifugation at 12,000 
rpm for 30 seconds. Supernatant was discarded and the beads were washed 6 times with 
RIPA buffer, subsequently the beads were resuspended in 50µl of 1x LSB and heated at 
100
oC for 5 minutes. Beads were pelleted by centrifugation and the supernatant was 
transferred to a fresh Eppendorf tube. 
 
2.23.  Protein Transfer to Nitrocellulose Membrane 
Gels were soaked in cold transfer buffer (Table 2.1) for 10 minutes and transferred onto 
Hybond
TM  –C  extra  nitrocellulose  membrane  (Amersham)  using  a  Mini  Trans-Blot 74 
 
Electrophoretic  Transfer  cell  (Bio-Rad)  according  to  manufacturer’s  guide.  Protein 
transfers were carried out at 100 V at 4
oC, for 1 hour.  
 
2.24.  Western Blotting Analysis 
All the antibodies were diluted to their working dilutions (table 2.5) in 5% milk powder 
in  TBS-T  (Table  2.1).  After  transferring  of  protein  described  in  section  2.23, 
membranes  were  blocked  with  5%  milk  powder  in  TBS-T  for  1  hour  at  room 
temperature with gentle orbital shaking. Membranes were inserted into a 50 ml falcon 
tube  and  incubated  with  diluted  primary  antibody  overnight  at  4
oC  with  constant 
rotation of the tube. Membranes were washed in TBS-T for four 15 minutes washes. 
The appropriate HRP-conjugated secondary antibody (Table 2.5) was used to detect the 
membrane-bound  primary  antibody  by  incubating  the  membrane  with  the  diluted 
secondary antibody for 1 hour at room temperature. Membranes were washed twice in 
TBS-T  followed  by  TBS  twice,  15  minutes  each  time.  Immobilised  proteins  were 
detected  by  chemiluminescent  reaction  with  ECL
TM  Western  Blotting  Detection 
Reagents and detection of signal with Hyperfilm
TM ECL (GE Healthcare, UK). 
Table 6 Table 2.5 Antibodies used for Western blotting 
Table 2.5 Antibodies used for Western blotting 
Name  Manufacturer  Species  
of Origin  Isotype  Working Dilution 
Anti-FLAG (M2)  Sigma  Mouse  IgG1  1:2000 
Anti-α-tubulin (YL1/2)  Serotec, Oxford, UK  Rat  IgG2a  1:5000 
Anti-actin  Abcam  Rabbit  IgG  1:2000 
Anti-TWIST1 (3E11)  Abnova  Mouse  IgG1  3µg/ml 
Anti-TWIST1 (H-81)  Santa Cruz  Rabbit  IgG  1:200 
Anti-mouse IgG -HRP   Santa Cruz  Goat  IgG  1:2000 
Anti-rabbit IgG – HRP   Santa Cruz  Goat  IgG  1:3000 
Anti-rat IgG – HRP   Santa Cruz  Goat  IgG  1:3000 
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3. CHAPTER 3 – Results 1 
Immunogenic HLA-A*0201-restricted peptides 
derived from human TWIST1 76 
 
3.1.  Background 
 
3.1.1.  Prediction of CTL epitopes derived from the TWIST1 protein sequence 
The  potential  immunogenicity  of  TWIST1  was  first  examined  by  adopting  a 
bioinformatics approach, also known as the ‘reverse immunology’ approach. Previous 
studies  have  successfully  used  the  same  strategy  to  identify  immunogenic  peptide 
sequences  from  tumour  associated  antigens;  for  example  the  HLA-A*01-restricted 
epitope from amino acids 317 to 327 of tumour antigen Wilms tumour protein 1 (WT1) 
(Asemissen et al., 2006).  
 
  At the onset of the study, a list of potential CTL epitopes derived from the 
TWIST1 protein sequence was generated using computational prediction tools, which 
are developed by other research groups and made available on the web. The likelihood 
of a peptide with a specific amino acid sequence to be naturally presented as a CTL 
epitope is governed by, but not limted to, the following factors: proteasomal processing, 
TAP binding affinity and HLA class I molecule binding affinity.  
 
  BIMAS  (Parker  et  al.,  1994)  and  SYFPEITHI  (Rammensee  et  al.,  1999) 
computational  methods  were  used  to  predict  TWIST1-derived  peptides  with  high 
binding affinity to HLA-A*0201. By using the amino acid sequence of TWIST1 as the 
data input, the prediction tools generated a list of all possible peptides and ranked them 
according to their relative strengths of interaction with HLA-A*0201. MHC class  I 
variants  bind  preferentially  to  peptides  containing  certain  amino  acid  patterns. 
Predictions  are  based  on  published  data  on  HLA  allele  specific  binding-motifs  and 
anchor  residues.  The  predictive  models  assume  each  amino  acid  along  a  peptide 
contributes a certain amount of energy to the peptide-MHC class I complex interaction. 
The level of contribution by an amino acid is also dependent on its relative position. The 
overall  binding  score  given  to  a  peptide  is  the  summation  of  these  individual 
contributions. High peptide binding affinity for MHC class I molecules is essential for 
antigen presentation on APCs and is a good predictor of peptide immunogenicity. 
  Processing  of  peptides  was  also  taken  into  consideration  when  evaluating 
candidate CTL epitopes. The Immune Epitope Database Analysis Resource provides an 77 
 
algorithm, which combines predictions on proteasomal cleavage of protein and TAP-
mediated transport efficiency of the generated peptides into the ER, for loading onto 
MHC class I complexes (Tenzer et al., 2005). The algorithm analyses every peptide 
bond along the TWIST1 amino acid sequence and classifies them as either cleavable or 
non-cleavable. Peptide sequences with favourable cleavage sites at the N-terminal and 
C-terminal residues are predicted to have higher potential of being a T cell epitope. 
Predicted cleavage sites for a given sequence may differ dependent on the prediction 
model chosen; either ‘constitutive proteasome’ or ‘immunoproteasome’. As described in 
Section 1.2.2, immunoproteasomes are induced upon interferon-γ stimulation resulting 
in the upregulation of LMP2 and LMP7 β-subunits – the active sites of the protease 
complex. The TAP complex is responsible for transporting peptides into the ER. The 
TAP transport efficiency for a given peptide is predicted based on its binding affinity 
for TAP, and this is mostly determined by the C-terminus and the first three residues at 
the N-terminus (Peters et al., 2003). The higher the predicted TAP transport efficiency 
for a given peptide, the more likely it would be available in the ER for peptide-loading 
onto MHC class I complexes.  
 
  The work described in the following chapter focuses on the identification of 
TWIST1-derived peptides which bind HLA-A*0201. The rationale for choosing this 
particular HLA class I variant is its high frequency among the Caucasian population in 
the  Western  countries.  The  discovery  of  a  novel  HLA-A*0201-restricted  TWIST1 
tumour antigen could potentially benefit more patients compared to an epitope restricted 
to an uncommon MHC class I allele.  
 
3.1.2.  Generation of peptide-specific CTL lines from HLA-A2 donors 
A  schematic  overview  of  the  steps  involved  in  screening  HLA-A2
+  individuals  for 
peptide-specific  CTL  responses  is  illustrated  in  Figure  3.1.  Autologous  matured 
dendritic cells and CD40L-activated B cells were generated from each HLA-A2
+ donor 
and used as  78 
 
Figure 7 Figure 3.1 Flowchart illustrating the steps involved in the generation of CTL lines from HLA-A2+ 
donors 
Figure 3.1. Flowchart illustrating the steps involved in the generation of CTL 
lines  from  HLA-A2
+  donors.  Details  of  the  procedure  are  described  in  the 
methods and materials section 2.8.4. 
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peptide-pulsed  stimulator  cells.  The  aim  was  to  activate  and  differentiate  peptide-
specific  CD8
+  T  cells  into  cytotoxic  effector  cells  over  four  rounds  or  more  of 
stimulations. Details of the procedure are found in section 2.8.4.  
 
  The four-week in vitro stimulation system used in this work was developed in 
the laboratory of Dr. John Anderson (Yan et al., 2008; Himoudi et al., 2007; Himoudi et 
al., 2008). The main goal of this method is to activate specific naïve CD8
+ T cells 
through  TCR  stimulation  by  peptide-MHC  class  I  ligands,  whilst  minimising  non-
specific  activation  of  CD8
+  T  cells  with  other  TCR  specificities.  Incubation  of 
stimulator cells with high concentrations of exogenous peptide causes the displacement 
of endogenous peptides from MHC complexes. At equilibrium, a large proportion of the 
appropriate  MHC  restricted  molecules  would  be  presenting  the  exogenously  loaded 
peptide. Productive T cell activation occurs only when the TCR stimulation is greater 
than the required threshold. The increased surface concentration of exogenous peptide-
MHC class I ligands on APCs should in turn provide a higher level of TCR stimulation, 
upon CD8
+ T cell recognition, and should therefore result in more productive T cell 
activation. 
 
  LPS  matured  monocyte-derived  dendritic  cells  were  used  for  the  first  two 
stimulations due to their potent T cell stimulatory capacity. DC maturation with LPS 
causes the upregulation of B7 molecules, such as CD80 and CD86, which are important 
T  cell  co-stimulatory  molecules.  Monocyte-derived  DCs  were  also  stimulated  with 
interferon-γ (IFN-γ) and CD40L. IFN-γ stimulation increases surface MHC expression 
(Gaczynska et al., 1993) and CD40 activation results in the ‘licensing’ of DCs, thereby 
enhancing the capacity to prime CD8
+ naïve T cells (Cella et al., 1996).  
 
  The regime of supplementing culture medium exclusively with IL-7 for the first 
two  stimulations,  and  later  with  IL-2,  was  specifically  designed  to  minimise  non-
specific proliferation initially and maximise clonal T cell expansion subsequently. IL-
2/IL-2  receptor  signalling  promotes  proliferation,  differentiation  and  survival  of 
cytotoxic effector T cells; whereas IL-7/IL-7 receptor signalling is important in naïve 
and memory T cell homeostasis. 80 
 
  Preliminary  data  generated  by  Dr.  N.  Himoudi  showed  that  the  predicted 
TWIST1-derived  decamer  peptide,  KLAARYIDFL  (KLA),  was  a  potential  CTL 
epitope. A peptide-specific CTL line was successfully induced from one out of two 
HLA-A2
+ healthy donors using the four-week stimulation protocol (Appendix Figure 
A.1(A)). Subsequently, the T cell line was tested against HLA-A2
+ 293T cells that were 
transfected with either pCI-neo vector only or pCI-neo-TWIST1; the KLA-specific CTL 
line  lysed  60%  of  the  293T/Twist1
  (TWIST1
+/HLA-A2
+)  cells  in  a  chromium-51 
cytotoxicity assay, compared to 5% lytic activity of 293T/vector (TWIST1
-/HLA-A2
+) 
cells at 30 to 1 effector to target ratio (Appendix Figure A.1(B)). The data suggested 
both  natural  presentation  and  immunogenicity  of  the  KLA  peptide;  therefore 
encouraging further evaluation of this peptide as a tumour-associated antigen. 
 
3.1.3.  Antigen specific peptide-MHC complex multimer technology 
Fluorescently labelled peptide-MHC Class I multimeric complexes are valuable tools 
for enumerating T cells with particular antigen specificity. In the work described in this 
thesis,  antigen-specific  T  cells  were  detected  using  Pro5®  MHC  Class  I  Pentamers 
(ProImmune). Traditionally, tetramers were generated by first refolding the MHC class 
I  α-chain  in  vitro,  in  the  presence  of  β2-microglobulin  protein  and  the  peptide  of 
interest.  Monomeric  complexes  were  then  biotinylated  and  coupled  to  fluorophore-
conjugated  streptavidin  protein,  which  contains  four  biotin  binding  sites  thereby 
generating tetrameric complexes (Sun and Bowness, 2001). 
 
  Peptide-MHC Class  I multimers bind to specific T cells as TCR ligands. In 
contrast to antibody-antigen interactions, the binding affinity of monomeric peptide-
MHC Class I complexes with their corresponding TCRs is very low. A study on TCR 
binding kinetics to specific peptide-I-E
k complexes has shown interaction half-life’s of 
2-12 seconds (Matsui et al., 1994) with slow association rates, as measured by surface 
plasmon resonance. Multimerisation of MHC class I molecules increases the strength 
and the duration of the interaction with TCR. The technology was first introduced by 
Altman et al. in 1996 (Altman et al., 1996) to detect human immunodeficiency virus 
(HIV)-derived peptide-specific cytotoxic T cells in infected patients. Pro5® MHC Class 
I  Pentamers  is  a  proprietary  technology  comprising  of  five  peptide-MHC  class  I 81 
 
complexes; it is extensively used in research looking at tumour-specific CTL responses, 
especially for well characterised antigens derived from melanoma. 82 
 
3.2.  Results 
3.2.1.  Expression levels of TWIST1 mRNA 
In order to consider the suitability of TWIST1 as an immunotherapy target, the relative 
expression levels of TWIST1 mRNA in tumour cell lines and in normal tissues were 
profiled.  According  to  published  studies  TWIST1  up-regulation  has  been  found  in 
various types of cancers (Puisieux et al., 2006; Man et al., 2005; Maestro et al., 1999). 
A panel of cancer cell lines derived from the following tumour types were examined: 
neuroblastoma,  osteosarcoma,  rhabdomyosacrcoma,  melanoma,  leukemia,  Ewing’s 
sarcoma, pancreatic, lung, gastric and breast carcinomas. They were cultured until the 
log phase of growth and were harvested for extraction of total RNA. 
 
  The relative expression of TWIST1 in the cancer cell lines were analysed at the 
transcript level. Similarly, a panel of total RNA samples derived from normal adult 
tissues (Clonetech) were also examined. First strand cDNA were synthesised first from 
the total RNA samples and then specific primers and probe sets were used to measure 
the relative expression levels of TWIST1 mRNA in the samples by real-time quantitative 
PCR. 
 
  The relative expression levels of TWIST1 in most normal tissues were either low 
or absent, except in the placenta where it was elevated comparatively (see figure 3.2). 
This finding is consistent with previous reports (Wang et al., 1997) and placenta was 
subsequently used as a positive control for the qPCR analysis experiments. Expression 
of TWIST1 transcripts were comparatively higher amongst the neuroblastoma cell lines 
(SH-SY5Y in particular), RH30 (rhabdomyosarcoma) and TC32 (Ewing’s sarcoma). 
 
3.2.2.  Validating commercial anti-human TWIST1 antibodies 
It was important to verify that these cell lines identified with TWIST1 expression at the 
mRNA level were also expressing the gene at the protein level. There were several 
commercial  antibodies  available  at  the  time,  which  were  raised  against  partial 
recombinant protein of TWIST1: 3E11 (Abnova), H-81 (Santa Cruz Biotechnology) and 
ab49254 (Abcam). Initially, they were tested in Western Blots to ascertain whether they 83 
 
were detecting TWIST1 protein specifically, with a  view that subsequently the best 
antibody would be chosen to characterise the cell lines. 
 
  TWIST1  positive  and  negative  cell  lysates  were  generated  by  transiently 
transfecting 293T cell lines with the pCI-neo/Twist1 plasmid (293T/Twist1) or pCI-
neo/vector plasimd (293T/Vector). Whole cell lysates were prepared in RIPA buffer 
after  48  hours  post-transfection  and  TWIST1  protein  expression  was  analysed  by 
Western Blotting using the commercial antibodies.  
 
  3E11 (Abnova) is a monoclonal mouse IgG1 antibody raised against a partial 
recombinant  protein  corresponding  to  amino  acids  100-203  of  TWIST1  with  a 
glutathione S-transferase (GST) tag. Even when used at very high concentration, it did 
not detect any TWIST1 signal at the predicted size of 21 kDa by Western Blotting 
(Figure  3.3).  The antibody  ab49254  (Abcam)  is  a  rabbit  polyclonal antibody  raised 
against a synthetic peptide corresponding to amino acids 146-195 but when tested it 
gave no signal at all (data not shown). H-81 (Santa Cruz) is a rabbit polyclonal antibody 
raised against amino acids 121-202 of TWIST1 that is widely cited in the literature. As 
shown in Figure 3.3(b), H-81 bound non-specifically and a band was detected near the 
predicted size of TWIST1 in both positive and negative cell lysates, 293T/Twist1 and 
293T/Vector. In summary, the three commercial antibodies tested were not capable of 
detecting TWIST1 protein expression by Western blotting. 
 
3.2.3.  Target cell lines for in vitro assays 
The aim of this study was to demonstrate the induction of cellular responses directed 
against TWIST1 expressing tumours; in particular the CD8
+ T cell HLA-A*0201 MHC-
class I restricted response. Briefly, this involves the in vitro expansion of CTLs against 
TWIST1-derived epitopes and then testing for their capacity to recognise tumour cell 
lines expressing TWIST1 with the relevant MHC-restriction. In order to characterise the 
specificity and MHC-restriction of these CTLs the appropriate positive and negative 
target cell lines must be chosen carefully. 
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Figure 8 Figure 3.2. Relative expression levels of TWIST1 mRNA in cancer cell lines and in normal tissues 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Relative expression levels of TWIST1 mRNA in cancer cell lines and 
in normal tissues. The graph shows the relative mRNA expression (2
-∆∆CT value) of 
TWIST1 in 24 different cancer cell lines (grouped by their types) and in a range of 
normal adult tissue types. Results are means of triplicate measurements and error 
bars represents the standard deviations. mRNA expression levels were measured 
relative to a reference (RH30) and 293T was included in all the assays as an inter-
assay control.  
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Figure 3.3. Validation of antibodies for Western blot analysis of TWIST1 (a) 
Western blot analysis of transiently transfected 293T/Vector cell lysate (TWIST1-
negative),  293T/Twist1  and  SH-SY5Y  cell  lysates  (TWIST1-positive). 
Approximately 50µg of protein were resolved by SDS-PAGE and transferred to 
nitrocellulose  membranes.  They  were  then  incubated  with  3E11  (Abnova) 
monoclonal antibody at a concentration of 3µg/ml (b) Western blot analysis of the 
above cell lysates and HeLa cell derived nuclear extracts (Santa Cruz, Cat # sc-
2120) as an additional positive control. Again 50µg of protein were resolved, 
transferred onto nitrocellulose membranes and incubated with H-81 (Santa Cruz) 
polyclonal antibody at a 1:200 dilution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Figure 3.3. Validation of antibodies for Western blot analysis of TWIST1 
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Three groups of target cell lines were required and were defined by their TWIST1 
protein expression and HLA-A*0201 MHC molecule expression status. The groups are 
called  TWIST1
+/  HLA-A*0201
+,  TWIST1
-  /  HLA-A*0201
+  and  TWIST1
+/  HLA-
A*0201
- with the latter two groups serving as negative controls in target recognition 
assays.  All  the  cell  lines  which  showed  relatively  high  TWIST1  expression  in 
comparison to normal tissues were analysed by  flow cytometry using anti-HLA-A2 
antibody (BB7.2) (data summarised in Table 3.1, not all data shown). All the TWIST1
+ 
neuroblastoma cell lines analysed have little to no expression of HLA-A2 (data not 
shown).  It  is  interesting  to  note  that  the  cell  lines  identified  to  be  HLA-A2
+  have 
relatively low to negligible levels of TWIST1 mRNA.  
Table 7 Table 3.1 Summary of TWIST1 and HLA-A2 expression on target cells 
Target Group Cell line HLA-A2 expression 
(MFI )a
Relative TWIST mRNA 
expression level b
TWIST1+/ HLA-
A*0201+
293T/Twist1 c 4.81 ++++
SH-SY5Y-A2 d 3.02 +
Saos2 8.23 -/+
TWIST1+/ HLA-
A*0201-
SH-SY5Y 0.98 +++
RH30 1.03 ++
SKNAS 1.11 +
TWIST1-/ HLA-
A*0201+ 
SW480 5.81 -
293T/Vector c 4.97 -
aMean Fluorescence Index – calculated by dividing HLA-A2 mean fluorescence intensity by Isotype 
mean fluorescence intensity 
b TWIST mRNA expression level – relative to levels of 293T parental cell line
c 293T cells transfected with either pCI-neo/Twist1  or pCI-neo/Vector plasmids
d SH-SY5Y-A2 is a stably transduced cell line expressing HLA-A*0201 transgene
Table  3.1 Summary of TWIST1 and HLA-A2 expression on target cells
 
 
The lack of TWIST1
+/ HLA-A2
+ cell lines available for use in future assays posed a 
problem.  Therefore,  SH-SY5Y-A2  (a  kind  gift  from  Dr.  Liquan  Gao)  cells  stably 
transduced  with  a  HLA-A*0201  transgene  and  293T/Twist1  a  cell  line  transiently 
transfected with pCI-neo/TWIST1 expression vector will be used as target cell lines for 
the  TWIST1
+/  HLA-A2
+  group.  The  relative  TWIST1  mRNA  expression  levels  and 87 
 
HLA-A2 surface expression for the two cell lines were verified by qPCR and flow 
cytometric analysis, respectively (data not shown). 
 
3.2.4.  In silico prediction of HLA-A0201 binding epitopes 
The  prediction  phase  of  ‘reverse  immunology’  involves  the  in  silico  screening  of 
potential  CTL  epitopes  within  the  TWIST1  protein.  The  algorithms  making  the 
predictions, take into account various parameters and the most important one is the 
predicted binding affinity of a given peptide to a specific MHC molecule. Previous 
experiments have shown that highly stable peptide-MHC complexes are predicted to be 
more immunogenic (van der Burg et al., 1996).  
 
  An in silico screen was carried out to identify potential peptides that may bind to 
HLA-A*0201 molecule with high affinity using the BIMAS (Parker et al., 1994) and 
the SYFPEITHI algorithms. (Rammensee et al., 1999) The top five predicted binders, 
for nonamer and decamer sequences as identified by the two programs, were compared. 
KLAARYIDFL  (KLA)  was  predicted to  have  the  highest  binding  affinity  to  HLA-
A*0201  by  both  algorithms.  SLNEAFAAL  (SLN)  was  ranked  the  best  binder  by 
BIMAS and second by SYFPEITHI for nonamer sequences. The top nonamer binder 
predicted  by  SYFPEITHI  (ALRKIIPTL)  was  ranked  6
th  by  the  other  algorithm, 
therefore SLN epitope was selected on the bases of having the highest overall ranking. 
A summary of the predicted scores and HLA-A*0201 association half-life are given in 
Table  3.2.  Amino  acid  sequences  of  FLU  and  HBV128-140  peptides  were  analysed 
similarly and the predicted half-lifes and scores are also shown in the table below. 
Table 8 Table 3.2 Predicted HLA-A*0201 binding peptides 
Name Sequence Predicted half-life a Score b
FLU GILGFVFTL 550.927 30
SLN SLNEAFAAL 166.413 28
KLA KLAARYIDFL 463.452 27
HBVc128-140 
c TPPATRPPNAPIL < 0.1 19
aBIMAS algorithm program -http://www-bimas.cit.nih.gov/molbio/hla_bind/
bSYFPEITHI algorithm program -http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm
c predictions based on nonamerssequences derived from the HBVc128-140 13 amino acid peptide
Table 3.2 Predicted HLA-A0201 binding peptides
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3.2.5.  In silico prediction of peptide processing score 
The  protein  sequence  of  TWIST1  was  analysed  further  using  the  Immune  Epitope 
Database  (IEDB)  Analysis  Resource  (Vita  et  al.,  2010).  It  provides  combinational 
predictions of proteasome cleavage, TAP transport efficiency and MHC class I binding 
for peptides derived from the input amino acid sequence. Predictions for nonomers and 
decamer peptides, with HLA-A*0201
+ restrictions, were performed and the predicted 
‘Total Score’ given to SLN and KLA were second highest in their respective groups 
(Table  3.3 and  Table  3.4).  In  comparison  to  the top  scoring  decamer  and  nonamer 
epitopes,  KLA  and  SLN  had  higher  predicted  processing  scores  of  1.61  and  1.39, 
respectively.  FLU  peptide was analysed similarly and  it had  a predicted processing 
score of 2.0. The HBV128-140 peptide is 13 amino acid long, the consensus length of a 
MHC-class I restricted-peptide is 8 to 10; therefore it is not likely to be processed and 
found on a naturally occuring MHC class I complex. 
Table 9 Table 3.3 Top five predicted nonameric CTL epitopes from TWIST1 protein sequence 
Table 10 Table 3.4 Top five predicted decameric CTL epitopes from TWIST1 protein sequence 
Sequence Proteasome
Score 
TAP Score MHC IC50 
(nM)
Processing 
Score 
Total Score
KMASCSYVA 1.09 -0.10 9.9 0.99 -0.01
SLNEAFAAL 1.01 0.39 43.9 1.39 -0.25
RYIDFLYQV 1.00 0.45 75.6 1.46 -0.42
SKMASCSYV 1.04 0.15 42.5 1.18 -0.45
LAARYIDFL 1.11 0.49 124.3 1.60 -0.49
T cell epitope prediction using the Proteasomalcleavage/TAP transport/MHC class I combined predictor 
from www.immuneepitope.org
Table 3.3 Top five predicted nonameric CTL epitopes  from TWIST1 protein sequence
 
Sequence Proteasome 
Score a TAP Score b MHC IC50 
(nM)c
Processing 
Score d Total Score
ARYIDFLYQV 1.00 0.44 119.6 1.44 -0.64
KLAARYIDFL 1.11 0.50 274.8 1.61 -0.83
MMQDVSSSPV 0.72 0.15 85.5 0.87 -1.07
LAARYIDFLY 0.93 1.35 3200.5 2.27 -1.23
QSLNEAFAAL 1.01 0.45 505.2 1.46 -1.24
T cell epitope prediction using the Proteasomalcleavage/TAP transport/MHC class I combined predictor 
from www.immuneepitope.org
Table 3.4 Top five predicted decamericCTL epitopes  from TWIST1 protein sequence
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3.2.6.  Identical SLN and KLA amino acid sequences in TWIST2 
A BLAST search was performed to identify genes encoding proteins that may share 
homology  with  TWIST1  protein.  Searching  against  the  human  protein  database, 
TWIST2 was identified to have a high degree of similarity to TWIST1. The alignment 
of the two sequences had a bit score of 228, E-value of 1e-59 and approximately 66% 
sequence  homology.  The  two  peptide  sequences,  SLN  and  KLA,  predicted  to  be 
immunogenic are also found encoded by TWIST2 (Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Figure 3.4. Alignment of TWIST1 and TWIST2 protein sequences 
 
Figure 3.4. Alignment of TWIST1 and TWIST2 protein sequences. TWIST1 
and TWIST2 from NCBI reference sequences NP_000465.1 and NP_476527.1.  
The  alignment  was  generated  using  the  Constraint-based  Multiple  Alignment 
Tool. Dashes represent gaps in the protein sequence. Red letters indicates the 
amino acid sequences for SLN and KLA as predicted in silico. 
  1         10         20         30         40         50         60 
  |         |          |          |          |          |          |           
TWIST1:  MMQDVSSSP VSPADDSLSN SEEEPDRQQP PSGKRGGRKR RSSRRSAGGG AGPGGAAGGG VGGGDEPGSP  
TWIST2:  -MEEGSSSP VSPVD-SLGT SEEELERQP- ---KRFGRKR RYSKKSS--- ---------- -----EDGSP  
 
 
 
 
  70         80         90         100        110        120        130 
  |          |          |          |          |          |          |           
TWIST1:  AQGKRGKKSA GCGGGGGAGG GGGSSSGGGS PQSYEELQTQ RVMANVRERQ RTQSLNEAFA ALRKIIPTLP  
TWIST2:  TPGKRGKK-- ---------- ------GSPS AQSFEELQSQ RILANVRERQ RTQSLNEAFA ALRKIIPTLP  
 
 
 
  140        150        160        170        180        190        200 
  |          |          |          |          |          |          |    
TWIST1:  SDKLSKIQTL KLAARYIDFL YQVLQSDELD SKMASCSYVA HERLSYAFSV WRMEGAWSMS ASH 
TWIST2:  SDKLSKIQTL KLAARYIDFL YQVLQSDEMD NKMTSCSYVA HERLSYAFSV WRMEGAWSMS ASH 
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3.2.7.  Binding affinity of KLA and SLN synthetic peptides to HLA-A*0201 
molecule 
Peptides were synthesised according to the predictions and were tested for their binding 
affinity to MHC Class-I molecules in a T2 binding assay. T2 cell line is TAP-deficient 
and expresses minimal level of HLA-A2 on its surfaces. However, in the presence of 
exogenous  peptide  HLA-A2  expression  increases  due  to  the  stabilisation  effect  of 
peptide-MHC-I  interaction.  This  assay  measures  the  level  of  HLA-A2  upregulation 
upon incubation of test peptide with the T2 cells and HLA-A2 expression is considered 
to be a read out of peptide binding (Figure 3.5(a)).  
 
  Increasing the concentration of peptides incubated with the T2 cells resulted in 
an  increase  of  surface  expression  of  peptide-HLA-A2  molecules  represented  by  the 
mean  fluorescence  index  (MFI).  The  lowest  peptide  concentrations  at  which  up-
regulation  of  HLA-A2  expression  were  observed,  were  approximately  at  1µM  and 
100µM, for SLN and KLA peptides respectively. 
 
  An  ELISA-based  assay  capable  of  measuring  the  equilibrium  dissociation 
constant (Kd) of the peptide-MHC interaction (Sylvester-Hvid et al., 2002) was also 
used  for  confirming  the  data  generated  with  the  T2  binding  assay.  The  assay  was 
performed by Dr. K. Lamberth from the Laboratory of Professor Søren Buus, Denmark 
(Figure 3.5(b)). The first part of the assay involved a ‘renaturation step’, which is the de 
novo formation of MHC-I complexes with the peptide of interest in solution.  The test 
peptide was added to a mixture containing highly purified and denatured HLA-A*0201 
and beta-2-microglobulin; and the higher the affinity of the peptide is for the MHC-I 
molecule, the greater the amount of stable peptide-MHC Class- I complexes that form. 
This is then followed by a quantification step which measures the concentration of 
peptide-HLA-A*0201 complexes by a sandwich ELISA. The peptide concentration at 
which the MHC Class-I molecules are half-saturated is an approximation of the Kd. The 
Kd values for the peptide SLN and KLA were 9nM and 105nM, respectively.  
 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 11 Figure 3.5. Validating the in vitro binding affinity of the predicted peptides 
 
 
 
 
 
 
Figure 3.5. Validating the in vitro binding affinity of the predicted peptides (a) 
Test peptides KLA (number refers to different batches), SLN, FLU and IRR (helper) 
peptides were incubated with T2 cells with increasing concentration (0.1, 1, 10 and 
50µM)  in  a  T2  binding  assay.  Stabilised  peptide-HLA-A2  complexes  on  T2  cell 
surfaces were detected by  FITC-conjugated anti-HLA-A2 mAb. Mean fluorescent 
index (MFI) was calculated with the following formula: mean fluorescent intensity of 
test peptide divided by mean fluorescent intensity of no peptide control. Experiment 
was repeated more than twice. (b) ELISA-based assay measuring the equilibrium 
dissociation constant (Kd) of test peptide-HLA-A*0201 interaction (Sylvester-Hvid 
et al., 2002). 
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3.2.8.  Generation of peptide-specific human cytotoxic T lymphocytes 
The  predicted  peptides  need  to  fulfil  two  criteria  before  considered  as  ‘true’  CTL 
epitopes. Firstly, they must be immunogenic – the ability to induce a class I MHC-
restricted CTL-mediated immune response. Secondly, they are naturally processed and 
presented on cell surfaces as part of a peptide-MHC Class-I complex, preferably on 
tumour cells.  
 
  In  order  to  demonstrate  immunogenicity,  a  method  developed  in  Dr.  John 
Anderson’s group was used to generate peptide-specific CTL lines (Figure 3.1), from 
HLA-A2
+ blood donors. After four weeks of in vitro stimulations, the CTL lines were 
tested for KLA or SLN peptide-specific effector functions such as cytolytic activity and 
interferon-γ release. 
 
  Peripheral blood mononuclear cells (PBMC) isolated from healthy donors were 
first  screened  for  HLA-A2  surface expression  by  flow  cytometric analysis.  Positive 
donors were then used for generating CTL lines against either KLA or SLN epitope. 
Antigen presenting cells such as dendritic cells and B cells were first generated from the 
autologous HLA-A2
+ PBMC. Synthetic peptides were then exogenously loaded onto the 
surface MHC-Class I molecules on the APCs and used as stimulator cells for autologous 
CD8
+ T cells. 
 
  Flow cytometric analysis were performed as a ‘cell quality check’ step on the in 
vitro generated dendritic cells and CD40L-activated B cell cultures before proceeding 
with using them as peptide-pulsed APCs at various stages of the protocol (Figure 3.1). 
For the latter cells, they were stimulated twice weekly with irradiated t-CD40L cells 
until more than 75% of the cells were CD19
+ (data not shown). On day 6 of monocyte-
derived  DC  culturing,  the  following  factors  were  added  to  induce  maturation: 
lipopolysaccharide (LPS), soluble CD40L and Interferon-γ (IFN-γ). Twenty-four hours 
later  matured  DCs  were  phenotyped  by  flow  cytometric  analysis  and  were  found 
consistently to express high levels of surface HLA-DR, CD80, CD86, and CD11c whilst 
staining negatively for the monocyte/macrophage CD14 marker. The following figure 
demonstrates a typical flow cytometric analysis of the in vitro generated mature DC 
culture (Figure 3.6).  93 
 
 
 
 
 
Figure 12 Figure 3.6. A typical flow cytometric analysis of a monocyte-derived dendrtic cell culture 
 
 
 
 
  Figure 3.6. A typical flow cytometric analysis of a monocyte-derived dendrtic 
cell culture. Cells separated by the plastic adherence method were used to generate 
monocyte-derived DCs (see Section 2.8.2). 24 hours after maturation with LPS, 
CD40L and IFN- γ the cells were analysed by flow cytometry using the following 
antibodies: PE-conjugated anti-human CD80 (BD Pharmingen), FITC-conjugated 
anti-human  HLA-DR  (BD  Pharmingen),  PE-conjugated  anti-human  CD11c  (BD 
Pharmingen),  FITC-conjugated  anti-human  CD14  (BD  Pharmigen)  and  FITC-
conjugated anti-human CD86 (BD Pharmingen). Gates were established with the 
following isotypes: PE Mouse IgG1, FITC Mouse IgG2a and FITC Mouse IgG1. 
Red histograms in the bottom panel indicates the isotype controls. 
CD11c
CD14 CD86
CD80 HLA-DR94 
 
3.2.9.  Generation of KLA-specific CTL lines 
To assess the immunogenicity of the peptide sequence, KLA, four different HLA-A2
+ 
donors were tested for the presence of KLA-specific CTL-mediated immune response 
(Table 3.5). Isolated CD8
+ T cells, with purity of more than 95%, were co-cultured with 
matured  autologous  dendritic  cells  (irradiated  at  30Gy)  pulsed  with  50μg/ml  of 
synthetic KLA peptide. The T cell cultures were further stimulated once with KLA-
peptide pulsed DCs and twice with KLA-peptide pulsed autologous CD40L-activated B 
cells at weekly intervals. At the end of the fourth week the CTL lines were counted 
using the trypan blue exclusion method and the fold changes since the initial stimulation 
were calculated (Table 3.5). All the CTL lines decreased in cell numbers, except for the 
BCNH2 CTL line which increased by 1.65 fold. CTL line, BCEP13, failed to expand 
despite  further  re-stimulation  and  insufficient  cell  number  meant  it  could  not  be 
assessed further. Phenotypic analysis of the bulk CTL lines showed that more than 90% 
of the gated live lymphocyte population were CD8
+ (data not shown).  
Table 3.5 Fold change in viable cell count after the fourth peptide stimulation
CTL Line Peptide a Fold change b
BCEP07 KLA 0.5
BC38 KLA 0.6
BCNH2 KLA 1.65
BCEP13 KLA - c
aPeptide used for T cell stimulation in vitro as described in the ‘Materials and methods’
bno. of viable cells after 4thstimulation divided by no. of viable cells in initial        
starting culture
c cultures were stimulated six times in vitro and were discarded due to low cell counts  
 
Table 11 Table 3.5 Fold change in viable cell count after the fourth peptide stimulation 
  In  order  to  assess  the  cytotoxicity  and  peptide-specificity  of  the  CTL  lines 
generated,  a  chromium-51  cytotoxicity  assay  was  used.  T2  cells  pulsed  with  either 
10µM of KLA or FLU peptides were used as target cells. The CTL line generated from 
donor BC38 killed target cells non-specifically, lysing T2/IRR targets more effectively 
than T2/KLA (Figure 3.7(A)). The other two CTL lines, BCNH2 and BCEP7, showed 
little to no cytolytic activities even at a 30 to 1, effector to target ratio (Figure 3.7(B) & 
(C)). 95 
 
  The three CTL lines were re-stimulated again with autologous CD40L-activated 
B cells, in the hope that the limiting number of KLA-specific effector CTLs that maybe 
present would proliferate and expand. At the end of the fifth week, the chromium-51 
cytotoxicity assay was repeated using the same target cells. However, the specific lysis 
of  KLA-pulsed  T2  target  cells  in  comparison  with  T2/IRR  target  cells  were  not 
observed (data not shown). 
 
  To  further  investigate  the  presence  or  lack  of  KLA  peptide  induced  CTL 
immune response in the repeatedly stimulated CTL lines, flow cytometric analysis was 
performed  on  the  BCNH2  CTL  line.  Using  a  PE-conjugated  KLAARYIDFL/HLA-
A*0201 pentamer, CD8
+ T cells that have TCR specificity for the same peptide-MHC 
Class-I complex would  be detected. However, the 0.3% percent KLA/HLA-A*0201 
pentamer positive population detected  was the same as the background non-specific 
staining  when  using  the  control  pentamer  (PE-conjugated  VILKKATEYV/HLA-
A*0201 pentamer) (Figure 3.8).  
 
3.2.10. Generation of SLN-specific CTL lines 
To assess the immunogenicity of peptide SLN, five different HLA-A*0201
+  donors 
were tested for the presence of SLN-specific CTL-mediated immune response (Table 
3.6). As before, CTL lines were generated using the ‘four-week stimulation protocol’ 
starting with isolated CD8
+ T cells and were then in vitro stimulated with SLN peptide-
pulsed  
Table 12 Table 3.6 Peptide directed CTL lines generated from HLA-A2
+ donors 
 
Donor name Peptidesa
BCEP18 SLN, NY
BCEP22 SLN
BCEP23 SLN
BCEP25 SLN, NY, FLU
BCEP28 SLN, FLU
aPeptides used for T cell stimulation in vitro as described in the ‘Materials and methods’
Table 3.6 Peptide directed CTL lines generated from HLA-A2+donors 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Figure 3.7. Cytotoxic activities of KLA peptide-induced CTL lines from HLA-A2+ donors after four 
week stimulation 
Figure 3.7. Cytotoxic activities of KLA peptide-induced CTL lines from HLA-
A2
+ donors after four week stimulation. Purified CD8
+ cells from three separate 
donors (A) BC38 (B) BCNH2 (C) BCEP7 were stimulated with the peptide KLA 
(see Section 2.8.4) before testing in assay. Target cells used were T2 cells pulsed 
with  10M  of  either  KLA  peptide  (T2/KLA)  or  FLU  peptide  (T2/IRR).  The 
chromium-51  cytotoxicity  assays  were  performed  as  described  in  Section  2.9. 
Three different ratios of effector T cells to target cells were tested. Data shown are 
means of triplicate measurement of percentage lysis of target cells within a single 
experiment. The CTL  lines were  restimulated and the assays were repeated to 
confirm results.  
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Figure 14 Figure 3.8. Antigen-specific T cells were not detected in the BCNH2 CTL line 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Antigen-specific T cells were not detected in the BCNH2 CTL line. 
CD8
+ T cells from BCNH2 donor were stimulat ed in vitro for four weeks (see 
Section 2.8.4). On day 5, after the fourth restimulation the CTL line was analysed 
by  flow  cytometry  for  the  presence  of  antigen-specific  T  cells.  PE-conjugated 
KLAARYIDFL/HLA-A*0201  and  VILKKATEYV/HLA-A*0201  pentamers, 
FITC conjugated anti-CD8 antibody. Cytometer gates were established with the 
following isotype control antibody FITC Mouse IgG1.  98 
 
autologous APCs. For positive controls, CTL lines against NY-ESO-1157-165 (NY) and 
FLU peptides were also generated in parallel. The names of the CTL lines will be 
referred to by their donor name followed by the peptide used for stimulation. 
 
  The five CTL lines stimulated with the peptide SLN were analysed by flow 
cytometry  for  CD8  T  cell  marker  and  their  TCR-specificity  for  SLN/HLA-A*0201 
MHC class I complexes by MHC Class-I pentamer staining. Seven days after the second 
stimulation more than 85% of the gated population expressed the CD8 marker in all the 
CTL  lines.  However,  there  were  no  notable  differences  between  the  percentages  of 
pentamer/CD8
+ double-positive cells when stained with SLN//HLA-A*0201 pentamer 
compared with the control pentamer staining (Left hand panels in Figure 3.9). Analysis 
was repeated again seven days after the third stimulation and SLN specific CTLs were 
detected in one of the CTL lines. Flow cytometric analysis of BCEP18 SLN CTL line 
showed that 0.28% of the total CD8-positive cell population were also SLN//HLA-
A*0201 pentamer positive compared to the 0.02% of cells stained positively with the 
control  pentamer  (right  hand  panel,  Figure  3.9(a)).  FLU/HLA-A*0201  pentamer-
positive CD8
+ T cells were also detected after the second and third stimulation in both 
BCEP25 FLU and BCEP28 FLU CTL lines (Figure 3.10 (c-d)). In contrast, there were 
no detectable NY/HLA-A*0201 pentamer-positive CD8
+ T cells within the other two 
control CTL lines generated against the peptide NY-ESO-1157-165 (Figure 3.10 (a-b)). 
 
  A week after the fourth re-stimulation, the cytotoxicity of the CTL lines was 
assessed in a chromium-51 cytotoxicity assay (data shown in Figure 3.11). Labelled T2 
cells were used as target cells and they were pulsed with one of the following peptides 
SLN, FLU or NY peptide. Target cells were co-cultured with CTL responder cells and 
incubated  at  37
oC  for  4  hours.  Supernatants  containing  chromium-51  released  from 
lysed  target  cells  were  harvested  and  quantified.    One  out  of  the  five  CTL  lines 
generated against the SLN peptide showed specific lysis of T2/SLN target cells. The 
BCEP18 SLN CTL line was able to lyse 51% of T2/SLN targets, at a 20 to 1 (E:T) 
ratio, compared to 31% specific lysis of T2/FLU target cells (Figure 3.11(a)). BCEP18 
SLN CTL line lysed a greater percentage of T2/SLN targets at a 10:1, effector to target 
ratio, in comparison to T2/FLU targets, but no peptide-specificity was observed at a 2:1 
ratio. 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  15  Figure  3.9  Analysis  of  SLN/HLA-A*0201  specific  CD8+  T  cells  by  flow  cytometry
Figure  3.9.  Analysis  of  SLN/HLA-A*0201  specific  CD8
+  T  cells  by  flow 
cytometry. The following CTL lines were analysed by flow cytometry seven days 
after the 2
nd and 3
rd restimulation by peptide-pulsed autologous APCs (A) BCEP18 
SLN (B) BCEP22  SLN (C)  BCEP23 SLN (D) BCEP25 SLN and (E) BCEP28 
SLN.  Antigen  specific  T  cells  were  detected  using  biotinylated 
SLNEAFAAL/HLA-A*0201  pentamer  and  streptavidin-PE.  For  background 
staining control – a biotinylated pentamer with a different peptide/HLA-A*0201 
combination was used (IRR/ HLA-A*0201). APC-conjugated anti-CD19 antibody 
and FITC-conjugated CD8 antibodies were used for staining. 
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Figure 16 Figure 3.10. Analysis of FLU/HLA-A*0201 and NY/HLA-A*0201 specific CD8+ T cells by flow 
cytometry
Figure  3.10.  Analysis  of  FLU/HLA-A*0201  and  NY/HLA-A*0201  specific 
CD8
+ T cells by flow cytometry. The following CTL lines were analysed by flow 
cytometry seven days after the 2
nd and 3
rd in vitro stimulation by peptide-pulsed 
autologous APCs (A) BCEP18 NY (B) BCEP25 NY (C) BCEP25 FLU and (D) 
BCEP28 FLU. Antigen specific T cells were detected using biotinylated NY/HLA-
A*0201  (SLLMWITQV/HLA-A*0201)  or  FLU/HLA-A*0201  pentamer  and 
streptavidin-PE.  For  background  staining  control  and  setting  gating  –  a 
biotinylated pentamer with a different peptide/HLA-A*0201 combination (IRR/ 
HLA-A*0201) and FITC Mouse IgG1 isotype control were used. APC-conjugated 
anti-CD19, FITC-conjugated CD8 antibodies were also used for staining.  
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Figure 17 Figure 3.11. Cytotoxic activities of peptide-induced CTL lines from HLA-A2+ donors after four 
week stimulation 
Figure  3.11.  Cytotoxic  activities  of  peptide-induced  CTL  lines  from  HLA-A2
+ 
donors after four week stimulation CTL lines from HLA-A2
+ donors (a) (top row 
from left-right) BCEP18, BCEP22, BCEP23, (bottom row) BCEP25 and BCEP28 were 
generated  against  SLN  peptide  (b)  BCEP18  and  BCEP25  were  generated  against 
NYESO1 peptide (c) BCEP25 and BCEP28 were generated against the FLU peptide. 
Target cells used were T2 cells pulsed with 10M of either KLA peptide (T2/KLA), 
FLU  peptide  (T2/FLU)  or  NY-ESO-1  peptide  (T2/NYESO1).  Different  ratios  of 
effector CTLs to peptide-pulsed T2 target cells were tested (E:T).  The assays were 
performed as described in ‘Materials and methods’. Data shown are means of triplicate 
measurement of percentage lysis of target cells within a single experiment. 
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Three out of the four CTL lines, induced against FLU and NY-ESO-1 peptides, lysed 
greater percentages of T2 cells pulsed with their relevant peptides in comparison to the 
control peptide loaded T2 cells (Figure 3.11(b-c)).  The increased capacity to lyse SLN-
peptide loaded targets by the BCEP18 SLN CTL line suggests the presence of antigen-
specific CTLs. Furthermore, the detection of pentamer binding CD8
+ T cells by flow 
cytometry correlates with the observation of enhanced killing of T2 cells pulsed with 
the appropriate peptide. 
 
  For further confirmation, IFN-γ ELISPOT was used to assess the specificity of 
IFN-γ production upon peptide re-stimulation of the CTL lines. Seven days after the 
fourth re-stimulation effector cells from the CTL lines were co-cultured with target cells 
pulsed with different peptides at different effector to target ratios. They were incubated 
in wells of a96-well filter plate pre-coated with capture antibody for 22 hours. The IFN-
γ secreted in response to antigen recognition bound to the pre-coated capture antibody 
and was then detected by a biotinylated antibody specific for IFN-γ and visualised as 
spots using extravidin-HRP and substrates. The number of spots detected indicates the 
number of IFN-γ secreting cells present. When effector cells from the BCEP18 SLN 
CTL line were co-cultured with T2/SLN cells at a 2 to 1 E:T ratio (see Figure 3.12), the 
mean number of spots detected was higher in comparison to T2/FLU target cells. The 
data shown here is in line with previous data which demonstrated SLN peptide-specific 
cytotoxicity by the BCEP18 SLN CTL line.  There was no T2/SLN specific response 
observed in the other two CTL lines BCEP22 and BCEP23. 
 
3.2.11. Single cell cloning of BCEP18 SLN CTL line by limiting dilution 
A  CTL  line  contains  a  heterogeneous  population  of  T  cells  with  different  antigen-
specificity and their ability to recognise low concentrations of a given antigen-MHC 
class I complexes normally found on target cells are limited. In order to circumvent this 
problem and to enable the study of T cells that solely recognise a single antigen-MHC 
class I  
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Figure 18 Figure 3.12. Antigen-specific CTLs secrete interferon-γ in response to peptide recognition in an 
ELISPOT assay 
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Figure 3.12. Antigen-specific CTLs secrete interferon-γ in response to peptide 
recognition in an ELISPOT assay. MultiScreenHTS-IP Filter Plates were coated 
with 10µg/ml of anti-IFN-γ capture antibody at 4
oC, overnight. At the end of the 
fourth  stimulation,  SLN -directed  CTL  lines  generated  from  donors  BCEP18, 
BCEP22 and BCEP23; and NY-ESO-1 peptide directed CTL line generated from 
donor BCEP18 were co-cultured with T2 cells pulsed with 10µM of peptide (SLN, 
FLU or NYESO1) at two different effector to target ratios (E:T) in the pre -coated 
filter plates. Cells were incubated at 37
oC in 5% CO 2, for 20 hours. Cells we re 
discarded and secreted IFN-γ was detected using biotinylated anti-IFN-γ detection 
antibody and ExtrAvidin®- alkaline phosphatase. Spots were then developed and 
counted by an ELISPOT plate reader. Data show means of duplicate measurement 
of  spots  formed  within  a  single  experiment.  (Details  of  above  procedures  are 
described in section 2.12) 
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complex; these antigen specific T cells have to be isolated from the CTL line first. The 
technique used to achieve this was single cell cloning by limiting dilution.   
 
  Cells thawed from cryo-preserved aliquots of the BCEP18 SLN CTL line were 
re-stimulated for the 5
th time, and cloning by limiting dilution was performed on the 
seventh day. Cells were diluted with a large volume of culture medium so that every 
100μl in volume it would contain approximately 1 cell. 300 wells containing 1 cell and 
60 wells containing 10 cells, were established with irradiated autologous feeder cells, 
and stimulated with PHA and IL-2. Two weeks later, a chromium-51 release split-well 
assay was performed to screen for antigen-specific sub-cultures. However, none of the 
sub-cultures  showed  any  cytotoxicity  against  both  T2/SLN  and  T2/FLU  (data  not 
shown). Analysis of a selected few sub-cultures revealed only approximately 5% of 
total gated cells were positive for the CD8 marker (data not shown). 
 
 
3.3.  Discussion 
 
3.3.1.  TWIST1 expression is elevated in a range of cancer cell lines in comparison 
to levels in healthy adult tissues 
The relative expression levels of TWIST1 were profiled across a range of cancer cell 
types and normal tissues using real-time quantitative PCR. The objective of screening 
different cancer cell lines is two-fold: first to confirm published findings of aberrant 
TWIST1 expression in specific cancers; and secondly to identify cell lines to be used as 
model targets in subsequent functional assays screening for TWIST1-derived antigen-
specific T cells. 
 
  Data from the screening showed that the relative expression levels of TWIST1 
mRNA  in  neuroblastoma  (SH-SY5Y,  CLB-Bab,  SKNMC)  and  rhabdomyosarcoma 
(RH30) cell lines were significantly higher in comparison to most normal tissues, which 
conferred with previous findings (Puisieux et al., 2006; Maestro et al., 1999). Analysis 
of  breast  carcinoma  (MDA-MB-231,  MCF-7  and  ZR-75-1)  cells  did  not  reveal  an 
elevated  gene  expression  profile.  However,  previous  studies  have  found  that  cells 105 
 
positively  selected  for  their  invasive  abilities  from  MCF-7  cells  had  high  levels  of 
TWIST1 expression, whereas the parental cell line did not (Cheng et al., 2007). TWIST1 
was also shown to play an important role in the epithelial-to-mesenchymal transition 
(EMT) process in murine breast carcinoma in vivo (Yang et al., 2004) and was found to 
be  upregulated  in  samples  from  hepatocellular  carcinoma  patients  with  metastatic 
lesions (Lee et al., 2006). TWIST1 is not constitutively expressed in the breast cancer 
cell lines used, but may have the capacity to upregulate gene expression when the cells 
undergo EMT changes. 
 
  Analysis of total mRNA from a panel of human tissues (Clonetech) showed that 
TWIST1  transcript  levels  were  low  but,  with  the  exception  of  the  placenta  and  the 
uterus, concurred with previous findings (Wang et al., 1997). The low levels found in 
most adult tissues suggest the chances of toxicity as a result of targeting TWIST1 by 
immunotherapy are small. The higher expression levels found in placenta and uterus 
tissues suggest a higher risk for treating females. An ideal immunotherapy target would 
have high expression levels in a broad range of cancers with little to no expression in 
the normal tissues of the body. These are important characteristics to consider in order 
to maximise the chances of successful immunotherapy treatment and minimising the 
chances of triggering an adverse autoimmune response. 
 
  Validation of TWIST1 expression in cancer cell lines by immunoblotting would 
have  given  a  clearer  indication  regarding  which  tumour types  could  be targeted  by 
cellular therapy. Three commercial antibodies were tested on protein lysates made from 
293T cells transfected with either pCI-neo vector or pCI-neo-TWIST1, and SH-SY5Y 
cells  previously  shown  to  express  high  levels  of  TWIST1  transcript.  The  numerous 
bands detected made it difficult to distinguish the specific signals. However, taking 
together  the  real-time  quantitative  PCR  data  and  the  reported  roles  of  TWIST1  in 
tumour progression, further assessment of TWIST1 as a therapeutic target is warranted. 
The  early  indication  suggests  that  targeting  TWIST1  could  be  beneficial  for 
neuroblastoma and rhabdomyosarcoma cancer patients and in addition, could also be a 
potential adjuvant immunotherapy treatment for prevention or eradication of TWIST1
 
expressing micro-metastatic tumours. 
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3.3.2.  Identification of two potential CTL epitopes in TWIST1 
Prediction tools were used to identify candidate HLA-A*0201-restricted CTL epitopes 
within the TWIST1 protein. Two potential epitopes were selected for further evaluation: 
a decamer peptide – KLAARYIDFL (KLA) from TWIST1 amino acids 150-159 and a 
nonamer  peptide  –  SLNEAFAAL  (SLN)  from  amino  acids  123-131.  HLA  class  I 
molecules preferentially bind to nonamers, but peptides of 8 to 11 amino acids have also 
been reported through peptide elution studies, to associate with HLA class I molecules 
(Escobar et al., 2008). 
 
   Selection of the two epitopes was based on the overall ranking of HLA-A*0201 
binding  and  peptide  processing  by  three  different  computer-based  prediction  tools. 
However, the MHC binding ‘scores’ given to KLA and SLN epitopes varied across the 
methods.  SYFPEITHI  algorithm  predicted  the two  epitopes  to  have  similar  binding 
affinity to HLA-A*0201; the other two methods predicted SLN to have 2.8 to 6.2 fold 
greater MHC binding affinity than KLA. 
   
  Binding capacity of KLA and SLN peptides to HLA-A*0201 was confirmed by 
the T2 binding assay and quantitative ELISA (Sylvester-Hvid et al., 2002), performed 
by Dr. K. Lamberth (Denmark). In agreement with initial predictions, the in vitro data 
showed that the SLN peptide had a higher HLA-A*0201 binding affinity than KLA. 
High affinity peptides are selectively loaded onto MHC class I molecules in the ER, 
whereas peptides with low affinity are actively displaced from the MHC complexes by 
tapasin-ERp57 heterodimer interaction (Wearsch and Cresswell, 2007). Therefore, the 
data suggests that the SLN peptide is more likely to form a stable peptide-HLA-A*0201 
complex than the KLA peptide during the peptide-loading process in the ER. However, 
without  profiling  a  range  of  known  tumour  antigens  with  varying  degrees  of 
immunogenicity it is difficult to infer whether the binding activities of the two peptides 
are sufficient for antigen presentation. 
 
  Prediction  of  peptide  processing  was  performed  using  the  IEDB  Analysis 
Resource.  The  prediction  outcome  suggests  KLA  and  SLN  peptides  to  have  high 
potentials  of  being  T  cell  epitopes.  Retrospective  analysis  of  putative  C-terminal 
cleavage sites along the TWIST1 protein with NetChop 3.1 server (Nielsen et al., 2005), 107 
 
showed that a cleavage site was predicted for amino acid position 131 (SLN peptide) 
but  not  position  159  (KLA  peptide).  In  vitro  degradation  of  TWIST1  protein  with 
purified proteasomes and the analysis of cleavage products  (Asemissen et al., 2006; 
Kessler et al., 2001) may have provided clues to the natural processing of KLA and 
SLN epitopes.   
 
3.3.3.  TWIST1 and TWIST2 share high sequence homology 
KLA and SLN peptide sequences are also found in the TWIST2 protein sequence. This 
raises additional concerns of whether KLA and SLN specific cytotoxic T cells could 
potentially recognise and kill TWIST2
 expressing targets; and whether this might lead 
to  unwanted  toxicity  during  adoptive  T  cell  therapy  when  targeting  these  epitopes. 
TWIST2,  also  known  as  Dermo-1,  is  a  member  of  the  basic  helix-loop-helix 
transcription factor family. It is implicated to regulate osteoblast differentiation in early 
bone development, sharing similar but distinct functions to TWIST1 (Lee et al., 2000). 
Studies  on  Twist2  knockout  mice  revealed  its  possible  role  in  regulating  myeloid 
lineage development and in the suppression of pro-inflammatory cytokine production by 
mature myeloid cells (Sharabi et al., 2008). If the TWIST1-derived epitopes were to be 
assessed in the pre-clinical setting, it would be important to consider the implications of 
CTL response against TWIST2 expressing haemopoietic cells and effect on myeloid 
cell number and function.  
  
3.3.4.  No induction of KLA- specific CTL response in HLA-A2
+ donors screened 
The KLA peptide did not induce an antigen-specific CTL response in the four HLA-A2
+ 
donors screened, using the four week in vitro stimulation method as outlined in figure 
3.1. The number of viable CD8
+ T cells in three out of four CTL lines established 
decreased over the four week period. This suggests that the CD8
+ T cells isolated from 
these  individuals  were  not  activated  by  the  peptide-pulsed  antigen  presenting  cells, 
hence the lack of T cell expansion. The number of cells increased for one of the CTL 
lines (BCNH2) and this observation could be a result of either KLA-specific T cell 
activation or non-specific activation. However, none of the CTL lines showed specific 
cytotoxicity  against  T2  cells  pulsed  with  KLA  peptide.  Further  examination  of  the 
BCNH2  CTL  line  with  a  KLA/HLA-A*0201  pentamer  reagent  failed  to  detect  the 108 
 
presence of antigen-specific CTLs. This indicates that at the time of testing the CTL 
lines  did  not  contain  significant  numbers  of  CTLs  with  TCR  specificity  for  the 
KLA/HLA-A*0201 complexes. 
 
  The lack of KLA-specific immune response observed could be explained by the 
absence of KLA-specific CTL precursors within the T cell repertoires of the HLA-A2
+ 
individuals  analysed.  T  cells  that  react  against  self-antigens  are  negatively  selected 
during T cell development in the thymus. One could speculate that the central tolerance 
mechanism eliminated T cells with high-avidity for the KLA epitope and only the T 
cells  with  low-avidity  were  able  to  mature,  and  enter  the  peripheral  circulation. 
However, the presence of KLA-specific CTL precursors could not be excluded because 
the  peptide-pulsed  APCs  could  have  failed  to  provide  the  necessary  T  cell  co-
stimulation in order to trigger the differentiation of naïve CD8
+ T cells into activated 
effector CTLs. The low HLA-A*0201 binding affinity of the KLA peptide, relative to 
FLU, could limit the amount of KLA peptide-loaded MHC class I complexes available 
on the surfaces of APCs. Studies have previously looked at the effects of gp100 peptide-
class I MHC surface density on dendritic cells and the size of CTL response generated, 
and have demonstrated a positive correlation between the two (Bullock et al., 2000b). 
Therefore, the intrinsic HLA-A*0201 binding affinity of KLA could be detrimental to 
its  immunogenic  potential.  Screening  more  HLA-A2
+  individuals  or  patients  with 
TWIST1
+ tumours would give a clearer indication of the immunogenicity of the KLA 
epitope. 
 
3.3.5.  Induction of a SLN- specific CTL response in HLA-A2
+ donors screened 
The SLN peptide was able to induce an antigen-specific CTL response in one out of the 
five HLA-A2
+ donors screened, using the same in vitro culturing system. In order to 
gain confidence in the stimulation method that was being used, CTL lines  from the 
same donors were also induced against known antigens such as Influenza A virus MP58-
66 and NY-ESO-1157-165. Antigen-specific CTL responses were assessed by MHC class I 
pentamer staining, chromium-51 cytotoxicity assay and enumeration of IFN-γ secreting 
cells by ELISPOT assay.  
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  The  HLA-A*0201-restricted  influenza  A  MP58-66  peptide  (FLU)  is  highly 
immunogenic as demonstrated by previous studies (list of references can be found at 
IEDB  website  –  www.immuneepitope.org,  Epitope  ID:  20354).  Most  individuals 
possess  pre-existing  memory  CD8
+  T  cells  against  the  FLU  epitope,  generated  by 
previous seasonal human influenza A infections  (Lee et al., 2008). In this instance, 
FLU-specific CTL responses were induced in both of the individuals tested. Donor 
BCEP25 had a higher percentage of FLU/HLA-A*0201 pentamer
+ and CD8
+ cells than 
donor BCEP28; and the FLU induced CTL line from the former donor demonstrated a 
higher level of cytotoxicity against the FLU-pulsed T2 cells than donor BCEP28, which 
is  consistent  with  the  higher  number  of  antigen-specific  CTLs  observed  in  donor 
BCEP25.  
 
  NY-ESO-1157-165 peptide was shown to induce CTL responses against the self-
antigen NY-ESO-1, a cancer-testis antigen, which is found to be expressed in a range of 
cancers  (Zhao  et  al.,  2005).  Relative  to  the  FLU  peptide,  NY-ESO-1157-165  is  less 
immunogenic and of the two individuals tested only one demonstrated specific CTL 
response. It was reassuring to be able to generate peptide-specific CTL lines against 
these known antigens using the four-stimulation protocol. However, the caveat of not 
demonstrating  FLU  or  NY-ESO-1  specific  responses  in  parallel to  the  induction  of 
SLN-specific CTL response, for the same donor, is that a negative outcome could be 
attributed to the quality of the autologous APCs generated; rather than the absence of 
SLN-specific CTL precursors. 
  Nonetheless, the work here has demonstrated that the putative TWIST1-derived 
SLN epitope was immunogenic in donor BCEP18, but suggests that the CTL precursor 
frequency in the T cell repertoire of healthy HLA-A2
+ individuals could be low. A small 
population  of  SLN/HLA-A*0201
+  and  CD8
+  T  cells  became  detectable  by  flow 
cytometry,  seven  days  after  the  third  in  vitro  re-stimulation.  In  contrast,  a  higher 
percentage of FLU-specific CTLs became detectable after only two rounds of peptide 
stimulation. This observation might be due to the lower frequency of SLN-specific CTL 
precursors to begin with; alternatively memory T cells specific for FLU but not SLN 
could  be  present  which  have  the  ability  to  respond  rapidly  to  antigen  stimulation 
resulting in a faster expansion of the FLU-specific T cell population. Effector function 
analysis of BCEP18 SLN CTL line confirmed the antigen-specificity by demonstrating 110 
 
specific cytotoxicity and interferon-γ secretion activity against SLN-pulsed T2 cells but 
not irrelevant peptide-pulsed T2 cells.  
 
  Unfortunately, attempts to isolate clonal T cells from the BCEP18 SLN CTL 
line were unsuccessful. In order to study the avidity of the SLN-specific T cells, further 
work would require the isolation of SLN-specific T cell clones and assessment of their 
cytotoxicity against titrating concentrations of peptide-pulsed T2 cells. Although the 
work presented here has demonstrated the immunogenicity of the SLN peptide, it is still 
unclear whether it would be processed endogenously by tumour cells and presented as 
peptide-MHC class I complexes on the cell surface.  111 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. CHAPTER 4 – Results 2 
Generation of peptide-specific alloreactive CTL lines 
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4.1.  Background 
 
The  autologous  T-cell  repertoire  is  shaped  by  central  tolerance  mechanisms 
(Rammensee and Bevan, 1984); self-MHC-restricted T cells with high-avidity for self-
antigens  are  negatively  selected  during  thymic  development.  The  following  chapter 
describes  work  exploring  alternate  strategies  to  circumvent  self-tolerance  and  to 
generate  CTL  responses  against  the  HLA-A*0201-restricted  TWIST1  epitopes, 
described in chapter 3. 
 
4.1.1.  HLA-A*0201 transgenic mice model 
The HLA-A*0201
+ transgenic mice, also known as the HHD mice, are homozygous for 
H-2D
b -/- and mouse β2-microglobulin
 -/- (β2m), and transgenic for a recombinant HLA-
A2.1/H-2D
b monochain, which is covalently linked to a human β2m at the N-terminal 
(Pascolo et al., 1997). The engineered α-chain region comprises of the human α1 and 
α2,  mouse  α3,  transmembrane  and  cytoplasmic  domains.  The  HLA-A2.1/H-2D
b 
chimera  molecule  allows  the  binding  and  presentation  of  HLA-A*0201-restricted 
peptides on the humanised regions, whilst retaining the capacity of CD8 co-receptor on 
T cells to interact with the mouse H-2D
b α3 domain. CD8 functions as a co-receptor 
during T cell activation by stabilising the TCR-peptide-MHC class I interaction. The 
requirement for CD8 is more apparent for T cells with lower TCR avidity than T cells 
with high-avidity TCRs because the latter could form stable peptide-MHC interactions 
without significant CD8 help (Wooldridge et al., 2005). 
 
  HLA-A*0201
+  transgenic  mice  are  commonly  used  for  studying  the  HLA-
A*0201-restricted  immune  responses  against  tumour  antigens  (Firat  et  al.,  1999). 
Studies have utilised this model to generate CD8
+ T cell responses against a variety of 
epitopes derived from tumour antigens such as MAGE-A1 (Pascolo et al., 2001), p53 
(Hernandez et al., 2000) and gp100 (Bullock et al., 2000a). It can also be used as an 
investigative tool for the identification and characterisation of potential HLA-A*0201-
restricted epitopes from within whole protein sequences. 113 
 
4.1.2.  Molecular basis of allorecognition 
Alloreactivity refers to the vigorous immune responses observed in mixed lymphocyte 
reactions  (MLR),  acute  allograft  rejections  and  in  graft-versus-host  diseases. 
Alloreactive  T  cells  are  activated  via  the  recognition  of  allogeneic  peptide-MHC 
complexes (allo-MHC). The precursor frequency of alloreactive T cells to an allo-MHC 
complex is several orders of magnitude higher than any T cell recognition of peptide-
self-MHC ligands. However, the role of peptide determinants in the allorecognition of 
foreign MHC complexes has long been controversial. Comparison of crystal structure 
analysis of 2C TCR co-complexed with its peptide-allo-MHC ligand (H-2L
d-restricted 
QLSPFPFDL)  or  with  its  peptide-self-MHC  ligand  (H-2K
b-restricted  EQYKFYSV) 
indicated that a single TCR can recognise both self and allogeneic peptide-MHC ligands 
by adopting two different binding orientations; yet the interaction is peptide-specific 
because analysis of the surface interaction of the 2C TCR involved both the bound-
peptide determinant and the MHC molecule (Colf et al., 2007). Peptide-pulsing of allo-
MHC  molecule  expressing  APCs,  which  are  deficient  for  antigen  processing 
machineries, have been used extensively to investigate the specificity of alloreactivity 
(Gao et al., 2005; Heath and Sherman, 1991; Heath et al., 1991; Obst et al., 1998; 
Sadovnikova and Stauss, 1996; Sadovnikova et al., 1998; Udaka et al., 1992). In these 
studies both highly peptide-specific allo-restricted T cells and peptide-degenerate T cell 
responses were identified. It was suggested that the TCR possess a certain level of 
flexibility which allows for differential ligand-binding conformations to occur, but to 
what extent, and if it is intrinsic for all TCRs, is still unclear. Interestingly, isolated 
alloreactive  T  cell  clones  have  also  been  shown  to  recognise  multiple  but  distinct 
peptides  presented  on  the  same  allogeneic  MHC  molecule,  with  a  high  degree  of 
specificity (Felix et al., 2007).  
 
  The consensus is that both the bound-peptide and the TCR contacting surface of 
the allogeneic MHC molecule contribute towards T cell allorecognition. However, the 
degree of contribution by the bound-peptide versus the allogeneic MHC molecule may 
vary between clonal alloreactive T cells. The studies mentioned previously, suggest that 
a subset of alloreactive T cells could be peptide degenerate – whereby the interaction is 
dominated  by  the  TCR  binding  to  the  allo-MHC  determinants,  whereas  the  bound-
peptide contributes to a lesser extent towards the allorecognition, resulting in lower 114 
 
peptide  specificity.  At  the  other  end  of  the  spectrum,  allorecognition  by  certain 
alloreactive T cell subsets are peptide-dominated; characterised by high specificity for a 
single  or  even  multiple  peptide  determinants,  as  indicated  by  the  studies  described 
above.  
 
  Maturing  thymocytes  undergo  positive  and  negative  selections  against  self-
peptide-MHC  complexes.  On  the  other hand,  positively  selected thymocytes  do  not 
encounter non-self MHC variants during thymic development. Therefore, the allogeneic 
MHC-restricted T cell repertoire may possibly contain T cells with high-avidity  for 
peptide  determinants  derived  from  self-proteins  but  presented  on  allogeneic  MHC 
molecules.  
 
4.1.3.  Induction of allo-restricted peptide-specific CTLs 
The alloreactive T cell repertoire could potentially be exploited for isolating allogeneic 
HLA-A*0201-restricted CD8
+ T cells with specificities for epitopes derived from the 
TWIST1 protein. Two sources of alloreactive T cells have been investigated in this 
work.  
 
  The first approach involves testing the ability of peptide-pulsed HLA-A*0201
+ 
dendritic cells, generated from the HLA-A*0201 transgenic mice, to induce peptide-
dependent  allo-HLA-A*0201-restricted  CTL  responses  in  syngeneic  C57BL/6 
recipients. The genetic background between the donor and recipient strains are identical, 
except for the xenogenic HLA-A*0201 molecule, hence any non-HLA-A*0201 directed 
alloresponses should be eliminated. A schematic overview of the immunisation protocol 
and the steps involved to screen for peptide-specific allo-restricted CTL responses are 
illustrated in Figure 4.1. 
 
  Xenotransplantation of skin from HLA-A2 transgenic mice to C57BL/6 mice 
resulted  in  acute  graft  rejection;  using  an  isolated  HLA-A2  reactive  CTL  line,  the 
researchers  went  on  to  show  T  cell  recognition  of  HLA-A2-derived  determinants 
presented on self-H-2D
b complexes, thus indicating an indirect recognition mechanism 
(Jurcevic et al., 2001). However, anti-rat MHC antibodies were shown to inhibit the 115 
 
xenogeneic MHC-restricted T cell recognition of mouse CTL clones against rat APCs, 
thus implying the use of the direct recognition pathway (Borenstein et al., 2004). 
 
  The  second  approach  involves  the  in  vitro  induction  of  allo-HLA-A*0201-
restricted peptide-specific CTL responses derived from HLA-A2
- donors, using peptide-
pulsed HLA-A2
+ APCs as stimulators. A schematic overview of the steps involved in 
order  to  screen  for  peptide-specific  allo-HLA-A*0201-restricted  CTL  responses  in 
HLA-A2
- donors are illustrated in Figure 4.2. The stimulation protocol is an adaptation 
of the strategy used by Dr. Liquan Gao, from the laboratory of Professor Hans Stauss 
(University College London, UK) (Gao et al., 2005; Sadovnikova et al., 1998). Peptide-
pulsed monocyte-derived DCs generated from HLA-A2
+ donors were used to stimulate 
CD8
+  T  cells,  isolated  from  HLA-A2
-  donors.  Without  performing  a  detailed  HLA 
typing by gene sequencing, alloreactivity towards the peptide-HLA-A2 complexes, as 
well as other allogeneic MHC variants (total of six possible MHC class I molecules) 
may occur. To avoid further expansion of non-specific alloreactive T cells in subsequent 
in  vitro  re-stimulations;  peptide-pulsed  T2  cells  were  used  to  drive  the  specific 
expansion  of  allo-HLA-A*0201-restricted  peptide-specific  CTLs.  T2  cells  have  a 
defective endogenous antigen presentation pathway and are suited for the presentation 
of exogenously loaded peptides  (Sadovnikova et al., 1998). The resulting bulk CTL 
lines  should  be  enriched  for  anti-HLA-A2  alloreactive  CTLs.  Analyses  were  then 
carried out to identify peptide-specific CTL clones within the bulk line.  The goal is to 
isolate allo-restricted peptide-specific CTLs from the bulk line using various techniques 
such as limiting dilution and magnetic cell sorting.  
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Figure 19 Figure 4.1. Experimental strategy used to induce peptide-dependent allo-HLA-A*0201-restricted 
CTL responses in syngeneic C57BL/6 mouse 
 
 
C57BL/6 mouse 
Day 0: 1
st s.c. immunisation of 0.5-1 x 10
6 cells 
Day 7: 2
nd s.c. immunisation of 0.5-1 x 10
6 cells 
Day 14: 3
rd s.c. immunisation of 0.5-1 x 10
6 
cells 
Day 21: Harvest splenocytes 
In vitro stimulation 
Stimulator cells: 
Irradiated peptide-pulsed T2 cells 
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 Day 28: Repeat in vitro stimulation 
 
Chromium-51 cytotoxicity assays 
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Mature BMDC with TNF-α 
Peptide-pulse BMDC 
Figure  4.1.  Experimental  strategy  used  to  induce  peptide-dependent  allo-
HLA-A*0201-restricted  CTL  responses  in  syngeneic  C57BL/6  mouse. 
Matured bone-marrow-derived dendritic cells (BM-DC) were pulsed with 10M 
of  HBVc128-140  peptide,  with  or  without  pulsing  with  100M  of  KLA  peptide 
before immunisation. Tumour-necrosis factor-α (TNF-α), subcutaneous injection 
(s.c.). Details of the procedure are described in the methods and materials section 
2.16 and 2.17. 117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 Figure 4.2 Experimental strategy used to screen for peptide-specific allo-HLA-A*0201-restricted 
CTL responses in HLA-A2- donors 
 
 
 
Figure 4.2 Experimental strategy used to screen for peptide-specific allo-HLA-
A*0201-restricted CTL responses in HLA-A2- donors. HLA-A2
+ and HLA-A2
- 
donors were identified by flow cytometric analysis using fluorescein isothiocyanate 
(FITC)-conjugated anti-HLA-A2 mAB, clone BB7.2, (BD Pharmingen).  Details of 
the procedures are described in the methods and materials section 2.8.1  – 2.8.2 and 
2.8.5 – 2.13. 
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and interferon-γ ELISPOT assay
Day 14: Second stimulation with peptide-pulsed T2 cells,
Irradiated autologous PBMC feeder cells, IL-2 and IL-7 118 
 
4.2.  Results 
 
4.2.1.  HLA-A*0201 transgenic mice vaccinated with KLA-peptide 
The HLA-A*0201 transgenic mice model is useful for studying HLA-A*0201-restricted 
CTL  responses  (Pascolo  et  al.,  1997).  A  group  of  six  HHD  mice  were  immunised 
subcutaneously (s.c.) at the base of the tail with KLA peptide together with HBVc128-140 
peptide (adjuvant for inducing a stronger CTL response compared to immunisation of 
peptide alone (Firat et al., 1999)), and a group of two control mice with the HBVc128-140 
peptide  only.  The  peptides  were  initially  mixed  with  Incomplete  Freud’s  Adjuvant 
(IFA) to form stable emulsions. By preparing it this way the peptide would be presented 
to the host immune system for a prolonged period of time. Seven days after the second 
immunisation splenocytes were prepared from each individual mouse and were cultured 
ex vivo for a further two weeks by stimulating with 5µM of KLA on day 0 and day 7 
and low-dose Il-2. The six HLA-A*0201 transgenic mice vaccinated with KLA and 
HBVc128-140 peptides will be referred to as M1 to M6, below. The cytotoxic activities of 
the cultures were assessed in a chromium-51 cytotoxicity assay, five days after the 
second  in  vitro  restimulation,  as  shown  in  Figure  4.3.  The  results  showed  that  the 
restimulated splenocytes established from the M1 to M6 mice showed no preferential 
killing against the T2 cells pulsed with either the KLA peptide or the irrelevant (IRR) 
control peptide. In addition, there was no significant difference in activity levels of M1 
to M5 mice against the two peptide-pulsed T2 targets, compared to the negative control 
mice (specific lysis of 24% and 30%).  
 
 
 
 
 
 119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fi 
 
 
 
 
 
 
 
 
 
gure 21 Figure 4.3. Chromium-51 cytotoxic assay testing for the presence of KLA peptide-specific CTLs within 
the cultures established from peptide-sensitised HLA-A*0201 transgenic mice 
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Figure  4.3.  Chromium-51  cytotoxic  assay  testing  for  the  presence  of  KLA 
peptide-specific CTLs within the cultures established from peptide-sensitised 
HLA-A*0201 transgenic mice. Harvested splenocytes were stimulated twice ex 
vivo following the procedures described in section 2.15, before testing in the assay. 
Effector cells from M1-M6 mice, were cultured from splenocytes generated from 
individual HLA-A*0201 transgenic mouse immunised with the KLA-peptide (see 
section 2.14). The ‘Control’ is a splenocyte culture established from the pooled 
samples of two mice, immunised with the HBVc128-140 peptide only, followed by 
ex vivo culturing with interleukin-2. Target cells used were T2 cells pulsed with 
100M of either KLA peptide (T2/KLA) or FLU peptide (T2/IRR). Data shown 
are means of triplicates. Effector to target ratio used was 100:1. 
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4.2.2.  Induction of allo-restricted KLA-specific CTL response in C57BL/6 mice 
The mouse equivalent of TWIST1 contains the same KLA and SLN peptide sequences 
as the human protein. Potentially, the same peptides could be presented on self-MHC 
molecules  in  the  HLA-A2*0201  transgenic  mice  model  and  this  could  lead  to  the 
negative  selection  of  CTLs  with  high-avidity  TCR.    One  way  of  circumventing 
tolerance mechanism, as shown in previous studies (Sadovnikova et al., 1998), is to 
raise CTLs against peptides presented by allogeneic MHC class I molecules. In this 
instance, we hypothesised that the CTL repertoire of C57BL/6 (H-2
b) would not be 
tolerant  to  TWIST1-dervied  peptide  presented  by  the  HLA-A*0201  molecules.  To 
examine this, C57BL/6 mice were immunised with peptide-pulsed HLA-A*0201
+ bone-
marrow-derived  DCs  (BM-DC)  generated  from  HLA-A*0201
+  transgenic  mice 
(C57BL/6 genetic background). 
 
  To generate the BM-DC, bone marrow cells were first isolated from the femur 
and tibia of the HLA-A*0201
+ transgenic mice and were cultured in vitro for 8 days 
with murine cytokines GM-CSF and IL-4 (see section 2.16 for details of procedure). 
BM-DCs  were  analysed  by  flow  cytometry,  24  hours  after  maturation  with  TNF-α 
(Figure 4.4). The analysis showed that approximately 60% of gated cells have high 
levels of CD80 and mouse MHC class II surface expression. Moreover, all of the gated 
cells also expressed human HLA-A2 molecules on their cell surfaces (Figure 4.4)  
 
  The feasibility of using C57BL/6 mice to mount a HLA-A2.1 allo-restricted 
response against the KLA epitope was investigated. Three groups of C57BL/6 mice 
received s.c immunisation of KLA and HBVc128-140 peptide-pulsed HLA-A*0201
+ BM-
DCs (KLA group, mice designated 1 to 5), HBVc128-140 pulsed HLA-A*0201
+ BM-DCs 
(unpulsed  group)  or  phosphate-buffered  saline  (PBS  group)  only.  Splenocytes  were 
extracted after the third vaccination and re-stimulated twice in vitro with T2 cells pulsed 
with  100µM  of  KLA  peptide  and  irradiated  C57BL/6  splenocytes  as  feeder  cells. 
Splenocytes from the unpulsed and PBS group were stimulated with unpulsed T2 cells. 
The re-stimulated cultures were then analysed by flow cytometry and chromium-51 
release assay to determine whether CTLs responded to the allo-MHC-restricted KLA 
peptide.  
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Figure 22 Figure 4.4. Flow cytometric analysis of matured BM-DCs generated from HLA-A*0201 transgenic 
mice 
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MurineMHC class II
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Figure 4.4. Flow cytometric analysis of matured BM-DCs generated from HLA-
A*0201  transgenic  mice.  BMDCs  were  generated  in  vitro  and  matured  with 
100ng/ml of TNF-α, as described in the Section 2.16. The cells were analysed by 
flow cytometry using the following antibodies: FITC-conjugated anti-human HLA-
A2, PE-conjugated anti-mouse MHC class II and PE-conjugated anti-mouse CD80. 
Cytometer  gates  were  established  with  the  following  isotype  controls  (blue 
histogram): FITC Mouse IgG2b, PE Rat IgG2b and PE Armenian Hamster IgG. 
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4.2.3.  Greater CD8
+ T cell population in mice vaccinated with HLA-A2.1
+ BM-
DCs 
Flow cytometric analysis showed that the cultures established from the peptide-loaded 
HLA-A*0201
+ BM-DC vaccinated mice (pooled from 2 mice of the ‘KLA’ group) had 
an increased ratio of CD8
+ to CD4
+ T cells compared with the two control groups ‘PBS’ 
only and unpulsed  BM-DCs.  Figure 4.5 shows that the ‘KLA’  group contained the 
highest percentage of CD8
+ T cells (86%) compared to ‘PBS’ group (51%) and the 
unpulsed group (62%). In contrast, the ‘KLA’ group had the lowest percentage of CD4
+ 
T  cells  (7%)  compared  to  ‘PBS’  group  (14%)  and  the  unpulsed  group  (20%).  The 
increased ratio of CD8
+ to CD4
+ T cells in the ‘KLA’ group suggests an increased 
expansion of CD8 T cells in response to antigenic stimulation. 
 
4.2.4.  Cytotoxicity of ex vivo re-stimulated cultures established from immunised 
C57BL/6  
To evaluate whether there was any functional KLA-specific CTL expansion following 
the in vivo vaccination of KLA peptide-pulsed HLA-A*0201
+ BM-DC and two rounds 
of in vitro re-stimulations, the cultures were tested in a chromium-51 release assay. 
Figure 4.6 shows that the percentage lysis of EL4-A2 targets by splenocyte cultures 
number 1 to 5 (‘KLA’ group) and the unpulsed group, ranged approximately from 30% 
to 60%. However, there were no significant differences between the percentage lysis of 
EL4-A2  cells with or without pulsing of KLA or the negative control peptide. The 
‘PBS’ group demonstrated less than 5% lysis of target cells suggesting an absence of 
alloreactivity towards HLA-A*0201. 
 
4.2.5.  Separating the peptide-directed from the MHC-directed alloreactive 
response 
The  cytolytic  activities  of  the  cultures  measured  above  could  be  described  as  the 
summation of the allo-restricted peptide-specific CTLs and the non-specific, or MHC-
directed, alloreactive T cells. The alloreactivity of the latter group towards the HLA-
A*0201 molecule could have masked the effect of the CTLs responding in a peptide-
dependent manner. 123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 Figure 4.5. Phenotypic analysis of murine T cell lines generated from HLA-A0201+ peptide-pulsed 
DC vaccinated C57BL/6 mice 
86% 62% 51%
14% 20% 7%
CD3
CD4
PBS Unpulsed KLA
CD8
Figure 4.5. Phenotypic analysis of murine T cell lines generated from HLA-
A0201
+ peptide-pulsed DC vaccinated C57BL/6 mice. Flow cytometric analysis 
of splenocytes prepared from C57BL/6 mice after three immunisation with either: 
PBS,  HLA-A0201+  BM-DCs  with  (KLA)  or  without  (Unpulsed)  pulsing  with 
KLA peptide; followed by two weeks of in vitro re-stimulations using T2 cells, 
with or without peptide pulsing, and irradiated C57BL/6 splenocytes (see Section 
2.17).  Live  lymphoid  cells  were  analysed  by  setting  a  gate  according  to  the 
forward  and  side  scatter  profile.  The  cells  were  stained  using  the  following 
antibodies:  PE-conjugated  anti-mouse  CD3,  FITC-conjugated  anti-mouse  CD4, 
FITC-conjugated  anti-mouse  CD8.  Cytometer  gates  were  established  with  the 
following isotype control antibody PE Armenian Hamster IgG isotype control. 124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Figure 4.6. Splenocyte cultures from KLA immunised-C57BL/6 mice have non-specific cytotoxicity 
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Figure  4.6.  Splenocyte  cultures  from  KLA  immunised-C57BL/6  mice  have 
non-specific cytotoxicity. Splenocytes from mice immunised with either HLA-
A*0201+ BM-DC pulsed with KLA peptide (mice 1-5), PBS or HLA-A*0201+ 
BM-DC  only  (unpulsed)  were  stimulated  ex  vivo  for  one  week  before  testing. 
Target cells were EL4-A2 cells (HLA-A*0201+) pulsed with 100 M of KLA 
peptide (EL4/KLA), FLU peptide (EL4/IRR) or unpulsed (EL4). The effector to 
target  ratio  is  30  to  1.  Data  shown  are  means  of  triplicate  measurements  of 
percentage lysis of target cells within a single experiment. 
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  In  order  to  enrich  for  CTLs  with  greater  antigen-specific  reactivity  and  less 
alloreactivity, the primed splenocytes were seeded and stimulated at a lower cell density 
of 10
4 cells per well in a 96-well plate (Section 2.17). On day six, the individual cultures 
were tested in a split-well analysis assay. Each data point in Figure 4.7 represents an 
individual culture and its cytolytic activities towards EL4-A2/KLA and EL4-A2/IRR 
target cells.  
 
  The cultures were then separated into three groups based on their differences in 
percentage lysis against the two targets (% lysis difference = mean  % lysis of EL4-
A2/KLA cells minus mean % lysis of  EL4-A2/IRR cells). Cultures that had a lysis 
difference  between  -5%  and  5%  were  considered  non-specific  or  ‘MHC-directed’. 
Those  that  had  >5%  or  <  -5%  lysis  difference  might  be  recognising  a  peptide 
determinant  and  will  be  referred  to  as  either  ‘KLA-  directed’  or  ‘IRR-  directed’, 
respectively. On this basis, from the 240 cultures analysed, 10 were KLA-directed, 26 
were IRR-directed and 204 were MHC-directed. 
 
  The ten ‘KLA-directed’ cultures and the top three ‘IRR-directed’ cultures were 
re-stimulated with T2 cells pulsed with KLA peptide. After seven days, the expanded 
cultures were tested in a split-well analysis assay. Figure 4.8(A) shows that after the 
third re-stimulation, the percentage lysis difference of the ‘KLA-directed’ group (-2%) 
was markedly different to the IRR-directed group (-14%). The IRR-directed group had 
retained its preferential cytolytic activity towards the EL4-A2/IRR cells pulsed with the 
irrelevant control peptide (FLU). In contrary, the ‘KLA-directed’ group had apparently 
lost  its  peptide  specificity  against  KLA,  as  they  lysed  both  peptide-pulsed  EL4-A2 
targets equally (percentage lysis difference = 0%).  
 
  Each culture was further divided into six wells in a 96-well culture plate and re-
stimulated as described in section 2.17. Figure 4.8(B) shows that by the end of the 
fourth in vitro restimulation the previously observed difference in mean percentage lysis 
difference  between  KLA-directed  and  IRR-directed  group  had  disappeared.  Also  in 
contrast to the third restimulation, both groups lysed both targets equally, resulting in 
approximately 0% mean lysis difference. 126 
 
Figure 4.7. Split-well analysis of splenocyte cultures established from KLA 
peptide immunised-C57BL/6 mice have varied cytotoxic activities. Splenocytes 
from mouse numbers 1, 2 and 4 were seeded at a cell density of 10
4 cells per well, 
in 96-well culture plates. A total of 240 wells were established. Cultures were 
stimulated twice with T2 cells pulsed with  100µM of KLA peptide and irradiated 
splenocytes, see section 2.17. Split-well analysis was performed five days after the 
restimulation. Target cells used were EL4-A2 cells (HLA-A*0201+) pulsed with 
100 M of KLA peptide (EL4-A2/KLA) or FLU peptide (EL4-A2/IRR). Each data 
point on the scatter plot represents each of the 240 wells. Data points lying above 
or below the dotted lines represent wells with a greater percentage lysis of EL4-
A2/KLA targets by 5% or EL4-A2/IRR by 5% respectively. 
 
 
 
Figure 25 Figure 4.7. Split-well analysis of splenocyte cultures established from KLA peptide immunised-
C57BL/6 mice have varied cytotoxic activities 
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Figure  4.8.  Split-well  analysis  of  KLA-directed  and  IRR-directed  cultures 
after the 3
rd and 4
th in vitro restimulation with KLA-pulsed T2 cells.  (A) The 
activities of ten ‘KLA-directed’ and three ‘IRR-directed’ splenocyte cultures were 
determined in a split-well analysis, after the 3
rd in vitro restimulation. (B) Cultures 
were further divided into six wells and their lytic activities assessed after the 4
th in 
vitro restimulation. Target cells used were EL4-A2 cells (HLA-A*0201
+) pulsed 
with 100  M of KLA peptide (EL4-A2/KLA)  or  FLU peptide (EL4-A2/IRR). 
Each  data  point  represents  the  difference  in  percentage  lysis  against  the  two 
targets  by  an  individual  well  (%  lysis  differnce  =  percentage  lysis  of  EL4-
A2/KLA cells minus percentage lysis of  EL4-A2/IRR cells). The scatter plots 
show the means of percentage lysis difference and the error bars represent the 
standard error of mean.  
 
Figure 26 Figure 4.8. Split-well analysis of KLA-directed and IRR-directed cultures after the 3rd and 4th in 
vitro restimulation with KLA-pulsed T2 cells 
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4.2.6.  Circumventing T cell tolerance by generating CTLs from HLA-A2
- donors 
The same rationale was also applied to the human setting in an attempt to break  the 
tolerance against self-antigens. The T cell repertoires of HLA-A2 negative individuals 
are selected against self-MHC molecules and they should not be tolerant to peptides 
presented by non-self HLA-A*0201 molecules. To examine this, T cells from HLA-A2
- 
donors were isolated and screened using the strategy outlined in Figure 4.2. 
 
  CD8
+ T cells isolated from two HLA-A2
- donors were stimulated with KLA or 
SLN peptides presented on HLA-A2
+ DC. The cytolytic activities of the four bulk CTL 
lines were assessed after three rounds of in vitro stimulations and they showed high 
levels of cytotoxicity against T2 targets pulsed with the peptides of interest (KLA and 
SLN) and also the irrelevant (FLU). Figure 4.9 shows that AKLA2 and ASLN1 CTL 
lines  showed  greater  cytotoxicity  towards  the  relevant  targets  compared  with  the 
T2/IRR target, at two different effector to target (E:T) ratios. We hypothesised that the 
difference could potentially be contributed to a population of peptide-specific T cells 
within the bulk line. In comparison, AKLA1 and ASLN2 CTL lines showed increased 
activities against T2 targets pulsed with the peptide of interest at only 3:1 E:T ratio.  
 
  T cell cloning by limiting dilutions (see section 2.8.6) was performed in order to 
isolate peptide-specific CTL clones from the AKLA2 and ASLN1 CTL lines. Micro-
cultures were stimulated twice and screened for  peptide-specific CTLs by split-well 
analysis.  Data  is  summarised  in  Table  4.1;  8/1140  micro-cultures  analysed  had 
detectable  levels  of  cytotoxicity  (greater  than  5% lysis  of  target  cells).  Figure  4.10 
shows that 3 out of 5 positive wells (named 12E2, 7H3, and 11B2) identified from 
limiting dilution of the ASLN1 CTL line, showed 10% or  greater lysis of T2/SLN 
targets over T2/IRR targets. Potential CTL clones/lines were stimulated again in order 
to  obtain  more  cells  for  validation  of  peptide-specificity  observed.  12E2  failed  to 
expand,  whereas  7H3  and  11B2  microcultures  had  limited  expansion  even  in  the 
presence  of  PHA  and  SLN  peptide-loaded  T2  cells.  7H3  and  11B2  had  lost  their 
cytolytic activity when assessed in a chromium-51 release assay (data not shown). 
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Figure 27 Figure 4.9. Cytotoxicity of alloreactive CTL lines induced from healthy HLA-A2-negative donors 
 
 
 
 
 
Figure 4.9. Cytotoxicity of alloreactive CTL lines induced from healthy HLA-
A2-negative  donors.  CD8
+  T cells isolated   from  two HLA-A2
-  donors  were 
stimulated thrice  in vitro with allogeneic HLA-A2
+ monocyte-derived dendritic 
cells  and T2 cells, pulsed with 100µM of KLA or SLN peptide. AKLA1 and 
AKLA2 CTL lines were generated from two separate donors and directed against 
the KLA peptide.  ASLN1 and  ASLN2 CTL lines were  generated from two 
separate donors and directed against the SLN peptide. Details of the procedures 
involved are described in sections 2.8.1  – 2.8.2 and 2.8.5. Target cells used were 
T2  cells  pulsed  with  100M  of  either  KLA  peptide  (T2/KLA),  SLN  peptide 
(T2/SLN) or FLU peptide (T2/IRR). Data shown are means of triplicates and error 
bars represents the standard error of the mean. 
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Table 13 Table 4.1 Analysis and expansion of microcultures established from AKLA2 and ASLN1 CTL lines 
by limiting dilution 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 Figure 4.10. Split-well analysis of  microcultures established  from ASLN1 CTL line by  limiting 
dilution 
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Figure  4.10.  Split-well  analysis  of  microcultures  established  from  ASLN1 
CTL line by limiting dilution. Limiting dilution of ASLN1 CTL line followed 
by two in vitro restimulations, as described in the section 2.8.6, with the SLN 
peptide. 7H3, 11B2, 12E2, 10C2 and 10G1 were identified as positive wells, 
which demonstrated 5% or greater lysis of target cells. Target cells used were T2 
cells pulsed with 100M of SLN peptide (T2/SLN) or FLU peptide (T2/IRR). 
Data shown are single measurements. 
CTL Line Positive wells a Peptide specific wells b Expansion c Validation 
AKLA2 3/780 0/3 - -
ASLN1 5/360 3/5 2/3 Lost of cytolytic activity 
anumber of wells that showed >5% lysisof  either targets
bnumber of wells that showed peptide specificity (>10% difference between lysisof  relevant and irrelevant peptide-
loaded T2 targets)
c number of clones that had expanded sufficiently for further characterisation
Table 4.1: Analysis and expansion of microcutlures established from AKLA2 and ASLN1 CTL 
lines by limiting dilution131 
 
4.2.7.  Detecting antigen-specific T cells within the alloreactive CTL lines 
MHC class I pentamers bind to T cell receptors with defined specificities and are useful 
tools for detecting rare antigen-specific CD8
+ T cell populations by flow cytometry. The 
AKLA1 CTL line was analysed by KLA/HLA-A*0201 pentamer staining, after the fifth 
in  vitro  re-stimulation.  KLA-directed  AKLA3  CTL  line  was  induced  from  another 
HLA-A2
-  donor,  using  the  strategy  outlined  in  Figure  4.2,  and  was  analysed  by 
pentamer staining on day 7 after the third in vitro re-stimulation.  
 
  Flow cytometric analyses were performed on CTL lines AKLA1 and AKLA3 to 
identify CD8
+ T cells which are specific for the KLA/HLA-A*0201 pentamer. In order 
to maximise the chances of detecting a rare antigen-specific population, more than 6.7 
million and 1.8 million events were acquired during the flow cytometric analysis, for 
the  respective  CTL  lines.  Figure  4.11(A)  shows  that  within  the  AKLA1  CTL  line, 
0.22% (>8000 events) of the lymphocyte gated cells were CD8
+ and KLA/HLA-A*0201 
double  positive.  In  contrast,  the  negative  control  –  ASLN1  CTL  line,  which  was 
generated in parallel but against the SLN peptide, had only 0.01% of cells staining 
positive for KLA/HLA-A*201 pentamer and CD8. Antigen-specific CD8
+ T cells were 
not detected in the AKLA3 CTL line (see Figure 4.11(B)) 
 
  The  data  was  re-analysed  with  an  alternate  gating  strategy.  The  first  gate 
selected for the pentamer
high and CD3
+ population. Subsequently, the forward and side 
scatter profile, and the CD8 surface marker were used to characterise the pentamer 
positive population. Figure 4.12(A) shows that, for the AKLA1 CTL line, 89% of the 
KLA/HLA-A*0201 pentamer binding cells were CD3
+ and CD8
+. In comparison, in the 
the  ASLN1  CTL  line  only  33%  of  similarly  gated  cells  were  CD3
+  CD8
+  double 
positive.  Figure  4.12(B)  shows  that  for  the  AKLA3  CTL  line,  2.12%  of  the  gated 
CD8
+/KLA/HLA-A*0201  pentamer
+  cells  lie  within  the  lymphocyte  gate.  In 
comparison,  a  FLU/HLA-A*0201  pentamer
  was  used  to  determine  the  background 
staining of the AKLA3 CTL line and only 0.75% of the pentamer binding cells lie 
within the lymphocyte gate. 
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Figure 29 Figure 4.11. Analysis of alloreactive CTL lines generated against the KLA peptide for antigen-
specific T cells 
 
Figure  4.11.  Analysis  of  alloreactive  CTL  lines  generated  against  the  KLA 
peptide for antigen-specific T cells. (A) AKLA1 and (B) AKLA3 CTL lines were 
generated from different HLA-A2
- donors. They were analysed by flow cytometry 
after the 3
rd in vitro restimulation. 6.5 and 1.5 million events were collected for the 
CTL lines respectively for this analysis. Antigen-specific cells were detected using 
biotinylated KLAARYIDFL /HLA-A*0201 pentamer. Streptavidin-PE was used to 
visualise the pentamer-binding cells. ASLN1 CTL line generated against the SLN 
peptide, a biotinylated GILGFVFTL/ HLA-A*0201 (IRR/HLA-A80201) pentamer 
and FITC Mouse IgG1 isotype control antibody were used to establish cytometer 
gatings.  Cells  were  also  co-stained  with  FITC-conjugated  anti-CD8  and  APC-
conjugated anti-CD3 antibodies.  
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Figure 30 Figure 4.12. Analysis of alloreactive CTL lines generated against the KLA peptide for antigen-specific T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 4.12. Analysis of alloreactive CTL lines generated against the KLA peptide for antigen-specific T cells. Analysis of (A) 
AKLA1 and (B) AKLA3 CTL lines by flow cytometry (data is identical to analysis shown in Figure 4.11) using an alternative gating 
strategy. CD3
+ and KLA/HLA-A*0201 pentamer binding cells were identified first before using the forward  (FS) and side-scatter (SS) 
profiles to identify the lymphocyte populations. 
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4.2.8.  Enrichment of allo-restricted KLA-specific CTLs 
Anti-PE MicroBeads and magnetic cell sorting were used to enrich for antigen-specific 
CTLs from the alloreactive bulk line AKLA1 and AKLA3, pre-stained with the PE-
conjugated KLA/HLA-A*0201 pentamer. The enrichment step was followed by two 
rounds  of  peptide  restimulation  as  described  in  section  2.8.6.  The  aim  was  to 
preferentially  expand  allo-restricted  KLA-specific  T  cells,  instead  of  the  anti-HLA-
A*0201  alloreactive  T  cells;  thus  maximising  the  subsequent  chances  of  isolating 
peptide-specific  clones  by  limiting  dilution.  As  a  direct  comparison,  the  pentamer-
depleted fraction from the magnetic cell sorting  – cells without TCR specificity for 
KLA/HLA-A*0201 pentamer, were also re-stimulated twice under the same conditions.  
 
  Flow cytometric analyses were performed after magnetic cell sorting and two 
rounds of in vitro restimulation. Figure 4.13 shows that 1% (1333 events) of the CD3
+ 
cells  within  the  pentamer-selected  fraction  of  the  AKLA1  CTL  line  (named 
AKLA1
sorted) were CD8
+/pentamer double positive. In comparison, only 0.38% of the 
pentamer-depleted fraction (named AKLA1
depleted) was CD3
+/CD8
+/pentamer
 positive. 
Pentamer selection was also performed on the AKLA3 CTL line and was analysed 
similarly  by  flow  cytometry.  Figure  4.13  shows  that  0.25%  of  the  AKLA3
sorted 
(pentamer-sorted fraction) was CD8
+ and pentamer positive. However, the number of 
events collected for the analysis of AKLA3 was too low to be conclusive. 
 
4.2.9.  Effector function of KLA/HLA-A*0201 pentamer enriched alloreactive 
CTL lines 
AKLA1
sorted and AKLA1
depleted fractions were expanded by peptide restimulation until 
sufficient cell numbers were obtained. Their cytolytic activities were assessed against 
T2 cells pulsed with either KLA (relevant) or SLN (irrelevant) peptides in a chromium-
51 cytotoxicity assay. Figure 4.14(A) shows that by the fourth restimulation after cell 
sorting, the AKLA1
sorted CTL line demonstrated a 62% and 82% mean specific lysis of 
100µM KLA-pulsed T2 cells at 2:1 and 10:1 effector to target (E:T) ratios, respectively. 
In contrast, it showed minimal killing activity (2-6%) towards the 100µM SLN-pulsed 
T2 cells. The AKLA1
depleted CTL line in contrast showed the same level of cytolytic 
activities toward both targets.  135 
 
 
  The AKLA1
sorted CTL line was also tested in an ELISPOT assay to measure the 
number of IFN-γ secreting CTLs in response to antigenic stimulation. Cells recovered 
from cryopreservation were restimulated with KLA peptides and on day 5 after the 
seventh restimulation post-sorting, the AKLA1
sorted CTL line was tested in an ELISPOT 
assay. Figure 4.14(C) shows that the T2/KLA target cells induced a greater number of 
cells to respond, with a mean count of 182 IFN-γ secreting cells per 10
5 cells compared 
to a mean of 109 against T2/IRR (FLU peptide) target cells. However, the response 
towards T2/IRR was higher relative to unstimulated effector cells (data not shown) – 
representing  the  background  response,  suggests  that  the  AKLA1
sorted  contained 
significant numbers of non-specific alloreactive CTLs.  
 
  The AKLA1_PHA CTL line was also established from the pentamer positive 
fraction of the sorted AKLA1 CTL line; but instead of restimulating with peptides-
loaded onto T2 cells, a mitogen was used – phytohemagglutinin (PHA) (see section 
2.7.3). Cytotoxicity was evaluated after the fourth re-stimulation after sorting, as shown 
in Figure 4.14(A); the AKLA1_PHA CTL line lysed 18% and 49% of the KLA-pulsed 
T2 cells at the two E:T ratios; and in contrast it lysed only 2% and 10% of the T2/IRR 
targets, respectively. Figure 4.14(B) shows that the specific activity was retained after 
the  fifth  re-stimulation  with  increased  percentage  lysis  of  the  T2/KLA  target  cells 
killing an average of 39% and 72%, at 2:1 and 10:1 E:T ratios. 
 
  Effector  function  and  antigen  specificities  of  AKLA3
sorted  and  AKLA3
depleted 
CTL fractions were tested in an IFN-γ ELISPOT assay after the third restimulation post-
sorting. Figure 4.14(D) shows that slightly greater number of spot forming cells (sfc) 
were  counted  when  the  AKLA3
sorted  fraction  was  co-cultured  with  T2/KLA  targets 
compared with T2/FLU targets.  Interestingly, the AKLA3
depleted CTL line had a greater 
number of responding cells towards the T2/FLU targets (110 sfc) compared to T2/KLA 
(65 sfc). 136 
 
Figure  4.13.  Flow  cytometric  analysis  of  KLA/HLA-A*0201  pentamer 
sorted  and  depleted  alloreactive  CTL  lines  generated  against  the  KLA 
peptide. AKLA1 and AKLA3 CTL lines were generated from different HLA-
A2
-  donors.  After  the  second  in  vitro  re-stimulations  post-magnetic  cell 
sorting, pentamer sorted (right) and depleted (left) CTL lines were analysed by 
flow cytometry. Antigen-specific T cells were detected by staining with FITC-
conjugated  anti-CD8  antibody,  PE-conjugated  or  biotinylated  KLA/HLA-
A*0201  pentamer and the latter  visualised  with  streptavidin-PE.  Cytometer 
gates were established with FITC Mouse IgG1 isotype control antibody. 
 
  
 
Figure  31  Figure  4.13.  Flow  cytometric  analysis  of  KLA/HLA-A*0201  pentamer  sorted  and  depleted 
alloreactive CTL lines generated against the KLA peptide 
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Figure  32  Figure  4.14.  Functional  characterisation  of  KLA/HLA-A*0201  pentamer  sorted  and  depleted 
alloreactive CTL lines induced against the peptide KLA 
 
 
 
 
 
Figure  4.14.  Functional  characterisation  of  KLA/HLA-A*0201  pentamer 
sorted and depleted alloreactive CTL lines induced against the peptide KLA. 
(A)(B) AKLA1 CTL line was pentamer sorted and restimulated in vitro by either 
KLA  peptide-pulsed  T2  cells  or  PHA  (named  AKLA1
sorted  and AKLA1_PHA 
CTL lines). Pentamer-depleted fraction of AKLA1 was restimulated to generate 
the AKLA1
depleted CTL line. Chromium-51 cytotoxicity assay was performed on 
the 4
th and 5
th restimulation. Target cells used were T2 cells pulsed with 100M of 
either  KLA  peptide  (T2/KLA)  or  SLN  peptide  (T2/IRR).  Different  effector  to 
target (E:T) ratios were used  (C) ELISPOT assay was used to enumerate IFN-γ 
secreting cells within the AKLA1
sorted CTL line in response to PHA, T2/KLA or 
T2/IRR targets. (D) Enumeration of IFN-γ secreting cells within the AKLA3
sorted 
and AKLA3
depleted CTL lines in response to T2/KLA or T2/IRR targets at different 
E:T ratios. Data shown is the mean of triplicates and the error bars represents the 
standard error of the mean. 138 
 
4.2.10. Natural processing and presentation of KLA peptide 
The HEK 293T cell line expresses relatively low levels of endogenous TWIST1 mRNA, 
as  previously  shown  by  qPCR,  and  it  also  expresses  HLA-A*0201  MHC  class  I 
molecules. HEK 293T cells were transiently transfected with pCI-neo-TWIST1 or the 
vector backbone plasmid, pCI-neo. The transiently transfected cells will be referred to 
as 293T/twist and 293T/vector, respectively. In order to test whether the KLA peptide is 
processed  and  presented  endogenously  by  the  293T/twist  cells,  cytotoxicity  of 
AKLA1
sorted  CTL  line  towards  293T/twist  and  293T/vector  cells  were  examined  44 
hours post-transfection. Figure 4.15(A) shows that at 20 to 1 effector to target ratio, 
AKLA1
sorted CTL line lysed approximately 5% of 293T/twist and 293T/vector target 
cells. In the same assay, AKLA1
sorted was able to lyse 55% of the KLA-pulsed T2 cells 
at an E:T ratio of 2:1; and the alloreactive AKLA1
depleted CTL line lysed an average of 
19.4% and 19.2% of the 293T/twist and 293T/vector, respectively at a 10:1 E:T ratio. 
   
  The expression of TWIST1 and the HLA-A2 molecules in transfected 293T cells 
were verified. Total RNA were isolated from the 293T/twist and 293T/vector cells and 
the relative expression levels of TWIST1 transcripts were measured by qPCR. Figure 
4.15(C) shows that the relative expression level of TWIST1 in transfected 293T/twist 
cells was approximately  100-fold higher than the 293T/vector cells and the parental 
293T cells. Flow cytometric analysis of HLA-A2 surface expression on the transfected 
cells, shown in Figure 4.15(B), suggests that the liposome-based transfection process 
decreased the level of HLA-A2 expression, relative to the untransfected 293T cells.  
 
  Attempts to characterise the processing and presentation of the KLA epitope 
further was hampered by the loss of peptide-specific response by the AKLA1
sorted CTL 
line, when recovered from cryopreservation. Effector function of the AKLA1
sorted CTL 
line was tested after the 11
th in vitro re-stimulation post-sorting; against 293T/twist, 
293T/vector target cells or T2 cells pulsed with KLA or SLN peptides. The AKLA1
sorted 
CTL line did not kill T2 cells pulsed with KLA or SLN peptide (data not shown) and 
co-culturing with transfected 293T/twist and 293T/vector cells induced minimal IFN-γ 
production response, which indicates the lack of alloreactivity (data not shown).  139 
 
Figure  4.15.  Cytotoxicity  of  AKLA1
sorted  CTL  line  against  293T  cells 
transfected  with  TWIST1.  (A)  AKLA1
sorted  (asterisks and open symbols) and 
AKLA1
depleted (filled symbols) CTL lines were tested in a chromium-51 cytotoxicity 
assay.  293T  cells  transiently  transfected  with  pCI-neo-TWIST1  plasmid 
(293T/twist) or with the control plasmid (293T/vector) were used as target cells. T2 
cells pulsed with 100µM of KLA peptide (T2/KLA) were also used as targets . Data 
shown  against  transfected  293T  cells   are  means  of  triplicates  and  error  bars 
represents the standard error of the mean. (B) Flow cytometric analysis of HLA-A2 
surface expression on 293T cells before transfection, 293T/vector and 293T/twist 
transfected cells. Analysis was done before (black) and 44 hours (red) after transient 
transfection. Staining was performed using FITC conjugated anti-HLA-A2 antibody 
and  FITC  Mouse  IgG2b  isotype  control  (blue  histogram).  (C)  The  relative 
expression levels of TWIST1 mRNA in untransfected 293T cells, 293T/vector and 
293T/twist transfected cells were measured by real-time PCR as described in the 
section 2.4.  
 
 
Figure 33 Figure 4.15. Cytotoxicity of AKLA1sorted CTL line against 293T cells transfected with TWIST1 
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4.2.11. Antigen-specific CTLs failed to expand in response to mitogenic 
stimulations 
Expanding  the  numbers  of  antigen-specific  CTLs  had  been  challenging  and  the 
consequence of repeated TCR stimulation seemingly led to the functional impairment of 
the AKLA1
sorted CTL line, a phenomenon described as T cell exhaustion (Wherry et al., 
2003; Bucks et al., 2009). Therefore, the use of a potent mitogen was examined with an 
objective to expand the antigen-specific CTLs over a shorter period of time. To this end, 
antigen-specific CTL lines were generated from HLA-A2
+ healthy donors, against the 
HLA-A*0201-restricted FLU and NY-ESO-1 peptides (see Figure 3.1 for the strategy 
used). The expansion of antigen-specific T cell populations was monitored by MHC 
class I pentamer staining. When antigen-specific T cells were detected, the CTL lines 
were  subjected  to  either  stimulation  with  anti-CD3  and  anti-CD28  coupled  beads 
(Invitrogen); or to cell sorting for pentamer binding T cells by fluorescence activated 
cell sorting (FACS), followed by PHA stimulation. 
 
  Flow cytometric analysis of the CTL lines, induced against the FLU peptide, 
after the second restimulation showed that 2.7% and 10.7% of the gated cells were 
FLU-specific CD8
+ T cells (Figure 4.16). Cell sorting by FACS was carried out 7 days 
after the third stimulation; 2 to 3.5 million cells were incubated with FLU/HLA-A*0201 
pentamer  before  sorting.  FLU/HLA-A*0201  pentamer  positive  cells  were  then 
stimulated  in  bulk  with  1ug/ml  PHA,  100  IU/ml  of  IL-2  and  irradiated  autoglous 
PBMCs. Figure 4.14, shows that FLU-specific CD8 T cells were not detected after PHA 
stimulations and only 2% of the forward/side scatter gated cells were CD8
+ T cells in 
the BCEP19 FLU CTL line.  
 
  NYESO1/HLA-A*0201
 pentamer binding CD8
+ T cells were detectable in the 
BCEP18 NY CTL line (Figure 4.17), seven days after the third in vitro restimulation 
with NY-ESO-1157-165 peptide-pulsed APC.  The bulk CTL line was then restimulated 
twice for 14 days with anti-CD3 and anti-CD28 coupled beads, as described in section 
2.7.4. Flow cytometric analysis by NYESO1/HLA-A*0201
 pentamer staining revealed 
that the proportion of antigen-specific cells in the population had decreased whilst the 
proportion of CD8
+ T cells increased to 47%. 
 141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34 Figure 4.16. Flow cytometric analysis of Influenza A MP58-66 antigen-specific CTL lines before and 
after fluorescence activated cell sorting followed by PHA stimulation 
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Figure 4.16. Flow cytometric analysis of Influenza A MP58-66 antigen-specific 
CTL lines before and after fluorescence activated cell sorting followed by PHA 
stimulation. CTL lines induced against FLU peptide was generated from two HLA-
A2
+ donors using the method described in 2.8.4. BCEP18 FLU and BCEP19 FLU 
CTL lines were analysed by FLU/HLA -A*0201 pentamer and anti-CD8 staining, 
seven days after the 2
nd re-stimulation (left panel). CTL lines w ere stimulated for 
the third time and FLU/HLA -A*0201 pentamer binding cells were isolated by 
FACS (MoFlo
TM  XDP, Beckman Coulter). Cells were stimulated twice with  1 
µg/ml of PHA, 100 IU/ml of IL -2 and irradiated autologous PBMC (30Gy). CTL 
lines were re-analysed on day 14 by biotinylated  FLU/HLA-A*0201 pentamer, 
streptavidin-PE and FITC conjugated anti-CD8 staining (right panel).  Biotinylated 
KLA/HLA-A*0201 pentamer and FITC Mouse IgG2b isotype control were used for 
establishing the gatings. 
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Figure 35 Figure 4.17. Flow cytometric analysis of NY-ESO-1157-165 antigen-specific CTL line before and 
after anti-CD3/anti-CD28 antibody coated microbead T cell expansion 
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Figure 4.17. Flow cytometric analysis of NY-ESO-1157-165 antigen-specific CTL 
line  before  and  after  anti-CD3/anti-CD28  antibody  coated  microbead  T  cell 
expansion. BCEP18 NY CTL line induced against NY-ESO-1 peptide was generated 
from  a  HLA-A2
+  donor using the method de scribed in 2.8.4. The CTL line was 
analysed by NYESO1/HLA-A*0201 pentamer and anti -CD8 staining, seven days 
after the 3
rd re-stimulation (left). The CTL line was then stimulated twice, over 14 
days, with Dynabeads® Human T-Activator CD3/CD28 (Invitrogen) as described in 
section 2.7.4. The expanded CTL line was re-analysed by flow cytometry 7 days after 
the  last  re -stimulation  using  biotinylated  NYESO1/HLA-A*0201  pentamer, 
streptavidin-PE  and  FITC  conjugated  anti -CD8  staining  (right).  Biotinylated 
KLA/HLA-A*0201  pentamer  and  FITC  Mouse  IgG2b   isotype  control  were 
establishing the gatings. 143 
 
4.2.12. MHC Class I pentamer as a tool to generate allo-restricted peptide-specific 
CTLs 
MHC Class I pentamer staining and magnetic cell sorting was used to identify allo-
MHC restricted KLA peptide-specific CTLs from one out of two HLA-A2
 negative 
donors. Potentially, the same methodology could be applied for the identification of 
allo-restricted CTL responses induced against other antigens. The aim of this work was 
to assess how reproducible the process is in depleting alloreactive cells and enriching 
for  peptide/MHC  class  I  pentamer  specific  CTLs.  To  this  end,  two  extensively 
characterised  antigenic  peptides  were  used  -  NY-ESO-1157-165  (SLLMWITQV)  and 
Influenza A MP58-66 (GILGFVFTL). 
 
  AFLU1
sorted and ANY1
sorted CTL lines (positive fractions from pentamer sorting 
of AFLU1 and ANY1 bulk CTL lines) were generated from HLA-A2
- donors using the 
stimulation protocol outlined in Figure 4.2. Flow cytometric analyses were performed 
prior  to  cell  sorting  and  after  cell  sorting  followed  by  peptide-pulsed  T2  cell 
restimulation, in order to monitor for FLU/HLA-A*0201 and NYESO1/HLA-A*0201 
pentamer specific CD8
+ T cells. Figure 4.18 shows that a small population of CD8
+ T 
cells  within  the  AFLU1  CTL  line,  before  cell  sorting,  stained  specifically  for 
FLU/HLA-A*0201 pentamer relative to the control. However, the number of events 
collected  for  the antigen-specific T  cell  population  was  too  small  to  be  significant. 
Antigen-specific  CD8
+  T  cells  were  not  detected  after  the  in  vitro  restimulation  of 
AFLU1
sorted and ANY1
sorted CTL lines post-pentamer sorting. 
 
  AFLU1
sorted  and  AFLU1
depleted  CTL  lines  were  assessed  by  chromium-51 
cytotoxicity assay and IFN-γ ELISPOT assay after the second in vitro re-stimulation 
post-pentamer selection. AFLU1
sorted showed greater cytotoxicity towards the T2/FLU 
target cells compared to T2/IRR; 70% and 52% respectively at an effector to target ratio 
of 20:1 (Figure 4.19(A)); but AFLU1
depleted also showed preferential killing of T2/FLU 
targets.  Peptide-specificity  of  the  AFLU1
sorted  CTL  line  was  not  confirmed  in  the 
ELISPOT assay (Figure 4.19(B)) showing no significant differences in IFN-γ responses 
against the FLU and IRR peptide-pulsed T2 cells.  
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Figure  4.18.  Flow  cytometric  analysis  of  alloreactive  CTL  lines  generated 
against the FLU and NY-ESO-1 peptides before and after pentamer-sorting. 
Alloreactive AFLU1 and ANY1 CTL bulk lines were generated against FLU and 
NY-ESO-1 peptide, respectively. CTL lines were analysed by flow cytometry using 
biotinylated FLU/HLA-A*0201, NYESO1/HLA-A*0201 pentamers, and visualised 
with streptavidin-PE, and FITC conjugated anti-CD8 antibody (after the 3
rd in vitro 
re-stimulation before sorting). Enrichment for MHC Class I pentamer specific T 
cells  were  performed  on  the  bulk  CTL  lines.  Pentamer-sorted  AFLU1
sorted  and 
ANY1
sorted CTL lines were re-analysed by flow cytometry, seven days afte r the in 
vitro  restimulation of the sorted cells with peptide-pulsed T2 cells.  Biotinylated 
KLA/HLA-A*0201 pentamer and FITC Mouse IgG2b isotype control were used for 
establishing the gatings. 
 
 
 
 
Figure 36 Figure 4.18. Flow cytometric analysis of alloreactive CTL lines generated against the FLU and NY-
ESO-1 peptides before and after pentamer-sorting 
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  The effector functions of the ANY1
sorted and ANY1
depleted CTL lines (positive 
and negative fractions from pentamer sorting of ANY1 bulk CTL line) were analysed 
similarly.  Figure 4.20(A) shows that  the  ANY1
sorted effector cells  lysed 54% of the 
T2/NYESO1 targets at 20:1 E:T ratio compared to 39% of the T2/IRR. However, the 
preferential killing of T2/NYESO1 targets was not observed at lower E:T ratios. To 
further characterise the peptide-specificity of the ANY1
sorted CTL line, a cold target 
inhibition assay was performed, as described in section 2.11. Responder cells from the 
ANY1
sorted CTL line were co-cultured with either radioisotope labelled T2/NYESO1 or 
T2/IRR targets, in the presence or absence of unlabelled and unpulsed T2 cells (cold 
target). Figure 4.20(B) shows that the cytotoxicity against the T2/NYESO1 target was 
reduced by 30% in the presence of unlabelled T2 cells; in contrast a greater reduction in 
activity of 62% was observed, when cold targets were co-cultured with responder cells 
and the chromium-51 labelled T2/IRR target. ANY1
depleted CTL line was also tested, 
there was a 37% reduction in activity when co-cultured with T2/NYESO1 targets in the 
presence of cold target; 49% reduction was observed when co-cultured with T2/IRR 
targets in the presence of cold targets. The smaller percentage decrease in ANY1
sorted 
CTL line against T2/NYESO1 cells, in the presence of cold targets, is indicative of 
peptide-specificity; but the data is inconclusive due to the lack of data replicates. 
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Figure  4.19.  Functional  characterisation  of  pentamer  sorted  and  depleted 
alloreactive AFLU1 CTL line generated against the peptide FLU. AFLU1 CTL 
line was generated from an HLA-A2
- donor as outlined in Figure 4.2. AFLU1 was 
magnetically  sorted  into  pentamer -sorted  fraction  (AFLU1
sorted)  and  pentamer -
depleted fraction (AFLU1
depleted). AFLU1
sorted and AFLU1
depleted CTL lines were re-
stimulated twice  in vitro  by peptide-pulsed T2 cells.  (A) They were tested in a 
chromium-51  cytotoxicity  assay  on  the  day  5
th  day after the 2
nd  restimulation. 
Target cells used were T2 cell s pulsed with 100M of FLU peptide (T2/FLU) or 
SLN peptide (T2/IRR). Different effector to target (E:T) ratios were tested. (B) 
ELISPOT assay was used to enumerate IFN-γ secreting cells within the AFLU1
sorted 
CTL line (2
nd re-stimulation post-sorting) in response to T2/FLU and T2/IRR target 
cells at E:T ratios. Data shown is the mean of triplicates of a single experiment and 
the error bars represents the standard error of the mean. 
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Figure  4.20.  Functional  characterisation  of  pentamer  sorted  and  depleted 
alloreactive ANY1 CTL line generated against the NY-ESO-1 peptide. ANY1 
CTL line was generated from an HLA-A2
- donor as outlined  in Figure 4.2. ANY1 
was magnetically sorted into pentamer -sorted fraction (ANY1
sorted) and pentamer-
depleted fraction (ANY1
depleted). ANY1
sorted  and ANY1
depleted  CTL lines were re -
stimulated twice  in  vitro  by  peptide-pulsed  T2  cells.  (A)  They  were  tested  in  a 
chromium-51 cytotoxicity assay on the day 5
th day after the 2
nd restimulation.  Target 
cells used were T2 cells pulsed with 100M of NY-ESO-1 peptide (T2/NYESO1) or 
SLN peptide (T2/IRR).  Different effector to target (E:T) ratios were tested. Data 
shown is the mean of triplicates and the error bars represents the standard error of the 
mean.  (B)  ANY1
sorted  and  ANY1
depleted  CTL lines were tested in a cold target 
inhibition assay. Percentage lysis of chromium -51 labelled T2 targets, pulsed with 
100µM of either NY (NY-ESO-1 peptide) or IRR (SLN peptide) was measured in a 
chromium-51 cytotoxicity assay, in the presence or absence of 2 x10
4 unpulsed and 
unlabelled T2 cells (cold targets). Data shown in (B) is either single or duplicate 
measurements in a single assay. 
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Figure 38 Figure 4.20. Functional characterisation of pentamer sorted and depleted alloreactive ANY1 CTL 
line generated against the NY-ESO-1 peptide 
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4.3.    Discussion 
 
4.3.1.  KLA peptide vaccination of HLA-A*0201 transgenic mice does not induce a 
KLA-specific CTL response 
The HLA-A*0201 transgenic mouse model was used to evaluate the immunogenicity of 
the  predicted  TWIST1-epitope,  KLA.  In  this  experimental  system,  the  ex  vivo 
stimulated splenocytes from the KLA-immunised mice did not show preferential killing 
of  KLA-pulsed  T2  targets  compared  to  the  control  peptide-pulsed  T2  cells.  A 
comparative study of the immunogenicity of different TAAs demonstrated a positive 
correlation between peptide binding affinity to HLA*0201 molecules, and the peptides’ 
ability to induce a CTL response in the HLA-A*0201 transgenic mouse model (Firat et 
al., 1999). This suggests that the HLA-A*0201 binding and stabilising capacity of the 
KLA peptide may not be sufficient for the induction of a robust CTL response.  
 
  It is also important to consider other factors, such as the efficiency of synthetic 
peptide vaccines. CD8
+ T cells recognise antigenic peptides in the context of MHC class 
I presentation. Presentation of administered KLA peptides on HLA-A*0201 complexes 
could come about by the direct binding onto MHC class I molecules, expressed on cell 
surfaces. However, almost all nucleated cells express MHC class I molecules and the 
presentation of peptides on resting  B cells may have the opposite desired effect of 
inducing peptide-specific CTL tolerance  (Bennett et al., 1998b; Evans et al., 2000). 
Higher dosage amounts of peptide should also be examined. A higher dose of KLA may 
increase the density of peptides presented on the surfaces of professional APCs, and this 
may influence the size of the immune response generated (Bullock et al., 2000a). Serum 
endo-  and  exo-peptidases  have  been  shown  to  decrease  the  antigenicity  of  an 
ovalbumin-derived  CTL  epitope  (Falo,  Jr.  et  al.,  1992).  A  higher  dose  may  also 
compensate for the lost of available peptides through extracellular degradation. 
 
  HBVc128-140 peptide was co-administered with the KLA peptide as an adjuvant 
(Firat et al., 1999). The co-presentation of MHC class I-restricted peptide and HBVc128-
140 peptide on the same dendritic cell enables the delivery of CD4
+ T cell ‘help’ for 
antigen-specific CD8
+ T cell activation, via the CD40/CD40L-mediated activation of 
DCs. There are other vaccination strategies that could potentially improve the induction 149 
 
of  CTL  responses.  Dendritic  cells  acquire  potent  T  cell  stimulatory  capacity  when 
activated  and  matured  by  microbial  stimuli  in  vivo.  Inclusion  of  toll-like  receptor 
agonists such LPS and CpG oligodinucleotides, within the peptide vaccine preparation, 
could  enhance  the  size  of  the  CTL  response  induced  and  drive  differentiation  of 
activated  T  cells  into  functional  cytotoxic  effector  T  cells  (Brunner  et  al.,  2000; 
Hartmann et al., 1999; Speiser et al., 2005). Taking in consideration the limitations of 
the model system used, further studies would include the testing of higher peptide doses 
and  the  testing  of  alternative  peptide  vaccine  strategies  involving  the  use  of  TLR 
agonists.  
 
  Analysis of murine Twist1 protein revealed a 92% sequence homology to human 
TWIST1. Moreover, the predicted HLA-A*0201-restricted TWIST1 CTL epitopes are 
encoded in both the human and mouse genomes. A study comparing CTL responses 
against  p53-derived  epitopes  in  p53-null  HLA-A*0201
+  transgenic  mice  and  p53-
wildtype HLA-A*0201
+ transgenic mice, demonstrated the lack of p53-specific CTLs 
with high avidity TCRs, in the latter group (Hernandez et al., 2000). Therefore, self-
tolerance  mechanisms  within  the  Twist1
+  HLA-A*0201
+  transgenic  mice  may  have 
negatively  selected  against  CTLs  with  high-avidity  towards  the  Twist1-derived 
epitopes;  thus  offering  an  explanation  for  the  lack  of  KLA-specific  CTL  response 
observed here. It would be useful to look at Twist1-specific CTL responses in Twist1
-/- 
knockout transgenic mice; however this is not possible as they are embryonic lethal 
during gastrulation (Thisse et al., 1987).  
 
4.3.2.  Induction of anti-HLA-A*0201 CTL responses in C57BL/6 mice 
The aim was to identify and isolate KLA-specific CTLs from the anti-HLA-A*0201 
alloreactive  T  cell  repertoire  of  C56BL/6  mice.  The  ex  vivo  stimulation  of  bulk 
splenocyte  cultures  from  KLA  immunised  mice  (1-5)  and  ‘unpulsed’  BM-DC 
immunised mouse, resulted in the non-specific lysis of HLA-A*0201
+ EL4 target cells, 
irrespective of the peptide loaded (see figure 4.6). The stimulated cultures consisted of 
polyclonal CTLs, reactive against the peptide-allogeneic-HLA-A*0201 complexes. The 
hypothesis  was  that  CTL  clones,  specific  for  the  allogeneic-HLA-A*0201-restricted 
KLA  peptide,  may  exist  within  this  heterogeneous  pool  of  anti-HLA-A*0201 
alloreactive CTLs. Splenocytes from the PBS control group did not respond to HLA-150 
 
A*0201
+ EL4 cells, this correlates with previous data in which effector function against 
allo-MHC  antigens  was  not  observed  with  unactivated  naïve  C56BL/6  splenocytes 
(Jurcevic et al., 2001). 
 
  The rationale for peptide-pulsing of HLA-A*0201
+ BM-DC with KLA peptide 
is to induce an alloreactive response that is biased towards the allorecognition of the 
exogenously loaded peptide-allo-MHC class I complexes. However, the peptide-pulsing 
process would require the displacement of endogenous peptides already bound to the 
HLA-A*0201 molecules, and the efficiency of peptide-pulsing would be dependent on 
the HLA-A*0201 binding affinity of the KLA peptide. The incomplete displacement of 
endogenous  peptides  presented  by  HLA-A*0201  expressed  on  the  BM-DC  may 
confound efforts to identify KLA-specific alloreactive CTL clones. 
 
  The  alloreactive  response  observed  for  the  ‘unpulsed’  BM-DC  group  may 
represent  allorecognition  of  peptide-HLA-A*0201  complexes  by  peptide-degenerate 
CTLs  and/or  CTLs  specific  for  endogenous  peptides  presented  by  allogeneic HLA-
A*0201 molecules on EL4-A2 cells. It is also possible that the response was caused by 
the  indirect  recognition  of  HLA-A*0201-derived  antigens  presented  on  H-2D
b 
complexes,  which  are  co-expressed  on  the  HLA-A*0201
+  EL4  cells.  However,  the 
proliferative response observed during the ex vivo stimulation of splenocytes (from BM-
DC immunised mice) with HLA-A*0201
+ H-2D
b – T2 cells (data not shown) suggests a 
direct recognition pathway. 
 
  Establishment of low-seeding density splenocyte cultures was performed in an 
attempt  to  identify  micro-cultures  containing  KLA-specific  alloreactive  CTLs.  The 
split-well analysis data (see figure 4.7) shows that the majority of micro-cultures had 
similar cytotoxicity against EL4-A2 cells loaded with KLA peptide and IRR (FLU) 
peptide.  KLA-directed  cultures  and  IRR-directed  cultures  were  arbitrarily  selected, 
restimulated in vitro twice and assessed at weekly intervals. It was interesting to note 
that  after  the  second  stimulation,  the  IRR  (FLU)-directed  cultures  retained  their 
preferential  cytotoxicity  against  EL4-A2  cells  pulsed  with  FLU  peptide;  but  this 
apparent specificity was lost after the third in vitro restimulation.   
  In summary, the data here was inconclusive due to the polyclonal nature of the 
CTL lines established. The presence of alloreactive T cells could mask the functional 151 
 
response of peptide-specific CTLs. Hence, the data was unable to conclude whether 
allo-HLA-A*0201-restricted KLA-specific CTL precursors exist, or not, within the T 
cell repertoire of the C56BL/6 mice. Future studies should include an improved CTL 
cloning strategy which enables the study of peptide specificity of allo-restricted CTLs, 
at  a  clonal  level.  As  discussed  previously,  HLA-A*0201
+  BM-DCs  are  capable  of 
processing and presenting endogenous peptides. RMA-S (H-2
b) cells have a deleterious 
mutation  in  the  TAP  genes  (Yang  et  al.,  1992),  resulting  in  a  defective  antigen 
presentation pathway for endogenous peptides. The use of HLA-A*0201 transfected 
RMA-S cells, exogenously loaded with peptides, for the immunisation of C57Bl/6 mice 
could  potentially  induce  an  anti-HLA-A*0201  response,  with  greater  peptide-
specificity.  HLA-A*0201
+  RMA-S  cells  would  also  serve  as  a  better  target cell,  in 
comparison with EL4-A2 cells, when assessing the peptide-specificity of splenocyte 
cultures in chromium-51 cytotoxicity assays. This change in the assay may reduce the 
non-specific  lysis  of  target  cells  resulting  from  the  recognition  of  endogenously 
presented peptides, rather than the peptide of interest.  
 
4.3.3.  Cloning by limiting dilution generated few alloreactive CTL lines/clones 
from HLA-A2
- donors 
A similar strategy was used to identify and isolate allo-MHC-restricted peptide-specific 
CTLs from the human T cell repertoire, with greater emphasis on isolating alloreactive 
T cell clones. Alloreactive CTL lines were established by stimulating HLA-A2
- CD8 T 
cells with MHC-mismatched, HLA-A2
+ peptide-pulsed DCs. Figure 4.9 shows that the 
bulk  CTL  lines  lysed  T2  cells  non-specifically,  consistent  with  previous  results 
described  in  section  4.3.2.  In  order  to  identify  peptide-specific  CTLs,  low-seeding 
density of 1 cell per well cloning by limiting dilution was performed on the CTL lines 
AKLA2 and ASLN1. The frequency of wells with peptide specificity in the AKLA2 and 
ASLN1 CTL lines were 3/780 and 5/360, respectively. Although, the frequency of anti-
HLA-A2  CTLs  can  only  be  estimated  by  limiting  dilution  analysis,  the  numbers 
observed in this instance were lower than anticipated (Summarised in Table 4.1). In 
comparison,  a  previous  study  which  generated  human  allo-restricted  CTLs  against 
cyclin-D1-derived  c101  peptide  (Sadovnikova  et  al.,  1998);  16-34%  of  the  wells 
established  by  limiting  dilution,  demonstrated  either  peptide-specific  or  peptide-152 
 
independent  anti-HLA-A2  cytotoxicity.  This  suggests  that  the  in  vitro  stimulation 
strategy used here was ineffective at enriching for anti-HLA-A*0201 alloreactive CTLs. 
   
  Human dendritic cells can express up to six different HLA class I molecules due 
to the co-dominant expression of maternal and paternal MHC class I genes, at loci A, B 
and C. The HLA-A2
- and HLA-A2
+ donors used in this work most likely had multiple 
HLA mismatches. Therefore, when the HLA-A2
- CD8
+ T cells were stimulated with 
HLA-A2
+ DCs, alloreactivity against other non-self HLA class I molecules was likely 
to occur. The non-specific expansion of alloreactive CTLs could dilute the population of 
HLA-A2-specific  CTLs,  thus  explaining  the low  frequency  of  wells,  established  by 
limiting dilution, with anti-HLA-A2 cytotoxicity. 
 
4.3.4.  Identification and isolation of allo-restricted KLA-reactive CTLs by MHC 
class I pentamer enrichment 
Allo-HLA-A*0201-restricted KLA-specific CTLs could potentially be present in the 
CTL bulk lines generated, but at a frequency, which is too low to detect by single-cell 
cloning  by  limiting  dilution.  Flow  cytometric  analysis  of  AKLA1  and  AKLA3 
alloreactive  CTL  lines  revealed  a  small  population  of  KLA/HLA-A*0201  Pro5® 
pentamer binding CD8
+ T cells in the AKLA1 CTL line only. Antigen-specific T cells 
specific for KLA/HLA-A*0201 complexes made up 0.22% of the cells analysed and it 
was represented by a significant number of events. It was reasonable to use ASLN1 
CTL line as a negative control because it was generated from the same donor and it was 
sensitised against a different peptide; as demonstrated by the data, the relative frequency 
of KLA-specific CTLs in ASLN1 compared to AKLA1 was much lower. 
 
  KLA/HLA-A*0201  pentamer  staining  of  AKLA1  CTL  line  followed  by 
magnetic cell sorting was performed to enrich for antigen-specific T cells. Although the 
AKLA1 bulk CTL line was capable of lysing T2 cells regardless of the peptide-loaded 
(see Figure 4.9), killing of T2 targets could be mediated by peptide-specific but TAP-
independent alloreactive T cells. Unpulsed T2 cells express very low levels of MHC 
class  I  molecules  but  are  able  to  present  a  limited  set  of  endogenous  peptides  
(Henderson et al., 1992; Wei and Cresswell, 1992). Therefore, the enrichment step also 153 
 
aimed  to  separate  the  KLA-specific  CTLs  from  the  T2-specific  peptide-dependent 
alloreactive T cells.  
 
  Positively selected cells from the AKLA1 bulk CTL line was stimulated with 
antigenic  peptide  KLA  loaded  on  T2  cells  or  expanded  non-specifically  with  PHA 
(referred  to  as  AKLA1
sorted  and  AKLA1_PHA  respectively).  Both  CTL  lines 
demonstrated high levels of cytotoxicity against KLA peptide-pulsed T2 target cells, 
and have shown minimal activity against irrelevant peptide-pulsed T2 cells. Moreover, 
the AKLA1
depletd CTL line derived from the pentamer-depleted fraction of the magnetic 
cell sorted bulk line lysed both targets equally. This indicates that the AKLA1
sorted and 
AKLA1_PHA CTL lines recognised KLA/HLA-A*0201 ligands in a peptide-dependent 
manner,  and  were  devoid  of  anti-HLA-A*0201  alloreactive  T  cells.  The  lack  of 
cytotoxicity  against  HLA-A*0201  expressing  293T  cells,  as  shown  in  figure  4.15, 
further supports the peptide-specificity of the pentamer-selected CTL lines, or at least, 
they  do  not  recognise  endogenously  processed  HLA-A*0201-restricted  peptides, 
derived from T2 cells or 293T cells. 
 
  A small population of KLA/HLA-A*0201 pentamer specific CD8
+ T cells was 
detected  within  the  pentamer-selected  AKLA1
sorted  CTL  line.  The  apparent  KLA 
peptide-specificity shown in the cytotoxicity assays does not seem to correlate with this 
observation; however the data was obtained two weeks apart and the composition of 
cells  may  have  changed  over  time.    Fluorescent  intensity  of  peptide/MHC  class  I 
tetramer binding has been shown to correlate with T cell avidity  (Yee et al., 1999; 
Busch and Pamer, 1999; Hernandez et al., 2002). The KLA/HLA-A*0201 pentamer 
enriched AKLA1
sorted CTL line may consist predominantly of T cells with low-avidity. 
However,  this  raises  the  question  of  how  these  pentamer-negative  CD8
+  cells were 
positively selected during magnetic cell sorting. This group of cells could possibly be an 
artefact resulting from the insufficient irradiation of the initial HLA-A2
+ monocyte-
derived DC stimulator culture. Contaminating T cells derived from the HLA-A2
+ donor 
would respond against the irradiated HLA-A2
- PBMC feeder cells, thus generating an 
unanticipated alloresponse independent of the T2 cells driven alloreactivity. Moreover, 
this alloreactivity would not be directed against HLA-A*0201 complexes due to self-
tolerance mechanisms; this would explain the presence of pentamer negative CD8
+ T 
cells and the lack of HLA-A*0201 allorecognition.  154 
 
 
4.3.5.  Allo-restricted KLA-reactive CTL line does not kill TWIST1 transfected 
293T cells 
The  KLA-reactive  AKLA1
sorted  CTL  line  was  tested  against  293T  cells  transiently 
transfected  with  either  pCI-neo-TWIST1  or  the  vector  control  plasmids.  It  did  not 
demonstrate  any  cytolytic  activity  towards  either  of  the  transfected  293T  cells.  It 
recognised and killed T2 cells pulsed with the KLA peptide. The result shows that the 
AKLA1
sorted  CTL  line  does  not  demonstrate  ‘classical’  alloreactivity  –  recognising 
MHC class I determinants independent of the peptide bound. However, there are several 
reasons  which  could  explain  the  lack  of  cytotoxicity  demonstrated  by  AKLA1
sorted 
towards the TWIST1 transfected 293T cells. 
 
  The aim of this experiment was to test whether the KLA peptide is naturally 
processed and presented from the endogenously expressed TWIST1 protein. The lack of 
functional response against TWIST1
+ 293T cells, indirectly  suggests the absence of 
KLA/HLA-A*0201 ligands on the surfaces of the antigen presenting cells; thus the 
KLA CTL epitope may not occur naturally. Alternatively, the AKLA1
sorted CTL line 
might have consisted predominantly of CD8
+ T cells with low-avidity TCRs, and the 
density of KLA/HLA-A*0201 complexes on the TWIST1
+ 293T cells may not be at a 
sufficient level to trigger a T cell response. Expression levels of TWIST1 mRNA and 
HLA-A*0201 molecules were confirmed experimentally but the expression levels of 
TWIST1 protein was not validated, due to the lack of reliable anti-TWIST1 antibodies. 
Therefore, TWIST1 proteins could be absent in the 293T cells transfected with the pCI-
neo-TWIST1 plasmid, due to an unforeseen problem at the translational level, which 
would in turn limit the amount of TWIST1-derived peptides  generated.   For future 
studies, KLA-specific CTL clones should be established and their cytolytic efficiency 
measured in a peptide titration experiment. This would enable the selection of CTL 
clones with the highest avidity, thus increasing the sensitivity of the functional assays 
when testing for T cell recognition of TWIST1 expressing target cells. Peptide elution 
studies could also provide direct evidence for the natural processing and presentation of 
TWIST1-derived peptides (Pascolo et al., 2001). 155 
 
4.3.6.  Further method development is required for the isolation of allo-restricted 
peptide-specific CTLs from alloreactive bulk lines using MHC class I 
pentameric reagents 
The same methodology was applied to other alloreactive CTL lines induced against 
FLU and NY-ESO-1157-165 peptides, generated from HLA-A2
- donors. No significant 
numbers  of  antigen-specific  CD8
+  T  cells  were  detectable  within the  bulk  lines  by 
peptide-MHC  class  I  pentamer  staining,  after  the  third  in  vitro  re-stimulation.  For 
reasons stated in section 4.3.3, the initial induction of anti-HLA-A*0201 and peptide-
biased alloresponse was ineffective due to the possible mismatches of multiple HLA 
alleles.  Consequently,  non-specific  activation  and  expansion  of  alloreactive  CTLs 
directed at other allogeneic peptide-MHC class I complexes may have occurred. This 
would have an diluting effect on the enrichment of anti-HLA-A*0201 alloreactive CTLs 
and reduce the chance of expanding FLU or NY-ESO-1157-165 specific allo-restricted 
CTLs.  Pentamer-selected  AFLU1
sorted  and  ANY1
sorted  CTL  lines  were  tested  in 
cytotoxicity and IFN-γ secretion functional assays. No clear differences were observed 
for  their T  cell effector  function  against  T2  cells  pulsed  with  either  the  peptide  of 
interest or the irrelevant control peptide. The data correlated with the lack of detectable 
antigen-specific T cells present in the pre-sorted bulk CTL lines; and the magnetic cell 
sorting procedure failed to remove all the anti-HLA-A*0201 alloreactive CTLs from the 
positively selected fraction. 
 
  Nonetheless, the identification of KLA-specific CTLs within the alloreactive T 
cell repertoire, in one of the CTL lines generated, suggests that the strategy was feasible 
in principle. Improvement of this approach would enable the isolation of allo-restricted 
CTLs against self-antigens which may otherwise be absent in the tolerant autologous 
repertoire. However, the in vitro stimulation strategy required for the enrichment of 
alloresponse  towards  a  single  allogeneic  peptide-MHC  class  I  complex  will  need 
optimisation. Antigen-presenting cells expressing a single MHC allele would enable the 
induction of alloresponse directed at a specific MHC class I variant of interest. Previous 
studies  have  identified  peptide-specific  CTLs  in  the  allo-MHC-restricted  T  cell 
repertoire,  using  peptide-loading  deficient  APCs,  such  as  T2  cells  and  HLA-A2 
transfected RMA-S cells (Bellantuono et al., 2002; Moris et al., 2001; Sadovnikova and 
Stauss, 1996; Sadovnikova et al., 1998; Stanislawski et al., 2001). Peptide-HLA class I 156 
 
complexes  immobilised  on  the  surfaces  of  autologous  B  lymphocytes  or  artificial 
presenting cells were also used as immunogens to activate and expand allo-restricted 
antigen-specific CTL responses (Savage et al., 2004; Lu et al., 2007). 
 
  Application  of  multimers  for  cloning  T  cells  has  its  limitations.  Binding  of 
peptide-MHC  class  I  tetramer  to  TCR  can  trigger  T  cell  activation,  and  the 
concentration  of  tetramer  required  is  1000-fold  less  than  the  amount  required  to 
visualise tetramer staining by flow cytometry (Wooldridge et al., 2009). TCR activation 
by  tetramer  engagement  could  lead  to  normal  T  cell  activation  events  such  as 
intracellular  calcium  mobilisation,  upregulation  of  CD107a  –  a  marker  of  T  cell 
degranulation and tyrosine phosphorylation (Wooldridge et al., 2009; Guillaume et al., 
2003; Purbhoo et al., 2001). Moreover, it could lead to activation-induced cell death 
(AICD) of CTLs through mitochondrial dysfunction or FasL-induced apoptosis (Xu et 
al., 2001; Cebecauer et al., 2005). Therefore, alternative strategies for T cell sorting 
should be considered in conjunction with allo-restricted peptide-specific CTL induction; 
such  as  the  use  of  streptamers  (Knabel  et  al.,  2002)  or  desthiobiotin  multimers 
(Guillaume et al., 2006) which have reduced T cell activation capacity. 157 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. CHAPTER 5 – Results 3 
Lentiviral-mediated expression of TWIST1 by 
dendritic cells as an approach to induce an anti-
TWIST1 adaptive immunity 158 
 
5.1.  Background 
 
5.1.1.  Dendritic cell vaccine 
Tumour antigen genes encoding multiple antigenic peptides can be delivered into DCs 
using  lentiviral  vector  technology.  It  enables  the  sustained  expression  of  the  gene 
product in the transduced dendritic cells. Endogenously expressed tumour antigens are 
subjected  to  normal  protein  turnover.  Peptides  generated  as  a  result  of  protein 
degradation are released into the MHC class I and II antigen presentation pathways. 
Processed  peptides  with  the  appropriate  binding  affinity  are  loaded  onto  MHC 
complexes and presented on the cell surface where they can elicit an antigen-specific T 
cell response. Other investigators have shown that lentiviral transduced DCs expressing 
transgenic antigen proteins are capable of inducing a potent TAA-specific CD8
+ T cell 
response (Chapatte et al., 2006; Breckpot et al., 2004; Breckpot et al., 2003; Lopes et 
al., 2008; Lopes et al., 2006; Metharom et al., 2001). Growth of established tumours 
expressing  the  model antigen  OVA  in  mice can  be  inhibited  by  the  vaccination  of 
transduced DCs (He et al., 2005). 
 
  Lentivirus transduced dendritic cells can process and present multiple antigenic 
peptides  concurrently  from  a  single  transgenic  protein  (Breckpot  et  al.,  2004; 
Tuettenberg et al., 2003). Prior knowledge of T cell epitopes encoded within the antigen 
and their MHC-restriction is not required. This approach could be used to investigate 
the  immunogenicity  of  TWIST1  by  exploiting  the  cellular  machineries  of  DCs  to 
process and present TWIST1-derived peptides on surface MHC complexes. They can 
then be used to prime and stimulate autologous T cells, specifically CD8
+ T cells.  
   
  This  chapter  describes  the  development  of  a  mouse  model  system  that  uses 
dendritic cells transduced with a tumour antigen as a vaccine to induce antigen-specific 
CD8
+  T  cell  responses  in  vivo.  The  initial  focus  will  be  on  addressing  two  main 
questions:  firstly  the  efficient  delivery  and  expression  of  TWIST1  in  BM-DCs; 
secondly, the induction and detection of antigen-specific CTL responses in the HLA-
A*0201 transgenic mouse model by adopting a heterologous prime-boost vaccination 
protocol.  The  latter  involves  priming  the  mouse  immune  system  with  antigen-
expressing  transduced  BM-DCs  followed  by  boosting  with  naked  antigen-encoding 159 
 
DNA plasmids. The initial development of the model aimed to induce a specific T cell 
response against a characterised tumour antigen, NY-ESO-1157-165, encoded within a 
partial NY-ESO-1 transgene (Lopes et al., 2006; Palmowski et al., 2004). LNT-NY-
ESO-1 lentiviral vector (kindly provided by Prof. M. Collins) was generated from the 
pHR'SIN-cPPT-SEW by replacing the nucleotides encoding for EGFP for the partial 
NY-ESO-1 minigene (see figure 5.1(A)).  
 
5.1.2.  Lentiviral vectors selected for transgene expression in mouse BM-DC 
Lentiviral  vectors  are  attractive  tools  for  delivering  transgenes  into  terminally 
differentiated and  non-dividing  dendritic  cells  (Blesch,  2004;  Breckpot  et  al.,  2004; 
Breckpot et al., 2003; He et al., 2005; Lopes et al., 2006). Two lentiviral vectors were 
selected to direct constitutive expression of recombinant TWIST1 and NY-ESO-1 in 
mouse  bone-marrow  derived  dendritic  cells.  These  are  pHR'SIN-cPPT-SEW  (LNT-
GFP) and pHR’-SIN-IRES-WPRE. 
 
  The  generation  of  pHR'SIN-cPPT-SEW  (Figure  5.1(A))  has  been  described 
previously (Demaison et al., 2002); it is based on the human immunodeficiency virus 
type  1  (HIV-1).  Lentivirus  particles  generated  from  this  vector  are  replication 
incompetent, therefore allowing only one infectious cycle for gene transfer. Expression 
of  the  inserted  gene  is  under  the  control  of  the  spleen  focus  forming  virus  (Sffv) 
promoter. Various components are included to improve viral production and infectivity 
efficiency. Central polypurine tract (cPPT) improves the infectivity of viral particles 
(Blesch,  2004).  Woodchuck  hepatitis  virus  post-transcriptional  response  element 
(WPRE)  was  found  to  enhance  transgene  expression  in  target  cells  by  mRNA 
stabilization (Donello et al., 1998). A variety of cells of haematopoietic origin have 
been  successfully  transduced  with  this  lentiviral  vector.  These  include  human 
monocyte-derived dendritic cells and mouse bone-marrow derived DCs (Lopes et al., 
2008; Lopes et al., 2006). 
   
  The  pHR’-SIN-IRES-WPRE  is  a  bicistronic  lentiviral  vector  (Figure  5.1(B)) 
developed  from  pHR'SIN-cPPT-SEW.  It  retains  all  the  same  components  as  its 
predecessor and the gene of interest can be cloned downstream of the Sffv promoter. 
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Figure 5.1. Lentiviral vectors used for expressing NY-ESO-1 and TWIST1 in 
mouse  bone-marrow  derived  dendritic  cells.  (A)  pHR'SIN-cPPT-SEW 
(abbreviation: LNT-GFP) was used for generating the following constructs – LNT-
GFP,  LNT-TFULL,  LNT-Tx1  and  LNT-Tx2  (B)  pHR’-SIN-IRES-WPRE  a 
bicistronic lentiviral vector was used for generating the following constructs – LNT-
TF-EGFP,  LNT-Tx1A-EGFP,  LNT-Tx1B-EGFP,  LNT-Tx2A-EGFP,  LNT-Tx2B-
EGFP  and  LNT-Tx2C-EGFP.  EGFP,  enhanced  green  fluorescent  protein.  Sffv, 
spleen  focus-forming  virus  promoter.  cPPT,  central  polypurine  tract.  LTR,  long 
terminal  repeat.  WPRE,  woodchuck  hepatitis  virus  post-transcriptional  response 
element.  IRES,  internal  ribosome  entry  site.  gpt,  xanthine-guanine 
phosphoribosyltransferase.  Both  constructs  are  self-inactivating  (SIN)  lentiviral 
vectors by introducing a deletion into the U3 region of the HIV-1 3’LTR (Miyoshi et 
al. 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39 Figure 5.1. Lentiviral vectors used for expressing NY-ESO-1 and TWIST1 in mouse bone-marrow 
derived dendritic cells 
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The enhanced green fluorescent protein (EGFP) is expressed simultaneously with the 
inserted gene; but due to the internal ribosome entry site (IRES) sequence located in 
between  the  first  and  the  second  cistron,  the  proteins  are  translated  independently. 
Therefore,  the  detection  of  EGFP  protein  expression  in  transduced  cells  is  a  good 
indication that the inserted gene is also expressed. This is useful for monitoring the 
transduction efficiency in BM-DCs. The immunogenicity of EGFP has been reported to 
be weak but detectable in C57BL/6, in comparison to other strains such as Balb/c mice 
(Stripecke et al., 1999; Skelton et al., 2001); therefore caution needs to be taken when 
determining the immunogenicity of the co-expressed transgene.  
 
5.1.3.  TWIST1 constructs 
Lentiviral constructs encoding either full-length or partial TWIST1 cDNA are shown in 
Figure 5.2. The six partial TWIST1 cDNA generated had various lengths of protein-
coding nucleotides excluded from the 5’-end or 3’-end by PCR. They were designed so 
that the truncated gene products have overlapping amino acid sequences ensuring that 
the full sequence is covered by the minigenes. APCs transduced with vectors containing 
the full-length TWIST cDNA (named TFULL or TF) could be used to examine the 
immunogenicity of TWIST1 as a whole protein; whereas the partial TWIST1 constructs 
could  be  used  to  further  map  the  regions  of  TWIST1  protein  which  contains  the 
antigenic peptide sequences. In addition the over-expression of an oncogene, such as 
TWIST1, could be toxic to the cells being transduced; non-functional truncated proteins 
might circumvent this problem. 
 
  Due to the lack of reliable antibody available for the detection of TWIST1, a 
FLAG  synthetic  peptide  sequence  consisting  of  eight  amino  acids  (DYKDDDDK) 
(Hopp  et  al.,  1988)  was  added  onto  the  N-terminus  or  C-terminus  of  each  of  the 
constructs. This enables the detection of recombinant TWIST1 whole and truncated 
protein expression in transduced APCs by an anti-FLAG antibody. Kozak sequences 
play an important role in the initiation of the translation process. Each construct was 
engineered to have a Kozak sequence upstream of the start codon because it could 
potentially  enhance  protein  expression  levels  (Kozak,  1987).  The  3’-untranslated 
regions (3’UTR) of mRNA could contain elements, such as AU-rich element, which 162 
 
Figure  5.2.  Epitope  tagged  full  length  and  partial  TWIST1  constructs 
generated  for  the  lentiviral  transduction  of  mouse  BM-DCs.  TWIST1  gene 
contains 2 exons. The open-reading frame is located in exon 1 encoding a 202 
amino acid protein and exon 2 is untranslated. Red box represents inserted Kozak 
sequence.  Dark  grey  box  represents  N-terminus  or  C-terminus  FLAG-tagged 
epitope. TFULL cDNA encoding full-length TWIST1 protein, Tx1 and Tx2 cDNA 
encoding C-terminal and N-terminal truncated TWIST1 respectively were cloned 
into the pHR'SIN-cPPT-SEW construct. TF, Tx1A, Tx1B, Tx2A, Tx2B and Tx2C 
cDNA were cloned into the pHR’-SIN-IRES-WPRE construct 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 Figure 5.2. Epitope tagged full length and partial TWIST1 constructs generated for the lentiviral 
transduction of mouse BM-DCs 
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regulates  gene  expression  at  the  post-transcriptional  level  (Mignone  et  al.,  2002). 
Therefore,  the  3’UTR  of  TWIST1,  exon2,  was  included  in  half  of  the  constructs 
generated because it could potentially increase or decrease the mRNA stability.  
 
5.1.4.  Prime-boost vaccination 
An overview of the vaccination protocol and the  methods used for the detection of 
antigen-specific  CD8
+  T  cell  response  is  illustrated  in  Figure  5.3.  LNT-NYESO-1 
lentiviral vector transduced BM-DCs are capable of inducing NY-ESO-1157–165-specific 
CD8
+ T cell responses in the HLA-A*0201 transgenic mice (Palmowski et al., 2004). 
Transduced  HLA-A*0201
+  BM-DC  were  matured  with  TNF-α  for  24  hours  before 
immunisation. This has been shown to up-regulate costimulatory molecules and the 
secretion of IL-12 by matured BM-DCs; and also improves the induction of anti-tumour 
immune response in vivo (Brunner et al., 2000). 
 
  Many  factors  can  influence  the  strength  and  the  specificity  of  the  immune 
response induced by DC-based vaccines. This includes the design of the prime-boost 
vaccination regime. Other researchers have tested different vaccination protocols which 
involved administering different combinations of peptide, protein and viral vectors as 
immunogens. Although the mechanism is not fully understood, it was observed that 
heterologous  vaccination  protocols  induced  superior  cellular-mediated  immune 
responses  compared to  homologous  prime-boost  immunisation  (Newman,  2002;  Lu, 
2009). In addition, repeated immunisation of DC-based vaccines in mice resulted in 
weaker induction of CTL activity (Ribas et al., 2000; Serody et al., 2000).  
   
  In  the  work  described  in  the  following  chapter,  a  heterologous  prime-boost 
regime was used; priming with lentiviral transduced DC and boosting with antigen-
encoding DNA plasmids. The TLR9 ligand, CpG ODN 1826 was co-administered with 
the naked DNA plasmid. A study using a similar DC-prime and DNA-boost strategy has 
demonstrated the induction of high-avidity T cell responses, with broader specificity, 
against different epitopes derived from the HIV-1 Gag immunogen in comparison to 
alternative  approaches;  for  example,  the  DC-prime  and  peptide  boost  heterologous 
vaccination;  and  the  homologous  prime-boost  protocol  involving  the  repeated 
administration of naked DNA plasmids (Simon et al., 2010). 164 
 
Figure 5.3. Experimental strategy used to induce peptide-dependent allo-HLA-
A*0201-restricted CTL responses in C57BL/6 mouse. Dendritic cells generated 
from the bone-marrow of HLA-A*0201 transgenic mice were transduced with LNT-
NY-ESO-1 lentiviral particles as described in section 2.18.3. Transduced BM-DCs 
were  matured  with  tumour-necrosis  factor-alpha  (TNF-α)  for  24  hours  prior  to 
administration to HLA-A*0201 transgenic mice via subcutaneous (s.c.) injection. 
LNT-NY-ESO-1 naked plasmid DNA and CpG ODN 1826 were administered via 
intramuscular (i.m.) injections. (See Section 2.19 for more detail) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41 Figure 5.3. Experimental strategy used to induce peptide-dependent allo-HLA-A*0201-restricted 
CTL responses in C57BL/6 mouse 
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5.2.  Results 
 
5.2.1.  Generation of FLAG-tagged TWIST1 lentiviral construct 
The pCI-neo-TWIST1 plasmid (provided by Dr. S. Wittmann) was used as a template 
for molecular sub-cloning. Three cDNA fragments were generated from exon 1 of the 
TWIST1  coding  sequence;  encoding  for  amino  acid  residues  1-202  the  full  length 
TWIST1 protein (TFULL), 1-108 a.a. the N-terminus containing partial protein (Tx1) 
and 101-202 a.a (Tx2) the C-terminus containing partial protein. The cDNA inserts 
generated by PCR are illustrated in Figure 5.2. In each case, nucleotides encoding the 
FLAG epitope tag were inserted in frame at the C-terminus of the open reading frames. 
The eGFP encoding cDNA was cleaved from the pHR'SIN-cPPT-SEW lentiviral vector 
(provided by Professor A. Thrasher) by restriction enzyme digestion. The digest was 
subsequently resolved by gel electrophoresis and the vector backbone (8895bp) was 
extracted from the gel. Finally, the three TWIST1 cDNA fragments were inserted into 
the vector backbone by DNA ligation. The new vectors generated were validated by 
restriction enzyme digestion and the sizes of fragments analysed by gel electrophoresis. 
The sequences of the inserts were also validated by DNA sequencing. The resulting 
vectors were named LNT-TFULL, LNT-Tx1 and LNT-Tx2, suffixed with the name of 
the inserted TWIST1 cDNA. Details of the above procedures are described in Section 
2.18.1. 
 
5.2.2.  Expression of recombinant tagged TWIST1 and NY-ESO-1 in 293T cells 
Initially, it was important to verify that the constructs generated expressed the full-
length and the truncated forms of TWIST1 and were also  of the approximate sizes 
expected. To this end, 293T cells were transiently transfected with vectors containing 
TFULL, Tx1, Tx2 and NY-ESO-1 transgenes by liposome-mediated transfection. Cells 
were harvested and lysed after 24 hours in RIPA lysis buffer. Reducing SDS-PAGE was 
performed  to  resolve  the  protein  lysates,  which  were  then  transferred  on  to 
nitrocellulose  membranes.  Recombinant  tagged  proteins  were  then  detected  on  the 
membrane  with  a  monoclonal  anti-FLAG  antibody.  Epitope-tagged  recombinant 
proteins were detectable in the 293T cells transfected with the LNT-NY-ESO-1, LNT-
TFULL  and  LNT-Tx1  constructs,  but  not  with  LNT-Tx2  (Figure  5.4).  The  protein 166 
 
expressed by LNT-TFULL construct migrated at the expected size of approximately 25 
kDa. However for LNT-Tx1, the protein expressed migrated at approximately 20 kDa 
greater than the predicted averaged molecular weight of 11 kDa.  
 
5.2.3.  Optimisation of pHR'SIN-cPPT-SEW mediated transduction of BM-DC 
At the onset of the work, it was important to ensure that a large proportion of the 
transduced  APCs  expressed  the  antigen  by  optimising  the  lentivirus  transduction 
efficiency of HLA-A*0201
+ BM-DCs. This may in turn improve the priming of the 
immune  system  against  the antigen,  when  vaccinating  the transgenic  mice  with  the 
transduced BM-DCs.  
 
  Lentivirus particles were produced by co-transfection of 293FT packaging cell 
line with lentiviral vectors, encoding the transgenes, together with psPAX2 packaging 
plasmid,  and  were  pseudotyped  with  the  vesicular  stomatitis  virus  G  glycoprotein 
(VSV-G)  using  the  pMD2.G  envelope  plasmid.  Differentiating  BM-DCs  were 
transduced  with  concentrated  lentivirus  particles  on  day  4  of  in  vitro  culturing  and 
harvested on day 8 for transgene expression analysis. Details of the above procedures 
are described in Section 2.18.2 and 2.18.3. 
 
  LNT-TFULL and LNT-NY-ESO-1 vectors do not contain reporter genes that 
could  be easily  detected  for  the  purposes  of  measuring  stock  titre  and transduction 
efficiency of BM-DC. Therefore, pHR'SIN-cPPT-SEW (LNT-GFP) which encodes the 
enhanced  green  fluorescent  protein  (eGFP)  was  used  as  a  surrogate  vector  for  the 
optimisation of the BM-DC transduction protocol.  
 
Lentivirus titer was determined by two methods: flow cytometric analysis of 
eGFP  expression  in  transduced  BM-DCs  to  obtain  a  functional  titre  as  defined  by 
transducing units per ml (TU/ml); and the analysis of reverse transcriptase (RT) enzyme 
present in the lentivirus stock to obtain a physical titer described as weight of RT per ml 
(pg/ml).  
 
  Serial diluted volumes of concentrated LNT-GFP lentiviral stock were added to 
BM-DC cultures (on day 4 of culture) and eGFP expression was analysed by  flow 167 
 
cytometry on day 8. Figure 5.5(A) is a graph illustrating the percentage of eGFP
+ cells 
versus  the  volume  of  concentrated  LNT-GFP  stock  used  for  BM-DC  transduction. 
Fluorescence microscopy was used to confirm the expression of eGFP by cells observed 
with dendrite structures (Figure 5.5(C)). Flow cytometric analysis of transduced BM-
DCs inoculated with 12.5µl of concentrated LNT-GFP shows that more than 90% of the 
cells analysed were of the CD11c
+ lineage and 55.2% of the gated cells were eGFP
+ 
CD11c
+ double positive (Figure 5.5(B)).   
 
  Functional titre was calculated based on the transductions with dilution factors 
that resulted in approximately 10% of the cells becoming eGFP positive. In this case, 
10
3  and  10
4-fold  dilutions  gave  between  2.8%  and  17.5%  eGFP  positivity  and  the 
approximate functional titre of the concentrated LNT-GFP was calculated to be 1.15 
x10
8  TU/ml.  10-fold  dilution  or  1.15  x10
7  TU  (MOI  of  23)  gave  the  highest 
transduction efficiency in this instance, but it was at the upper limit of the dilution range 
tested,  therefore  higher  transduction  efficiency  would  be  possible  if  higher 
concentrations  were  used.  However,  to  produce  a  large  volume  of  concentrated 
lentivirus requires a lot of plasmid reagents therefore subsequent lentivirus transduction 
of BM-DCs were carried out at a MOI of 23. 
 
  Physical titers of LNT-TFULL,  LNT-NY-ESO-1 and LNT-GFP vectors were 
also measured in a reverse transcriptase assay by serial dilution of the lentivirus stocks 
(data not shown). It was determined that 100µl of concentrated LNT-GFP contained 2.4 
nanograms of RT enzyme, which is equivalent to a MOI of 23 when transducing BM-
DCs in a total volume of 1ml. In order to transduce BM-DCs at a MOI of approximately 
23 with LNT-TFULL and LNT-NY-ESO-1vectors; their physical titers were determined 
and volumes containing 2.4 nanograms of RT enzymes were used for subsequent BM-
DC transductions.  168 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42 Figure 5.4. Expression of recombinant FLAG epitope tagged TWIST1 and partial NY-ESO-1 in 
transiently transfected 293T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Expression of recombinant FLAG epitope tagged TWIST1 and 
partial NY-ESO-1 in transiently transfected 293T cells. Western blot analysis 
of protein lysates prepared from 293T cells transiently transfected with one of the 
following plasmids: LNT-TFULL, LNT-Tx1, LNT-Tx2, LNT-NY-ESO-1 or LNT-
GFP (not shown). After protein transfer, the nitrocellulose membrane was probed 
with the anti-FLAG® M2 monoclonal antibody. 
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Figure 43 Figure 5.5. EGFP expression in mouse BM-DC transduced with concentrated LNT-GFP stock 
 
 
 
 
Figure  5.5.  EGFP  expression  in  mouse  BM-DC  transduced  with 
concentrated LNT-GFP stock. (A) Serial dilution of concentrated LNT-GFP 
were used for transducing BM-DC cultures on day 4 and the percentages of cells 
expressing eGFP were determined by flow cytometric analysis on day 8 of in 
vitro culturing. (B) Flow cytometric analysis of transduced BM-DC, inoculated 
with 12.5µl of LNT-GFP stock, on day 8 stained with PE-conjugated anti-mouse 
CD11c antibody and PE Armenian Hamster IgG isotype control (C) Transduced 
mouse BM-DCs were visualised by fluorescence or light microscopy on day 8. 
Top  and  bottom  panel  shows  BM-DCs  inoculated  with  different  volumes  of 
concentrated LNT-GFP stock. 
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5.2.4.  pHR'SIN-cPPT-SEW mediated expression of NY-ESO-1 but not TWIST1 
in transduced BM-DCs 
Bone-marrow cells obtained from HLA-A*0201 transgenic mice were cultured in the 
presence of murine GM-CSF and IL-4, and transduced with LNT-TFULL and LNT-
NY-ESO-1  lentivirus  particles  at  a  MOI  of  approximately  23,  on  day  4,  by  spin-
transduction method and supplemented with polybrene. Cells were harvested on day 8 
for further expression analysis for tagged recombinant TWIST1 and NY-ESO-1 proteins 
by Western blotting. For controls, 293FT cells were also transduced concurrently as 
transgene  expressions  in  this  particular  cell  line  was  demonstrated  previously  by 
transient transfection of the lentiviral vectors. 
 
  Protein lysates from transduced cells were resolved by SDS-PAGE, transferred 
onto  nitrocellulose  membranes  and  incubated  with  the  anti-FLAG  antibody.  Figure 
5.6(A) shows that LNT-TFULL and LNT-NY-ESO-1 lentivirus transduced 293T cells 
expressed the epitope-tagged proteins at the expected molecular weights. However, only 
the  partial  NY-ESO-1  transgene  was  expressed  in  the  transduced  BM-DCs  and  not 
TWIST1. Human monocyte-derived DCs were also transduced, and similarly, only NY-
ESO-1 protein expression was detected (data not shown). Immunoprecipitations with 
the anti-FLAG antibody and Protein G-Sepharose® 4B were carried out in order to 
concentrate  the  epitope-tagged  recombinant  proteins  from  the  BM-DC  cell  lysates. 
Figure 5.6(B) shows that NY-ESO-1 protein was immunoprecipitated from transduced 
BM-DCs but not TWIST1, which is consistent with previous observations. 
 
5.2.5.  Phenotypic analysis of transduced bone-marrow derived dendritic cells 
In  order  to  characterise  whether  the  process  of  lentivirus  transduction  affected  DC 
maturation  marker  expression  such  as  MHC  Class  II  and  CD86,  flow  cytometric 
analysis  was  carried  out  on  BM-DCs  transduced  with  LNT-GFP,  LNT-NY-ESO-1, 
LNT-TFULL or left untransduced to represent immature DCs. Cells were analysed after 
9 days of culturing in total. 
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Figure 44 Figure 5.6. Expression of recombinant FLAG epitope tagged TWIST1 and partial NY-ESO-1 in 
lentiviral transduced 293T and mouse BM-DC 
 
 
 
 
 
 
 
Figure  5.6.  Expression  of  recombinant  FLAG  epitope  tagged  TWIST1  and 
partial NY-ESO-1 in lentiviral transduced 293T and mouse BM-DC. BM-DC 
cultures were transduced on day 4 of in vitro culture. Cells were lysed in RIPA 
buffer on day 8 and resolved by SDS-PAGE. (A) Western blot analysis of BM-DCs 
transduced with LNT-NY-ESO-1 or LNT-TFULL lentiviral particles and 293T cells 
transiently  transfected  with  LNT-NY-ESO-1  or  LNT-TFULL  plasmids. 
Immunoblotting was performed using an anti-FLAG® M2 monoclonal antibody. 
(B) Immunoprecipitation (IP) of cell extracts was performed using anti-FLAG M2 
monoclonal  antibody.  Negative  control  lysates  was  prepared  from  293T  cells 
transduced with the LNT-GFP vector.  Immunoprecipitates were resolved by SDS-
PAGE, transferred onto nitrocellulose membrane and probed with anti-FLAG M2 
antibody. 
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  The left hand panel of Figure 5.7 shows that approximately 45% of the untreated 
BM-DC  culture  (negative  control)  was  CD11c
+  indicating  that  the  BM-DC 
differentiation protocol yielded sub-optimal yield of DCs. A similar percentage of LNT-
TFULL transduced cells were CD11c
+. In contrast, smaller percentages of LNT-GFP 
and LNT-NY-ESO-1 transduced cells were CD11c
+. Further flow cytometric analysis 
demonstrated that all the cells expressed the myeloid cell marker  - CD11b (data not 
shown). 
 
  Transduced  BM-DC  cultures  were  stained  with  anti-CD11c  and  anit-CD86 
antibodies, and the relative expression levels of CD86 were analysed on CD11c
+ cells. 
As shown in Figure 5.7, CD86 expression levels of the lentivirus transduced CD11c
+ 
cells were lower relative to the negative control. However, the CD86 expression profiles 
of the three transduced populations seems to contain two peaks, indicative of a high and 
a medium CD86 expressing populations. CD11c - also known as the intergrin alpha X 
chain protein is known to be expressed at  low  levels on the monocyte-macrophage 
lineage and natural killer cells, therefore the analysis of CD86 expression on the BM-
DC cultures might have been confounded by the presence of other CD11c
+ cells.  
 
  Relative MHC Class II expression levels were analysed on transduced cells that 
expressed  high  levels  of  CD86  (CD86
HIGH).  As  shown  in  Figure  5.8,  the  median 
fluorescent intensities (MFI) of MHC Class II staining on LNT-TFULL and LNT-NY-
ESO-1 transduced CD86
HIGH  cells were 5411 and 3909, respectively. MFI of  MHC 
Class II staining on CD86
HIGH negative control cells was 464, 8 to 11-fold lower than 
that of LNT-TFULL and LNT-NY-ESO-1. 
 
5.2.6.  Cloning epitope tagged TWIST1 cDNA into pHR’-SIN-IRES-WPRE vector 
TWIST1 cDNA fragments – TFULL and Tx1 were cloned out of LNT-TFULL and 
LNT-Tx1 vectors by PCR; the Sbf1 restriction site at the 3’end was replaced with XhoI 
and  transferred  into  a  bicistronic  vector  -  pHR’-SIN-IRES-WPRE  (Professor  H. 
Gaspar).  They  will  be  referred  to  as  LNT-TF-EGFP  and  LNT-Tx1A-EGFP.  Four 
additional  TWIST1  cDNA  fragments  with  FLAG-epitope  sequences  were  also 
generated  by  PCR  amplification  from  the  pCI-neo-TWIST1  plasmid.  (See  Section 
2.18.1 for details of the procedures) 173 
 
 
Figure 45 Figure 5.7. Effect of lentivirus transduction on CD86 expression on CD11c+ BM-DCs 
 
Figure 5.7. Effect of lentivirus transduction  on  CD86 expression  on CD11c
+ 
BM-DCs. Flow cytometric analysis of BM-DC cultures transduced with LNT-GFP, 
LNT-NY-ESO-1 or LNT-TFULL vectors; or left untreated as the negative control. 
On day 8 of in vitro culturing, cells were stained with PE-conjugated anti-mouse 
CD11c and APC-conjugated anti-mouse CD86 monoclonal antibodies. Cytometer 
gates were established with the following isotypes control antibodies: PE Armenian 
Hamster IgG and APC Rat IgG2a isotype controls (grey filled histogram). Left panel 
of histograms shows CD11c expression on all gated cells. Right panel of histograms 
shows the anti-CD86 fluorescent profiles of CD11c
+ cells (from left panel). 174 
 
 
 
 
Figure 46 Figure 5.8. Effect of lentivirus transduction on MHC Class II expression on CD86
HIGH BM-DCs 
 
 
 
 
 
 
 
 
Figure 5.8. Effect of lentivirus transduction on MHC Class II expression on 
CD86
HIGH BM-DCs. Flow cytometric analysis of BM-DC cultures transduced with 
LNT-GFP,  LNT-NY-ESO-1  or  LNT-TFULL  vectors;  or  left  untreated  as  the 
negative  control.  On  day  8  of  in  vitro  culturing,  cells  were  stained  with  APC-
conjugated  anti-mouse  CD86  and  PE-conjugated  anti-mouse  MHC  class  II 
monoclonal antibodies. Cytometer gates were established with the following isotype 
control  antibodies:  PE  Rat  IgG2b  (grey  filled  histogram)  and  APC  Rat  IgG2a 
isotype controls. Left panel of histograms shows CD86 expression on all gated cells. 
Right panel of histograms shows the murine MHC Class II expression on CD86
HIGH-
gated (from left panel) cells. Median fluorescence intensities of MHC Class II 
staining on CD86
HIGH expressing cells are shown. 
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  One cDNA fragment generated had 153 nucleotides excluded from the 3’-end 
deleting part of the C-terminus (Tx1B). The other cDNA fragments - Tx2A, Tx2B and 
Tx2C  had  various  lengths  of  the  N-terminal  deleted  and  they  also  contained  the 
3’untranslated region of TWIST1 exon 2. The amplified products were then transferred 
into  pHR’-SIN-IRES-WPRE  and  validated  by  DNA  sequencing.  The  resulting 
constructs  were  named  LNT-Tx1B-EGFP,  LNT-Tx2A-EGFP,  LNT-Tx2B-EGFP  and 
LNT-Tx2C-EGFP. The cDNA inserts generated by PCR are illustrated in Figure 5.2. 
 
  The six constructs were tested by transiently transfecting 293T cells. After 24 
hours, half of the cells were lysed in RIPA buffer. Proteins were resolved by SDS-
PAGE  and  transferred  to  nitrocellulose  membrane.  Immunoblotting  was  performed 
using an anti-FLAG antibody. Figure 5.9 shows that transfection of 293T cells with 4 
out of 6 constructs resulted in recombinant TWIST1 expression. The protein detected 
for  LNT-TF-EGFP  migrated  at  approximately  25  kDa  which  is  the  expected  size. 
Recombinant protein expression was not detected in 293T transfected with LNT-Tx2B-
EGFP  and  LNT-Tx2C-EGFP  plasmids,  which  had  291 and  417  nucleotides  deleted 
from the 5’-end of the TWIST1 cDNA. 
 
  Co-expression of an eGFP reporter gene by the transfected 293T cells described 
above were analysed concurrently by flow cytometry. Figure 5.10(A) shows that the 
transfection efficiencies achieved ranged from 43% to 76% in terms of percentage of 
cells expressing eGFP. The fluorescence intensity of eGFP expression is also indicative 
of the inserted gene expression levels. Figure 5.10(B),  shows that pHR’-SIN-IRES-
WPRE  transfected  eGFP
+  cells  had  a  median  fluorescent  intensity  of  122,  which 
represents the basal level of eGFP expression by pHR’-SIN-IRES-WPRE which lacks a 
cDNA insert in the first cistron. Transgene expression of the first cistron may increase 
the eGFP expression above the basal level; this could be attributed to ribosomal read-
through mechanisms. LNT-Tx1B-EGFP transfected 293T cells had the highest median 
fluorescent intensity of 448 which is consistent with the high levels of protein detected 
in the Western blot analysis. LNT-Tx2B-EGFP and LNT-Tx2C-EGFP transfected 293T 
cells have low levels of eGFP expression similar to that of the pHR’-SIN-IRES-WPRE 
control,  this  is  also  consistent  with  the  lack  of  detectable  protein  by  Western  blot 
analysis. 
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Figure  47  Figure  5.9.  Expression  of  recombinant  epitope-tagged  full-length  and  truncated  TWIST1  in 
transiently  transfected  293T  cells
Figure  5.9.  Expression  of  recombinant  epitope-tagged  full-length  and 
truncated TWIST1 in transiently transfected 293T cells. Western blot analysis 
of 293T cells transiently transfected with one of the following plasmids: LNT-TF-
EGFP,  LNT-Tx1A-EGFP,  LNT-Tx1B-EGFP,  LNT-Tx2A-EGFP,  LNT-Tx2B-
EGFP and LNT-Tx2C-EGFP. Cells were lysed in RIPPA buffer 24 hours after 
transfection and resolved by SDS-PAGE. After protein transfer, the nitrocellulose 
membrane  was  probed  with  the  anti-FLAG®  M2  and  α-tubulin  monoclonal 
antibody. 177 
 
Figure 5.10. Co-expression of EGFP reporter gene in transient transfected 
293T cells. Flow cytometric analysis of 293T cells transiently transfected with one 
of the following plasmids: pHR’-SIN-IRES-WPRE, LNT-TF-EGFP, LNT-Tx1A-
EGFP, LNT-Tx1B-EGFP, LNT-Tx2A-EGFP, LNT-Tx2B-EGFP and LNT-Tx2C-
EGFP.  (A)  Transfection  efficiency  as  determined  by  the  percentage  of  cells 
expressing eGFP. (B) Median fluorescent intensity of eGFP
+ cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48 Figure 5.10. Co-expression of EGFP reporter gene in transient transfected 293T cells 
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5.2.7.  pHR’-SIN-IRES-WPRE mediated TWIST1 expression in dendritic cells 
In contrast to the vectors based on pHR'SIN-cPPT-SEW, the bicistronic vectors allow 
the monitoring of gene delivery efficiency by co-expressing a reporter gene encoding 
eGFP. Expression of LNT-TF-EGFP and LNT-TxB1-EGFP in transduced BM-DCs was 
tested.  Bone  marrow  cells  were  collected  from  HLA-A*0201  transgenic  mice  and 
cultured in the presence of murine GM-CSF and IL-4. Medium containing non-adherent 
cells was discarded and replaced with fresh medium containing cytokines on day two. 
Cells were transduced with lentiviral particles on day four and analysed for CD11c 
lineage marker and eGFP expression by flow cytometry on day eight. Figure 5.11 shows 
that 32% and 35% of the LNT-TF-EGFP and LNT-Tx1B-EGFP transduced BM-DCs 
cells,  respectively,  were  CD11c
+  and  eGFP
+.  In  addition,  the  mean  fluorescent 
intensities of eGFP expression were higher in comparison to BM-DCs transduced with 
the pHR’-SIN-IRES-WPRE control, which suggests the co-expression of TFULL and 
Tx1B transgenes. It’s worth noting that BM-DC cultures transduced with the bicistronic 
vectors had a lower percentage of CD11c
+ cells, ranging from 68% to 73%, compared to 
the untreated and LNT-NY-ESO-1 transduced cells. 
 
5.2.8.  DC vaccine priming and naked DNA boosting immunisation 
The  initial  objective  was  to  assess  whether  an  immunisation  strategy  that  involved 
priming with transduced BM-DCs expressing the cancer testis antigen, NY-ESO-1, and 
boosting with naked DNA encoding the same immunogen could elicit a specific CD8
+ T 
cell  response in the  HLA-A2  transgenic  mouse model.  The  LNT-NY-ESO-1  vector 
encodes the HLA-A2 restricted epitope NY-ESO-1 amino acids 157-165 (NY-ESO-1157-
165), and studies have used the same construct to induce a NY-ESO-1 specific CTL 
response  in  the  HLA-A2  transgenic  mice,  using  a  similar  vaccination  approach 
(Palmowski  et  al.,  2004).  Once  a  model  system  has  been  validated  against  a 
characterised tumour antigen and a robust CD8 T cell response  can be generated, it 
would  become  a  valuable  tool  to  assess  the  immunogenicity  of  lentiviral  vectors 
encoding TWIST1 gene fragments. 
 
  Two HLA-*0201
+ transgenic mice were immunised for each group with either 
LNT-NY-ESO-1 or pHR’-SIN-IRES-WPRE transduced BM-DCs by subcutaneous  179 
 
   
 
 
Figure 49 Figure 5.11. Expression of EGFP reporter gene in lentiviral transduced BM-DC 
 
Figure 5.11. Expression of EGFP reporter gene in lentiviral transduced BM-
DC. Bone marrow cells from HLA-A*0201 transgenic mice were incubated with 
GM-CSF and IL-4. Cells were transduced on day 4 of culturing with either pHR’-
SIN-IRES-WPRE,  LNT-TF-EGFP,  LNT-Tx1B-EGFP,  LNT-NY-ESO-1 
concentrated  lentivirus  stocks  or  left  untreated.  Flow  cytometric  analysis  was 
performed on day 8. Cells were stained with PE-conjugated anti-mouse CD11c 
antibody.  Cytometer  gates  were  established  with  PE  Armenian  Hamster  IgG 
isotype  control  and  GFP
-  cells  (untreated  group) .  The  percentages  of 
CD11c
+eGFP
- (left) and CD11c
+eGFP
+ (right) cells are indicated in each plot. 180 
 
 
injections at the base of tail.Subsequently, naked DNA plasmids of LNT-NY-ESO-1 or 
pHR’-SIN-IRES-WPRE were administered twice, once every ten days by intramuscular 
injection  together  with  CpG  ODN  1826  as  an  adjuvant.  Ten  days  after  the  third 
immunisation, the mice were euthanised and the pooled splenocytes were analysed for 
NY-ESO-1157-165 specific CTL response (see Section 2.19 for more detail) 
 
  MHC class I pentamers were used to detect NY-ESO-1157-165 antigen-specific 
CD8
+ T cells within the freshly isolated splenocytes by flow cytometric analysis. Figure 
5.12(A), shows that within the pooled splenocytes from LNT-NY-ESO-1 vaccinated 
mice, 0.78% of the gated CD8
+ cells were NY-ESO-1/HLA-A*0201 pentamer positive 
compared to 0.12% of the pHR’-SIN-IRES-WPRE vector control vaccinated mice. To 
verify the observation, splenocytes from the LNT-NY-ESO-1 group were restimulated 
with NY-ESO-1157-165 peptide in order to expand the antigen-specific population. The 
percentage of CD8
+ T cells binding specifically to NY-ESO-1/HLA-A*0201 pentamer 
(0.19%),  relative  to  the  control  pentamer,  decreased  after  the  restimulation  (Figure 
5.12(B)).  The  percentage  of  CD8
+  cells  within  the  splenocyte  culture  after  re-
stimulation increased from 9% to 37% of the total gated cells. The difference observed 
in  Figure  5.12(A)  was  not  significant and  the  brightness  as  measured  by  the  mean 
fluorescent  intensity  of  the  antigen-specific  CTL  population  was  relatively  low 
compared to the pentamer-negative CD8
+ population which could suggest a limitation 
in sensitivity in this assay. 
 
  Intracellular interferon-γ production by CD8
+ T cells in response to antigenic 
peptide stimulation was also evaluated by flow cytometric analysis. Pooled splenocytes 
from pHR’-SIN-IRES-WPRE or LNT-NY-ESO-1 vaccinated mice, were incubated with 
either 10µM of irrelevant control peptide (FLU) or NY-ESO-1 peptide, or 50ng/ml of 
phorbol 12-myristate 13-acetate (PMA) and 500ng/ml of ionomycin, all in the presence 
protein transport inhibitor – brefeldin A. Flow cytometric analysis, as shown in Figure 
5.13(A), showed that transgenic mice vaccinated with LNT-NY-ESO-1 immunogen did 
not  demonstrate  a  NY-ESO-1157-165  peptide-specific  CTL  immune  response.  Figure 
5.13(B)  shows  that  ex  vivo  re-stimulation  with  NY-ESO-1  peptide  increased  the 
percentage of IFN-γ producing CD8
+ T cells in response to non-specific PMA-  181 
 
Figure 50 Figure 5.12. NY-ESO-1157-165 specific CD8+ T cell response was not detected in vaccinated HLA-
A*0201 transgenic mice 
Figure 5.12. NY-ESO-1157-165 specific CD8
+ T cell response was not detected in 
vaccinated HLA-A*0201 transgenic mice. Two HLA-A*0201 transgenic mice per 
group were primed with BM-DCs in vitro transduced with pHR’-SIN-IRES-WPRE 
or  LNT-NY-ESO-1  followed  by  boosting  with  pHR’-SIN-IRES-WPRE  or  LNT-
NY-ESO-1  naked  plasmid  DNA.  (A)  Flow  cytometric  analysis  of  pooled 
splenocytes  with  NYESO1/HLA-A*0201  pentamer  or  irrelevant/HLA-A*0201 
pentamer,  visualised  with  streptavidin-PE,  and  APC-conjugated  anti-mouse  CD8 
monoclonal antibody. Gates were established with the following isotypes: APC Rat 
IgG2a  and  biotinylated  Rat  IgG1  isotype  controls.  (B)  Pooled  splenocytes  from 
LNT-NY-ESO-1 immunised mice were restimulated in vitro with 10µM of synthetic 
NY-ESO-1157-165 peptide and 20U/ml of recombinant murine IL-2 and cultured for 7 
days. Flow cytometric analysis as described above was performed seven days after 
ex vivo peptide restimulation. 182 
 
Figure 5.13. Splenocytes from vaccinated HLA-A*0201 transgenic mice did 
not respond to NY-ESO-1157-165 stimulation. Two HLA-A*0201 transgenic mice 
per group were primed with BM-DCs in vitro transduced with pHR’-SIN-IRES-
WPRE or LNT-NY-ESO-1 followed by boosting with pHR’-SIN-IRES-WPRE or 
LNT-NY-ESO-1 naked plasmid DNA. (A) Pooled splenocytes were incubated with 
10µM of NY-ESO-1 or FLU peptide and 10 µg/ml of Brefeldin A. Flow cytometric 
analysis  was  performed  after  24  hours  of  incubation  by  staining  with  APC-
conjugated anti-mouse CD8 antibody, intracellular staining with biotinylated anti-
mouse IFN-γ mAb and streptavidin-PE. Gates were established with the following 
isotypes: APC Rat IgG2a and biotinylated Rat IgG1 isotype controls. PMA and 
Ionomycin stimulation was used as a positive control. (B) Pooled splenocytes from 
LNT-NY-ESO-1  immunised  mice  were  restimulated  in  vitro  with  10µM  of 
synthetic NY-ESO-1157-165 peptide and 20U/ml of recombinant murine IL -2 and 
cultured for 7 days. Restimulated splenocytes were incubated with NY -ESO-1 or 
FLU peptide-pulsed HLA-A2
+ EL4 cells, at 30 to 1 effector to target cell ratio, and 
Brefeldin A. Flow cytometric analysis as described above was performed 24 hours 
after. 
 
Figure 51 Figure 5.13. Splenocytes from vaccinated HLA-A*0201 transgenic mice did not respond to NY-ESO-
1157-165 stimulation 
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ionomycin stimulation. However, cells did not respond to  either NY-ESO-1 or FLU 
peptide-pulsed HLA-A*0201
+ EL4 cells. Collectively, the data here suggests that the 
priming of HLA-A*0201 transgenic mice with LNT-NY-ESO-1 lentivirus transduced 
BM-DC, and boosting with two doses of LN-NY-ESO-1 plasmid DNA vaccine using 
this particular immunisation strategy does not induce a robustly detectable NY-ESO-
1157-165 specific CD8
+ T cell response. 
 
 
5.3.  Discussion 
 
In order to evaluate the immunogenicity of TWIST1-expressing transduced BM-DCs, a 
system was required whereby TWIST1 cDNA is delivered into bone-marrow-derived 
dendritic  cells.  HLA-A*0201  transgenic  mice  can  then  be  vaccinated  with  these 
genetically modified BM-DCs using a pre-established vaccination protocol – based  on 
the induction of CD8
+ T cell responses against NY-ESO-1-expressing BM-DCs.  
 
5.3.1.  Lentiviral vector mediated expression of TWIST1 and NY-ESO-1 
FLAG epitopes were engineered on to the C-terminus or N-terminus of TWIST1. This 
permitted the detection of full-length and truncated recombinant proteins by Western 
blotting  (Figure  5.4  and  5.9);  hence  the  confirmation  of  transgene  expression,  in 
transfected 293T cells, by six out of the nine constructs generated in this study. Gene 
expression from LNT-Tx2, LNT-Tx2B-EGFP and LNT-Tx2C-EGFP constructs were 
not detected in transfected 293T cells. For the latter two, the lack of TWIST1 expression 
was not due to poor transfection efficiency as indicated by the moderate percentages of 
cells expressing eGFP (Figure 5.10).  Since the inserted cDNA and the reporter gene are 
driven by a single Sffv promoter, thus transcribed into a single transcript; instability of 
the mRNA would affect both the expression levels of the gene of interest and the eGFP 
reporter gene, which is not the case here. Therefore, the lack of transgene expression 
could be influenced by translational or post-translational events.  
 
  Ectopic expression of Saethre-Chotzen-related TWIST1 mutations in COS7 cells 
has  shown  that  the  C-terminal  truncation  of  TWIST1  has  had  an  affect  on  protein 
stability, possibly through  the rapid degradation of  proteins  (El, V et al., 2000). In 184 
 
constrast, the finding here suggests that the C-terminal truncated proteins encoded by 
Tx1A and Tx1B are expressed at similar levels, if not higher, when compared to the 
wild-type protein. However, the discrepancy could be due to the differences between the 
experimental systems used. For example, the transfection was performed on different 
cell  lines;  the  length  of  C-terminal  truncation  analysed  was  not  identical  and  the 
expression levels was only monitored after a short incubation time of 24 hours. The 
expression of N-terminal truncated TWIST1 proteins however has not been examined as 
extensively. It could be interesting to test whether N-terminal truncated proteins are in 
fact synthesised but are unstable, by inhibiting protein degradation with proteasome 
inhibitors. 
 
  pHR'SIN-cPPT-SEW lentiviral vector was initially chosen to drive constitutive 
expression  of  TWIST1  cDNA  in  mouse  BM-DCs.  More  than  60%  transduction 
efficiency was achieved when differentiating BM-DC cultures were infected with LNT-
GFP at a MOI of 23 (Figure 5.5). Recombinant NY-ESO-1 protein expression in BM-
DCs transduced  with the  LNT-NY-ESO-1  was confirmed  (Palmowski et al., 2004). 
However, BM-DCs transduced with equivalent titers of LNT-TFULL did not express 
detectable  levels  of  TWIST1  protein  (Figure  5.6).  Transgene  expression  was  also 
undetectable  in  LNT-TFULL  transduced  human-monocyte  derived  DCs  (data  not 
shown).  The  BM-DC  transduction  efficiency  of  LNT-TFULL  was  expected  to  be 
similar  to  that  of  LNT-GFP  and  LNT-NY-ESO-1  constructs;  this  could  have  been 
confirmed by quantifying the number of lentiviral vectors integrated into the genome of 
transduced BM-DCs by real-time PCR (Sastry et al., 2002). It may also be interesting to 
assess whether TWIST1 mRNA transcripts were present.  
 
  To further assess the use of lentiviral vectors to deliver TWIST1 transgene into 
BM-DCs, wild-type TWIST1 cDNA was subcloned into the pHR’-SIN-IRES-WPRE 
vector (LNT-TF-EGFP); and five additional constructs containing different TWIST1 
cDNA were also generated. LNT-TF-EGFP and LNT-Tx1B-EGFP (see Figure 5.2 for 
an illustration of the vectors) were tested by transducing BM-DCs generated from HLA-
A*0201  transgenic  mice.  Flow  cytometric  analysis  revealed  that  the  transduction 
efficiencies  achieved  were  32%  and  35%,  respectively  (Figure  5.11).  As  discussed 
previously, the inserted cDNA and the reporter eGFP gene are transcribed into a single 185 
 
transcript; therefore it indicates that the TWIST1 genes were expressed at the mRNA 
level.  
 
  The median fluorescent intensities (MFI, data not shown) of the LNT-TF-EGFP 
and LNT-Tx1B-EGFP transduced eGFP
+ BM-DCs were higher relative to the control 
vector pHR’-SIN-IRES-WPRE (Figure 5.11).  This may be due to higher transduction 
efficiencies.  However,  the  true  transduction  efficiency  is  often  underestimated  by 
monitoring  eGFP  expression  by  flow  cytometry  because  the  method  has  a  limited 
sensitivity  to  detect  cells  expressing  below  a  certain  threshold.  Alternatively,  the 
increase in MFI may be a consequence of ribosomal readthrough or reinitiation of the 
first open reading frame (ORF) (Peabody and Berg, 1986), resulting in the enhanced 
expression of the second ORF. If the latter hypothesis is true, it would indicate that 
wild-type and truncated TWIST1 proteins were expressed in the transduced BM-DCs. 
 
5.3.2.  Heterologous transduced BM-DC prime and naked DNA boost vaccination 
HLA-A*0201  transgenic  mice  vaccinated  with  BM-DCs  transduced  with  LNT-NY-
ESO-1 vector and injected intramuscularly with LNT-NY-ESO-1 naked DNA plasmids, 
did not induce detectable NY-ESO-1157-165 peptide-specific CTL immune response, even 
after ex vivo re-stimulation with synthetic NY-ESO-1157-165 peptide (Figure 5.12 and 
5.13). Although the number of mice vaccinated was limited and a direct comparison 
was not performed; the data suggests that the immunisation protocol used in this study 
may  be  less  effective  at  inducing  a  peptide-specific  CTL  response,  than  using 
transduced BM-DCs to prime, followed by boosting with recombinant vaccinia virus 
encoding the TAA, as demonstrated in a previous study (Palmowski et al., 2004).  
   
  Recombinant poxviral vectors such as vaccinia virus, have long been exploited 
in the development of vaccines against cancer (Irvine et al., 1997a; Eder et al., 2000; 
Kass  et  al.,  1999).  In  the  context  of  heterologous  vaccination  design,  the  use  of 
recombinant vaccinia virus have shown to be particularly effective at boosting immune 
responses (Irvine et al., 1997b; Schneider et al., 1998). This may be explained by the 
stimulation  of  innate  immunity  by  viral  proteins  leading  to  the  production  of 
proinflammatory cytokines (Zhu et al., 2007), which may in turn increase the size of 
immune response induced against the gene of interest. Immunisation of recombinant 186 
 
vaccinia viruses is also known to induce anti-viral T cell responses (Harrington et al., 
2002); the recognition of viral antigens by CD4
+ T cells could potentially provide T cell 
help for the activation of cytotoxic T lymphocytes specific for the inserted transgene. 
The  use  of  poxviral  vectors  in  vaccinations  has  been  reported  extensively,  but  few 
studies have assessed its application in combination with DC-based vaccine. For future 
work, it may be interesting to evaluate the use of different vaccine platforms for the 
boosting of antigen-specific T cell responses after initial priming with a dendritic cell-
based vaccine. 
 
  There  are  many  ways  to  improve  the  immunogenicity  of  DNA  vaccines. 
Delivery  by  intramuscular  injection  followed  by  electroporation  has  been  shown  to 
increase the immunogenicity of a DNA vaccine encoding the AH1 epitope derived from 
CT26  colon  carcinoma  cells  (Buchan  et  al.,  2005).  The  co-administration  of  DNA 
plasmids encoding melanoma-associated antigen, gp100, and granulocyte-macrophage 
colony-stimulating  factor  (GM-CSF)  provided  greater tumour  protection  than  gp100 
plasmid  alone  (Rakhmilevich  et  al.,  2001).  Naked  LNT-NY-ESO-1  plasmid  co-
administered with CpG ODN as a DNA vaccine-boost may not be an effective way to 
activate and expand primed T cells.  
 
5.3.3.  Summary     
Overall this chapter describes the development of a system whereby full-length and 
truncated  TWIST1  cDNA  are  delivered  into  bone-marrow  derived  dendritic  cells 
generated from HLA*0201 transgenic mice. Although no definite conclusions can be 
drawn from these preliminary experiments, the work demonstrated that the constructs 
generated expressed recombinant TWIST1 proteins in 293T cells; and confirmed that 
BM-DCs  can  be  successfully  transduced  with  lentiviral  vectors.  The  tools  and  data 
generated here would aid the further development of an experimental immunisation 
model that could be used to investigate the immunogenicity of TWIST1. 
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6.1.  Final Discussion 
 
TWIST1  is  an  attractive  target  for  the  therapeutic  treatment  of  cancers.  It  could 
potentially  benefit  a  large  number  of  patients  as  it  has  been  found  to  be  widely 
expressed by different tumour types (Puisieux et al., 2006; Ma et al., 2007; Man et al., 
2005; Yuen et al., 2007; Maestro et al., 1999). The expression of TWIST1 in tumour 
cells  is  linked  to  tumour  progression  and  metastasis  and  is  supported  by  clinical 
observations; for example, the high expression levels of TWIST1 in tumour cells was 
correlated with late-stage breast cancers (Cheng et al., 2007; Yang et al., 2004). It has 
also  been  shown  to  play  an  important  role  in  promoting  tumour  cell  survival  by 
inhibiting  the  pro-apoptotic  ARF/  p53  signaling  pathway  (Puisieux  et  al.,  2006). 
TWIST1 has the characteristics of an ideal tumour-associated antigen but no studies to 
date have been undertaken to determine whether a TWIST1-mediated anti-tumour T cell 
response can be generated for the treatment of human cancers.  
    
  The original aims of this project were to identify potential CTL epitopes from 
TWIST1 that bind to HLA-A*0201 molecules, and to test the immunogenicity of the 
predicted epitopes in vitro by generating peptide-specific CTLs from HLA-A2
+ human 
donors. T cell recognition of TWIST1
+ tumour cells could then be evaluated in vitro 
using the characterised peptide-specific CTL lines or clones; hence indirectly providing 
evidence  for  the  natural  processing  and  presentation  of  the  predicted  peptides.  In 
addition, the use of HLA-A*0201 transgenic mice and the alloreactive T cell repertoires 
of HLA-A2
- blood donors were evaluated as alternative sources for the isolation of 
antigen-specific CTLs. The findings presented here contribute towards understanding 
whether  TWIST1  expression  in  cancer  can  be  targeted  by  a  T  cell-mediated 
immunotherapy approach. 
 
  The results presented in this thesis confirm the potential immunogenicity of one 
out of the two HLA-A*0201-binding peptides identified from TWIST1 protein using 
computer-based prediction algorithms (Chapter 3). Induction of CTLs specific for the 
peptide  SLNEAFAAL  (SLN)  was  observed  in  1  out  of  5  HLA-A2
+  healthy  blood 
donors  in  vitro.  Peptide-mediated  T  cell  recognition  of  target  cells  was  confirmed 
experimentally  using  cytotoxicity  and  interferon-γ  ELISPOT  assays.    Although  a 189 
 
KLAARYIDFL  (KLA)  peptide-specific  CTL  response  was  not  detected  in  the  four 
individuals screened, it had been observed in previous work conducted by the group 
(Appendix Figure A.1(B)). Collectively, the data provides evidence for the presence of 
precursor CTLs, specific for TWIST1-derived peptides in the peripheral blood of at 
least  a  proportion  of  healthy  individuals,  and  it  has  demonstrated  the  feasibility  of 
expanding such T cells ex vivo. It is still unclear whether these epitopes are presented on 
the tumour cells of patients; however the data provides the rationale of investigating 
TWIST1-specific CD8
+ T cells using MHC class I multimers complexed with the two 
peptides identified in this study.  
 
  TWIST1 transcript was expressed at relatively low levels across most normal 
adult tissue samples, compared to the TWIST1 expressing tumour cell lines. Relatively 
high levels of mRNA expression were detected in the uterus and placenta samples, 
highlighting  the  potential  risks  of  targeting  TWIST1  therapeutically.  The  mRNA 
expression profiling data would also guide future studies looking at normal tissue and 
tumour expression of TWIST1 protein by immunohistochemistry staining; this was not 
possible at the time of the study due to the lack of reliable anti-TWIST1 antibodies 
available. 
 
  Cytotoxic  T  lymphocytes  specific  for  the  HLA-A*0201-restricted,  TWIST1-
dervied  KLA  peptide  were  isolated  from  the  alloreactive  repertoire  of  a  HLA-A2
- 
healthy blood donor (Chapter 4). The CTL line showed specific cytotoxicity against T2 
cells pulsed with KLA peptide but not with the irrelevant control peptide. It was also 
devoid  of  ‘classical’  alloreactivity  -  directed  against  the  non-self  HLA-A*0201 
molecule. The result adds to the body of work demonstrating the feasibility of isolating 
allorestricted T cells, directed against specific epitopes derived from tumour-associated 
antigens such as WT1 (Gao et al., 2000; Savage et al., 2004), Melan-A and cyclin-D1 
(Sadovnikova et al., 1998).  
 
  The allogeneic T cell repertoire could be exploited for the isolation of high-
avidity  CTLs  with  specificities  against  tumour  antigens  (Gao  et  al.,  2005)  but it  is 
difficult to identify peptide-specific CTLs within an alloresponse. In order to overcome 
this, an experimental approach involving the use of MHC class I pentamers and the 
selection of pentamer-binding CTLs by magnetic cell separation was tested. The aim 190 
 
was to isolate peptide-specific CD8
+ T cells from alloreactive CTL lines, stimulated in 
vitro  with  allogeneic  peptide-pulsed  HLA-A2
+  APCs.  KLA-specific  CTLs  were 
identified in one out of two HLA-A2
- blood donors (Chapter 4). CTLs specific for NY-
ESO-1157-165  and  Influenza  A MP58-66 peptides  were not detectable in the other two 
HLA-A2
- donors screened. Overall, the results have shown that the method works in 
principle,  however  further  development  of  the  MHC  pentamer-guided  approach  is 
needed. 
    
  T  cell  receptors  found  on  CTLs  are  responsible  for  recognising  antigenic 
peptides bound to MHC class I molecules, and in the absence of antigen processing and 
presentation, target cells are not recognised by T cells. Therefore, T cell recognition of 
target  cells  is  indicative  of  endogenous  antigen  processing,  and  the  presentation  of 
peptides  on  surface  MHC  complexes.  The  original  aim  was  to  generate  CTL 
lines/clones, specific for TWIST1-derived peptides, to use as tools to test the natural 
processing and presentation of the TWIST1 protein. The allo-restricted KLA peptide-
specific CTL line generated did not recognise TWIST1 transfected 293T cells (Figure 
4.15(A)). This could be due to the lack of KLA peptide presentation by target cells; 
however,  low  numbers  of  antigen-specific  CTLs  present  within  the  heterogeneous 
population, or the absence of high-avidity CTLs could also account for the lack of T cell 
response observed. Overall, the preliminary experiments performed were inconclusive 
and further studies are required. The work also highlights the importance of isolating 
high-avidity CTL clones, when adopting the ‘reverse immunology’ approach, in order 
to maximise the sensitivity of peptide-MHC ligand detection on the surfaces of target 
cells.  
 
  Human and mouse dendritic cells transduced with lentiviral vectors encoding 
tumour antigen genes can generate antigen-specific immune responses in vitro and in 
vivo (Breckpot et al., 2003; Lopes et al., 2006). Lentiviral vectors encoding TWIST1 
were assessed for their capacity to deliver TWIST1 transgenes into mouse BM-DCs 
generated  from  HLA-A*0201  transgenic  mice.  Greater  than  30%  transduction 
efficiency of CD11c
+ cells was achieved with the lentiviral bicistronic vectors encoding 
full-length  or  truncated  TWIST1  cDNA.  These  preliminary  experiments  helped 
determine the conditions necessary for delivering genes encoding TAAs into dendritic 
cells. Future studies could look at the generation of TWIST1-specific immune response 191 
 
in  vivo  by  vaccinating  HLA-A*0201  transgenic  mice  with  the  lentiviral  transduced 
TWIST1
+ BM-DCs. The goal is to identify HLA-A*0201-restricted TWIST1-specific T 
cells for immunotherapy through TCR gene transfer (Stanislawski et al., 2001). Future 
studies that could be carried out are described in more detail in Section 6.2.3. 
 
6.2.  Future work 
 
6.2.1.  Processing and presentation of TWIST1 epitopes 
The presentation of TWIST1-derived peptides (for example SLN and KLA peptides) on 
tumour cell surfaces is essential to a viable T cell-mediated immunotherapy approach 
using these peptides as vaccines. Several experiments should be carried out to test how 
likely that the predicted epitopes from TWIST1 are processed and presented naturally 
on MHC class I complexes.   
   
  Human constitutive and immuno-20S proteasomes can be purified from Epstein-
Barr Virus (EBV)-transformed B cell line LCL-721.174, which lacks the LMP2 and 
LMP7 genes, and the parental cell line LCL-721 (Tenzer et al., 2004). Processing of the 
putative CTL epitopes can be tested in vitro by digesting TWIST1 protein, or precursor 
peptides encompassing the peptide of interest with purified 20S proteasomes, before 
separating and analysing the resulting cleaved products. This method has been used 
successfully  in  other  studies  to  identify  T  cell  epitopes  from  TAAs  such  as  WT1 
(Asemissen et al., 2006) and PRAME (Kessler et al., 2001). 
 
  A  published  study  reported  the  use  of  the  Predict-Calibrate-Detect  (PDC) 
approach that led to the identification of a novel HLA-A*0201-restricted MAGE-A1278-
286 CTL epitope (Pascolo et al., 2001). This approach involves the biochemical analysis 
of  peptides  extracted  from  isolated  HLA-A2  molecules,  from  MAGE-A1
+  KS24.22 
human breast carcinoma cells. The PDC method could be used to confirm the natural 
presentation of putative TWIST1-derived epitopes on HLA-A*0201
+ TWIST1
+ tumour 
cell lines. The same cell lines could then be used to demonstrate T cell recognition and 
tumour cell killing by peptide-specific CTL lines or clones.  
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6.2.2.  Determining the importance of putative epitopes SLN and KLA  
Endogenous epitope processing of the KLA and SLN peptides can be addressed with 
the experiments described in the previous section. However, the demonstration of CTL 
cytotoxicity  against  HLA-A*0201
+  TWIST1
+  tumour  cells,  in  a  MHC-restricted 
peptide-dependent manner, remains the most definitive way to show the potential of 
targeting TWIST1 in immunotherapy. The in vitro generation and characterisation of 
peptide-specific  CTLs  is  time-consuming  and  challenging.  Moreover,  the  precursor 
frequency of CTLs specific for  KLA or SLN peptides could be very low.  Keeping 
within the scope of the original aims of this study, if evidence supporting the processing 
of the two peptides is generated from the proposed experiments above; a larger panel of 
HLA-A2
+  human  blood  donors  should  be  tested  against  each  of  the  putative  CTL 
epitopes.  
 
  The aim of increasing the sample size is to assess the technical feasibility of 
isolating antigen-specific CTLs, within the constraints of the chosen in vitro stimulation 
experimental conditions. The frequency, at which peptide-specific CTL responses are 
induced from the panel of donors, may correlate to the precursor frequencies of peptide-
specific CTLs within the T cell repertoire of healthy individuals. The frequency and the 
overall sizes of immune responses induced would indicate the likelihood of isolating 
CTLs with high avidity TCRs. Ultimately, if the aim is to isolate the TCR genes from 
KLA or SLN peptide-specific CTL clones for use in adoptive transfer of TCR gene-
modified  T  cells;  the  feasibility  of  isolating  high-avidity  CTLs  should  also  be  an 
important factor in determining the immunotherapeutic potential of targeting TWIST1. 
 
  The induction of an anti-Twist, H2-K
d-restricted peptide-specific CTL response, 
was previously identified in a metastatic breast cancer mouse model which underwent 
treatment with localised radiation therapy and anti-CTLA-4 antibody (Demaria et al., 
2007). Other studies have suggested the use of peripheral blood from cancer patients, 
undergoing tumour regression, for the ex vivo screening of potential epitopes for T cell 
recognition (Scheibenbogen et al., 2002; Asemissen et al., 2006). This may increase the 
efficiency  of  isolating  CTLs  reactive  against  the  target  antigen,  such  as  TWIST1, 
because the patient may have an on-going T cell response against it. 
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6.2.3.  TWIST1 lentiviral transduced dendritic cells 
The  lentiviral  vectors  encoding  TWIST1  cDNA  (LNT-TF-EGFP,  LNT-Tx1B-EGFP 
vectors) were used to deliver genes into mouse BM-DCs. The expression of the eGFP 
reporter  gene  by  the  transduced  cells  suggested  the  co-expression  of  TWIST1. 
However, this is not direct evidence of TWIST1 protein expression; therefore it should 
be  confirmed  by  Western  blotting  using  an  anti-FLAG  antibody.  Low  transduction 
efficiency of BM-DCs could hamper the detection of TWIST1 protein. To avoid this 
risk,  eGFP
+  BM-DCs  could  be  isolated  first  by  fluorescence-activated  cell  sorting 
(FACS)  in  order  to  obtain  a  homogeneous  population  of  transduced  cells,  before 
carrying out the western blot analysis.  
   
  As mentioned previously, the aim of delivering TWIST1 into BM-DCs (from 
HLA-A*0201 transgenic mice) is to elicit TWIST1-specific immune responses in vivo 
by vaccinating HLA-A*0201 transgenic mice with the transduced TWIST1
+ BM-DCs. 
The induced immune response could be characterised by using a set of overlapping 
peptides which covers the TWIST1 protein. Briefly, splenocytes from the vaccinated 
mice could be restimulated in vitro by incubating with synthetic peptides derived from 
the TWIST1 protein sequence. After one week of culturing, TWIST1-specific CTLs 
could be identified in a chromium-51 cytotoxicity assay or an  IFN-γ release assay. 
Antigen-specificity  could  be  determined  by  using  TAP-deficient  RMA-S  cells, 
expressing  HLA-A2.1/H-2Db  β2-microglobulin-linked  monochain,  pulsed  with 
TWIST1 synthetic peptides or control peptides, and used as target cells. The method 
described would complement the ‘reverse immunology’ approach, as it may identify 
HLA-A*0201-restricted immunogenic peptides which do not contain consensus anchor 
residues (Breckpot et al., 2004; Schultz et al., 2001; Luiten et al., 2000). 
   
  An alternative to using peptides to characterise TWIST1-specific responses in 
vaccinated HLA-A*0201 transgenic mice, is the use of human tumour cells as target 
cells. Purified CD8
+ T cells from primed splenocytes could be tested against target cells 
expressing  both  HLA-A*0201  and  TWIST1,  compared  with  isogenic  target  cells 
expressing only HLA-A*0201 or TWIST1. Recognition of the HLA-A*0201
+ TWIST1
+ 
double positive target cells only would indicate the presence of antigen-specific CTLs.  
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  Lentiviral  vector-mediated  delivery  of  TWIST1  could  be  easily  applied  to 
human  dendritic  cells.  Transduced  monocyte-derived  DCs  can  be  used  to  stimulate 
autologous CD8
+ T cells in vitro and the induction of TWIST1-specific CTLs can be 
examined after several rounds of re-stimulation. Similar to the method described above, 
overlapping  peptide  pools  can  be  used  to  identify  TWIST1-specific  CTLs,  by  co-
culturing  in  vitro  primed  CTLs  with  peptide-pulsed  autologous  EBV-transformed 
lymphoblastoid cells (Neitzel, 1986); and assessing the specificity of the CTL effector 
functions. The advantage of this method is that the HLA haplotype of the blood donor 
need not to be determined until TWIST1-specific CTL clones are generated.  
 
6.3.  Final conclusion 
Two  peptides  that  bind  HLA-A*0201  molecules  in  vitro,  were  identified  from  the 
protein sequence of TWIST1 using the reverse immunology approach. TWIST1-derived 
SLN peptide has a higher HLA-A*0201-binding affinity than KLA. The SLN peptide 
was capable of inducing a peptide-specific CTL response in 1 out of 5 healthy HLA-
A2+ blood donors. Peptide/HLA-A*0201 pentamer reagents and magnetic cell sorting 
was  used  to  isolate  allo-MHC-restricted,  KLA  peptide-specific  CTLs  from  the 
alloreactive T cell repertoire of a HLA-A2- blood donor. In summary, the induction of 
these peptide-specific CTLs merits further efforts in determining the natural processing 
of these putative epitopes in tumour cells. 
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Figure 52 Figure A.1. Generation of a KLA peptide-specific CTL response from a HLA-A2+ healthy donor 
Figure A.1. Generation of a KLA peptide-specific CTL response from a HLA-
A2
+ healthy donor. Preliminary data generated by Dr. N. Himoudi. The CTL line 
was generated against the KLA peptide using the method described in Section 2.8.4. 
(A) The CTL line was tested in a chromium-51 cytotoxicity assay after the fourth 
restimulation. Target cells used were T2 cells pulsed with 10M of either irrelevant 
peptide (FLU) or KLA peptide. Three different ratios of effector T cells to target 
cells  (E:T)  were  tested.  Data  shown  are  means  of  triplicate  measurements  of 
percentage lysis of target cells within a single experiment. (B) CTL line was tested 
against  293T  cells  transiently  transfected  with  pCI-neo-TWIST1  plasmid 
(293T/twist); or the vector backbone only (293T/vector) or untransfected 293T cells 
(293T).  Data  shown  are  single  measurements  of  percentage  lysis  within  a  single 
experiment.  
 